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Anti-retroviral therapy (ART) is highly effective in suppressing human immunodeficiency 
virus (HIV) and restoring immunocompetence. However, residual levels of HIV-1 RNA persist 
in patients with consistent viral suppression (viral load <50 copies/mL) and some immune 
functions are not reversed. Characterisation of residual viraemia (HIV-1 RNA <10 copies/mL) 
will facilitate to understand HIV persistence.  
A systematic review of literature was conducted to identify predictors of low level viraemia 
(HIV-1 RNA = 10-200 copies/mL) in patients on successful ART. To investigate factors 
associated with residual viraemia, we recruited a cohort of stably treated patients on first 
line ART with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor 
(PI) based regimen and no evidence of virological failure. We measured HIV-1 RNA in plasma 
with our in-house single copy assay (SCA) and we studied total HIV-1 DNA in peripheral blood 
mononuclear cells (PBMC) and PD1 expression on memory CD4 and CD8 T populations. A 
subset of our study cohort was sampled twice during consecutive routine visits at the HIV 
clinic to perform a longitudinal analysis of HIV-1 RNA in plasma, total HIV-1 DNA in PBMC 
and drug levels. 
Residual viraemia was identified in over one third (35.9%, n=19 of N=53) of subjects with a 
median of 3 copies/mL. In the longitudinal cohort (n=32), HIV-1 RNA presence in plasma was 
reproducible within an interval period of 4 months with 53% (n=17) having undetectable 
HIV-1 RNA at both time points and 25% (n=8) experiencing consistently detectable HIV-1 
RNA. Total HIV-1 DNA in PBMC was strongly associated with residual viraemia (OR: 3.42, 
95% CI: 1.32-8.83, p=0.011) in our study population. In the systematic review, low level 
viraemia was also associated with markers reflecting a bigger cellular reservoir including 
higher pre-ART viral load, total HIV-1 DNA in PBMC and shorter ART duration. Moreover, 
low level viraemia was more frequent with reduced adherence and with PI-based ART. The 
same trends were also seen in our cohort, but the number of patients on PI-based regimens 
(n=11) and with sub-optimal efavirenz levels (n=6) were small to allow statistical 
comparisons. Microbial translocation and immune activation were associated with low level 
viraemia in the review. On the contrary, our patients with undetectable HIV-1 RNA had 
higher PD1 expression on effector memory CD4 cells (median 43.9% vs. 33.7%, p=0.028), 
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effector memory CD8 cells (median 37.5% vs. 23%, p=0.022) and central memory CD8 cells 
(median 24.9% vs. 15.7%, p=0.034) compared to those with detectable HIV-1 RNA. 
Our findings suggest that residual viraemia is probably clonal in our cohort of patients 
deriving mainly during activation of latently infected cells, which causes bursts of virus 
production. We noted that common factors were associated with both residual and low 
level viraemia. Although we consider residual and low level viraemia as two different 
entities, their sources may overlap. In this context, ongoing viral replication may drive 
residual viraemia in a small subset of patients. We also made an interesting observation as 
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1.1 Human immunodeficiency virus (HIV) 
 
1.1.1 Classification and origin 
In 2019, there were 38.0 million people living with HIV and 690,000 deaths related to 
acquired immunodeficiency syndrome (AIDS) (UNAIDS, 2020). There are two types of HIV 
(HIV-1 and HIV-2) which along with the simian immunodeficiency viruses (SIVs) and the 
human T cell leukaemia/lymphoma viruses (HTLVs) belong to the genus of Lentivirus of the 
family of Retroviridae (ICTV, 2018). HIV-1 is the most pathogenic and easily transmitted type 
and the main cause of infections worldwide, while HIV-2 is restricted mainly to West Africa 
(Dougan et al., 2005). HIV-2 will not be further described as it is not part of this work. HIV-1 
has four genetically distinct groups: major (M), outlier (O), nonmajor/ nonoutlier (N) and the 
recently discovered group P, which have derived from independent cross-species 
transmission events. HIV-1 group M is responsible for the HIV pandemic and has been 
closely related to SIVcpz strains, isolated from African chimpanzees in southeast Cameroon. 
It is yet unclear the exact mechanism of the zoonotic transmission, but it is believed that it 
was passed on to hunters through the bloodborne route around 1920. It was the transfer of 
the virus to the city of Kinshasa at the Democratic Republic of the Congo (DRC) and the 
spread through transport networks to other regions of sub-Saharan Africa that transformed 
an epidemic into a worldwide pandemic. Chimpazees were also the source of group N, 
whereas gorillas were the source of group O and P (Bbosa et al., 2019). 
Viral genetic factors and socio-economic circumstances provided with a favourable 
advantage group M to spread exponentially around 1960 compared to the confined spread 
of group O to west-central Africa regions  (Faria et al., 2014, Keele et al., 2006, Zhu et al., 
1998). M has many subtypes or clades (A, B, C, D, F, G, H, J, K and L) from which subtype C 
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accounted for almost half (47%) of all HIV-1 infections in the period from 2010 to 2015 
(Hemelaar et al., 2019). Subtypes emerge by genetical evolution (founder events) and differ 
in the amino acids in the envelope gene (env) and group-specific antigen (gag) gene by 30% 
and 15%, respectively, whereas the genetic distance within a subtype can be between 15% 
and 20%. Co-infection or super-infection with multiple strains in a subject can result in the 
emergence of a recombinant which has a mosaic genome composed of sequences from two 
or more distinct parental strains. Circulating recombinant forms (CRFs) are transmitted and 
spread within a population, whereas unique recombinant forms (URFs) are found only in an 
individual (Foley et al., 2018). There is significant increase in genetic diversity and prevalence 
of recombinants with over 100 CRFs reported to date (LANL, 2020). Subtype B dominates in 
Europe and America, whereas subtypes A, C and CRF02_AG are the most prevalent in Africa 
and CRF01_AE is mostly found in Asia (Bbosa et al., 2019). HIV diversity is constantly evolving 
with emergence of new strains and there has been an overall increase in the proportion of 
recombinant forms which accounted for almost a quarter (23%) of the global infections in 
the period between 2010 and 2015 (Hemelaar et al., 2019, Yamaguchi et al., 2020). 
 
1.1.2 Structural and functional properties 
HIV-1 is a round particle 100 nm in diameter which consists of three main structures: the 
envelope, the capsid and two molecules of single stranded ribonucleic acid (RNA). The 
envelope is an outer lipid bilayer membrane containing two viral glycoproteins (gp), the 
surface gp120 and the transmembrane gp41. Protein 24 (p24) is the main component of the 
conical capsid, which is covered by the matrix protein (p17). RNA is housed in two copies in 
the capsid along with important enzymes: protease, reverse transcriptase (RT), and 
integrase (Gelderblom, 1991). The HIV-1 genome is 9.2 kb in size and contains 9 open 
reading frames (ORF) encoding for 15 proteins. At the 5’ end is a long terminal repeat (LTR) 
followed by the gag gene, which encodes for the matrix and capsid proteins, and DNA 
polymerase (pol) gene, which is transcribed into the viral enzymes. At the 3’ end is also an 
LTR followed by the env gene encoding the precursor of envelope glycoproteins (gp160). 
ORFs are found between pol and the 3’ LTR and encode regulatory and accessory proteins 
that are important for gene expression and virus production (Figure 1.1). Of note, negative 
regulator factor (nef) and virus protein unique (vpu) facilitate immune escape by 
downregulating the expression of major histocompatibility complex class I (MHC-I) and 
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cluster of differentiation 4 (CD4) receptor in host cells (Deeks et al., 2015, Ghosn et al., 
2018).  
 
1.1.3 Viral replication cycle 
The human infectious dose of HIV-1 is estimated at 500-1,000 particles by any route of 
exposure (Zanetti et al., 2007). However, only one particle is required to enter a target cell 
and initiate recurrent cycles of replication for infection to be established. 
Gp120 binds to the CD4 receptor expressed on T lymphocytes, monocytes, macrophages, 
dendritic cells and astrocytes. This initial interaction drives a conformational change of 
gp120 with exposure of the V3 loop and additional binding sites which engage mainly the 
CC-chemokine receptor 5 (CCR5) found on memory T lymphocytes, macrophages and 
dendritic cells or alternatively the CXC-chemokine receptor 4 (CXCR4) on memory and naïve 
T cells. Based on preferential coreceptor use, the viral strain is defined as CCR5 tropic (R5), 
CXCR4 tropic (X4) or dual tropic (R5/X4). Co-receptor engagement is of paramount 
importance in the establishment of HIV infection and the transmitted virus is almost 
invariably a R5, since mucosal CD4 T cells express high levels of CCR5. A homozygous 
deletion of the Δ32 region of CCR5 gene offers natural resistance to infection with HIV-1 
(Allers and Schneider, 2015). During the course of infection, there may be a shift from CCR5-
tropic to CXCR4-tropic in some individuals (Deeks et al., 2015). 
Co-receptor engagement following the interaction between gp120 and the CD4 receptor 
results in fusion of viral gp41 into the cell membrane. Conformational changes within gp41 
including a critical folding step and the formation of a six helical hairpin-like structure brings 
the host cell membrane and viral envelope in close proximity. Host and viral membranes 
fuse with the formation of a pore through which the capsid containing viral RNA and 
enzymes enters the cell (Engelman and Cherepanov, 2012). 
The capsid shell then disassembles through a process called uncoating. This stage of the 
replication cycle is the most poorly understood. Three models propose that uncoating 
occurs immediately on viral entry, gradually as the virus moves from the entry point to the 
nucleus or before entering the nuclear pore (Campbell and Hope, 2015). Recent evidence 
shows that microtubule stabilisation is critical for virus capsid transport and release of its 
contents (Delaney et al., 2017). 
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Following uncoating reverse transcription of the HIV-1 RNA into double stranded 
deoxyribonucleic acid (DNA) occurs. RT has three enzymatic activities. First the RNA-
dependent DNA polymerase uses the viral RNA as template to synthesise a complementary 
DNA (cDNA) strand. Then the RNA strand is degraded with the RNAse H function. Eventually, 
the DNA-dependent DNA polymerase converts the single stranded cDNA to double helix 
DNA (Bhagavan and Ha, 2015). Of note is that cDNA is not an exact replicate of the original 
RNA due to a high error rate of RT with a frequency of 10−4 to 10−5 and lack of proof-reading 
ability. The error-prone transcription process results in the generation of mutant variants 
called quasispecies. A portion will escape immunological protective mechanisms and will 
become dominant. Others will have an impaired replication machinery resulting in reduced 
fitness and will either vanish or replicate at low level (Malim and Emerman, 2001). RT is also 
responsible for the generation of recombinant variants by its ability to switch from one RNA 
template to another in cells infected with different viruses (Delviks-Frankenberry et al., 
2011). Therefore, genetic diversity, a key characteristic of HIV infection and persistence, 
emerges mainly at the stage of cDNA generation. However, mutations are not only 
attributed to RT activity. The apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like (APOBEC) family, a host nucleic acid editing enzyme, adds to the genetic diversity by 
switching cytosine with thymine. Mutations occurring at other stages of the viral lifecycle, 
such as during viral gene transcription by host cellular RNA polymerase II, contribute less to 
genetic variation (Smyth et al., 2012). 
cDNA accompanied by viral and cellular proteins called the pre-integration complex is 
transferred to the nucleus. The complex enters the nucleus through pores and HIV DNA is 
integrated in a random site of host DNA forming the provirus. Integrase catalyses the release 
of a dinucleotide from the 3’ end of the HIV DNA exposing a conserved oligonucleotide 
region on the complementary strand (3’ processing). During a second reaction (strand 
transfer), integrase assists the formation of a covalent bond between the exposed viral 
region and host nuclear DNA (Craigie, 2012).  
The vast majority of cDNA is unintegrated (episomal DNA) and forms into a circle with one 
or two LTR regions (1- or 2-LTRc DNA). Linear episomal DNA survives for up to one month 
before being degraded, whereas LTRc DNAs are regarded as more stable.  Circular DNAs 
have been recently reported to contribute to HIV protein expression, such as nef and trans-
activator of transcription (tat). Although the levels of expression are very low, they are 
sufficient to trigger immune responses (Thierry et al., 2016). 
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In activated cells, viral gene expression is driven by host nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and nuclear factor of activated T cells (NFAT) and a 
promoter at 5’ LTR region of the viral DNA (Pessler and Cron, 2004, Stroud et al., 2009). The 
integrated viral DNA is transcribed into genomic and messenger ribonucleic acid (mRNA) by 
cellular enzymes the same way as host genes. mRNA is translated into viral proteins at 
cellular ribosomes and the accruing proteins depend on the degree of splicing. Unspliced 
mRNA produces the gag and gag-pol polyprotein which contain structural proteins (p17, 
p24, nucleocapsid or p7 and p6) and enzymes (protease, RT and integrase), respectively. 
Partially spliced mRNAs encode envelope and accessory (viral infectivity factor (vif) and vpu) 
proteins and fully spliced transcripts encode the regulator of expression of virion proteins 
(rev), tat, viral protein R (vpr) and nef. Viral particles are transformed into mature and 
infectious virions by protease-mediated cleavage of the gag-pol and gag polyprotein 
transcripts sequentially into nine sites. This action yields all important enzymes for HIV 
replication including RT, integrase and protease and a structural transformation to form the 
conical capsid core. Genomic RNA and viral precursor proteins assemble in the cytoplasm. 
Envelope proteins are transported to the cellular membrane and the viral envelope is 
acquired during budding (Dunn et al., 2002, Pedersen et al., 2011). 
 
1.1.4 Pathogenesis 
HIV is transmitted through body fluids such as blood, genital secretions and breast milk. 
Blood transfusion and mother-to-child transmission from an HIV infected source have the 
highest risk of HIV acquisition (9,250 infections and 2,260 infections per 10,000 contacts, 
respectively). However, these risks have nearly been eliminated due to laboratory testing of 
donated blood products and use of prophylactic anti-retroviral therapy (ART), respectively. 
Sexual exposure is the most frequent mode of transmission with HIV acquisition among 
discordant heterosexual couples accounting for nearly 70% of all infections globally. 
Receptive anal intercourse carries the highest risk (138 infections per 10,000 contacts) 
followed by injection drug use with sharing equipment (63 infections per 10,000 contacts) 
(Patel et al., 2014). Preventive strategies include the use of condoms, pre- and post- 
exposure prophylaxis with ART, male circumcision and above all early diagnosis and 
treatment initiation of those infected (Crepaz et al., 2015, Marrazzo, 2017, Rodger et al., 
2019, Rodger et al., 2016). 
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Effective transmission is instigated by a single founder virus, or a few genetic variants, which 
is fit enough to establish a productive infection. The virus spreads rapidly after transmission 
and establishes latent infection at the site of infection and then draining lymph nodes and 
eventually distal lymph nodes and mucosal-associated lymphoid tissue (Ananworanich et 
al., 2016, Keele et al., 2008a). The SIV macaque model has demonstrated that the latent 
reservoir, which is responsible for persistence despite effective treatment, is established in 
the first three days after infection (Whitney et al., 2014). HIV-1 RNA is detected in plasma 
around day 10 post infection (Fiebig I) and peaks in the following 2-4 weeks, coinciding with 
a transient reduction in CD4 T cell counts. Testing for p24 antigen can give a diagnosis of HIV 
around day 17 post infection (Fiebig II) (Fiebig et al., 2003). An immune response is initiated 
and seroconversion occurs with the clinical detection of antibodies against HIV around day 
22 (Fiebig III). This is often accompanied by a non-specific clinical syndrome comprising 
fatigue, fever, rash, lymphadenopathy, headache and diarrhoea. Onset of immune 
responses is accompanied by a reduction in viraemia and partial recovery of CD4 cell counts. 
At this point viral reservoirs are well-established within memory CD4 T cells, naïve CD4 T 
cells, cells of the monocyte and macrophage lineage and potentially other long-lived cells. 
Viral gene transcription is silenced in latently infected cells by complex mechanisms such as 
transition to a resting state and expression of immune checkpoints which down-regulate 
cellular activity (Ghosn et al., 2018). 
The levels of HIV-1 RNA in plasma – described as the viral load – decline to a semi-stable 
level within the first 6 months of the infection. The viral set point varies among individuals 
from a few copies to 106 copies per mL of blood depending on viral and host factors. In 
untreated patients, the viral load set point is predictive of the rate of disease progression 
(Deeks et al., 2015). Primary HIV infection is followed by the clinically asymptomatic phase, 
which is characterised by ongoing virus replication and chronic immune activation. These 
processes  gradually lead to a progressive exhaustion of immune responses which is 
reflected in a gradual decrease of the CD4 cell count at a rate predicted by the viral set point 
(Mellors et al., 1996). Eventually, severe immunodeficiency occurs, typically around 8 years 
from initial infection and once CD4 cell count drops below 200 cells/mL. At the final stage of 
AIDS there is an increase in viral load and a profound clinical deterioration characterised by 
recurrent infections, cancers, cachexia and eventually death (Pantaleo et al., 1993). 
The lag in time between transmission and antibody seroconversion can result in missed 
diagnoses if antibody-based assays are used (Geretti, 2017). Fourth generation tests detect 
22 
 
p24 antigen and antibodies (immunoglobulin (Ig) M and G) decreasing the period between 
infection and a positive result to 2-3 weeks. Earlier diagnosis can be achieved with RNA 
detection in the plasma with reverse transcriptase polymerase chain reaction (RT-PCR) 
assays around 10 days after infection (Delaney et al., 2016) (Figure 1.2). 
 
1.1.5 Anti-retroviral therapy 
Since Food and Drug Administration (FDA) approval of zidovudine (AZT), the first anti-
retroviral drug, in 1987, enormous advances have been achieved in HIV treatment, 
increasing substantially life expectancy of infected individuals (FDA, 2018, Mocroft et al., 
2003, Samji et al., 2013). Most recent data reveal that timely diagnosis and lifelong 
adherence to current drugs ensure a life expectancy almost the same as the healthy 
population (Trickey et al., 2017). Combination ART has led to an era of clinically sustained 
virological suppression for patients who remain on therapy continuously and without 
interruptions (Geretti and Tsakiroglou, 2014). Yet, immunological damage that occurred 
early in the course of infection is not completely reversed and persists despite long-term 
treatment (Deeks et al., 2015). Seven classes of antiretrovirals block various steps of the 
viral replication cycle (Table 1.1). 
Inhibition of HIV entry in host cells is achieved by compounds that interact with proteins on 
target cells or HIV particles which are involved in attachment, co-receptor binding and fusion 
(Kuritzkes, 2009). Maraviroc is a CCR5 antagonist that binds to the transmembrane region 
of the CCR5 preventing the interactions between the V3 loop of gp120 and the host cell co-
receptor. Maraviroc is active against R5 virus and tropism should be determined prior to 
use. Yet, failure of maraviroc may occur if X4 or R5/X4 quasispecies pre-exist and become 
dominant under pharmacological pressure. Otherwise, mutations causing resistance to 
maraviroc in R5 virus are rare. It is metabolised by cytochrome P450 and dose adjustments 
are required with concurrent use of CYP450 inducers or inhibitors. Maraviroc is well-
tolerated and the most frequent side effect is postural hypotension. It has been proposed 
to have immunomodulatory properties and, hence, trialled in inflammatory conditions, such 
as rheumatoid arthritis and non-alcoholic liver disease  (Lewis et al., 2018). Enfuvirtide (T-
20) is a fusion inhibitor targeting gp41. It is administered subcutaneously twice daily and 
injection site reactions are very common. The humanised monoclonal antibody ibalizumab 
is a post-attachment inhibitor which binds on CD4 receptors hindering interaction between 
CD4-bound gp120 and CCR5 or CXCR4 (Beccari et al., 2019, Kuritzkes, 2009). More entry 
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inhibitors (e.g. fostemsavir, leronlimab) are under development or in clinical trials (Cahn et 
al., 2018, Thompson, 2018). Guidelines reserve entry inhibitors for patients with multiple 
drug resistance or poor tolerability (DHHS, 2018, EACS, 2018). 
Nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTI and NNRTI) interact 
with RT inhibiting virus RNA conversion to cDNA (Table 1.1). NRTIs are nucleoside and 
nucleotide analogues which undergo phosphorylation by host enzymes into active 
triphosphate and diphosphate derivates, respectively. These active forms incorporate into 
nascent cDNA preventing further nucleotide addition and terminating the extension of the 
chain. Many NRTI resistance mutations impair virus fitness and antiviral activity is 
maintained. Also, cross-resistance among NRTIs does not always occur. A methionine to 
valine substitution at amino acid position 184 (M184V), for instance, reduces binding of the 
NRTI. M184V is selected by lamivudine, emtricitabine and abacavir causing high-level 
resistance to lamivudine and emtricitabine, but limited resistance to abacavir and increased 
susceptibility to tenofovir and zidovudine. Tenofovir is the most widely used NRTI and it is 
formulated as two prodrugs, tenofovir disoproxil fumarate (TDF) and the most recently 
developed tenofovir alafenamide fumarate (TAF). A combination of tenofovir with 
emtricitabine and a third agent is an effective first-line regimen. NRTI side effect profile 
includes peripheral neuropathy, lipoatrophy, pancreatitis and hepatic steatosis which are 
the consequences of mitochondrial toxicity and more frequent with older NRTIs such as 
stavudine (Lewis et al., 2003). Tenofovir can cause proximal tubulopathy with a broad 
spectrum of presentations (e.g. acute kidney injury, Fanconi syndrome, nephrogenic 
diabetes insipidus) particularly in patients with pre-existing kidney dysfunction. Also, 
patients on TDF may experience decreased bone mineral density (Bedimo et al., 2016). TAF 
has improved intracellular bioavailability and renal and bone toxicity profile compared to 
TDF (Sax et al., 2015), but appears to be associated with weight gain (Taramasso et al., 2020). 
Abacavir in combination with lamivudine and dolutegravir is an effective and frequently 
used regimen. Between 5% and 8% of patients develop a hypersensitive reaction which can 
be predicted by testing positive for human leukocyte antigen B*5701 (HLA-B*5701). 
Abacavir has also been associated with cardiovascular disease in patients with increased risk 
(Hetherington et al., 2001, Sabin et al., 2008). 
NNRTIs bind to a pocket near the active site of RT causing a conformational change which 
impairs its enzymatic activity. NNRTIs have a low genetic barrier to resistance and significant 
cross-resistance. Older NNRTIs are nevirapine and efavirenz and more recent are etravirine 
and rilpivirine which were followed by doravirine. Efavirenz was the preferred third agent in 
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first-line ART but its central nervous system (CNS) toxicity and the introduction of integrase 
strand transfer inhibitors (InSTIs) resulted in being phased out. Rilpivirine, on the other 
hand, is better tolerated than efavirenz. Due to increased risk of virological failure and 
emergence of cross-resistance mutations with higher levels of HIV-1 RNA in plasma, 
rilpivirine is recommended only for patients with viral load less than 100,000 copies/mL 
(Sanford, 2012). Doravirine is expected to overcome these drawbacks and may retain 
activity in the presence of some resistant mutations (Cohen et al., 2013, Colombier and 
Molina, 2018). NNRTIs have a long plasma half-life and drug levels are maintained 
therapeutic if a dose is missed occasionally. However, resistance mutations are easily 
developed if triple ART is discontinued as they remain for longer periods in blood (Geretti et 
al., 2013b). Common side effects resulting in drug class switch are neuropsychiatric 
disorders (e.g. vivid dreams, confusion), lipid abnormalities, hepatoxicity, skin rash, nausea 
and prolonged QT interval.  
InSTIs block integrase from joining the processed viral DNA ends in the host genome by 
binding to the pre-integration complex probably before it enters the nucleus (Pandey and 
Grandgenett, 2008). Second generation InSTIs, such as dolutegravir and bictegravir have a 
higher genetic barrier to resistance compared to raltegravir and elvitegravir (first generation 
InSTIs) and are currently the preferred choice for treatment initiation (Blanco et al., 2011, 
Doyle et al., 2015, Oliveira et al., 2018). Cabotegravir, an analogue of dolutegravir, is 
currently in phase 3 trials. Its long-acting nanoparticle injection formulation combined with 
long-acting rilpivirine is the most advanced long-acting regimen  (Stellbrink and Hoffmann, 
2018). Dolutegravir is currently the preferred third agent for first-line ART (DHHS, 2018, 
EACS, 2018), because comparative studies have demonstrated its superiority over efavirenz 
or boosted darunavir based regimens with improved safety profile and rapid viral load 
suppression (Osterholzer and Goldman, 2014). The most frequent side effects include 
weight gain, insomnia and neuropsychiatric disorders.  
Protease inhibitors (PIs) stop particle maturation through competitive binding to the viral 
protease and prevention of subsequent cleavage of gag and gag-pol polypeptides (Voshavar, 
2019).  Ritonavir and cobicistat are CYP3A4 inhibitors and are used as pharmacokinetic 
enhancers for PIs (and elvitegravir), which are metabolised by CYP450 (Larson et al., 2014). 
Boosted darunavir and atazanavir are currently the recommended PIs used in combination 
regimens or as stand-alone drugs (DHHS, 2018). They may not be first-line options due to 
their increased risk of side effects and drug-drug interactions, but their high barrier to 
resistance makes them the cornerstone in patients with drug mutations and adherence 
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issues (Geretti et al., 2019). PIs have a marked profile of side effects including metabolic 
dysfunction (e.g. insulin resistance, hyperlipidaemia) and increased risk of cardiovascular 
disease, gastrointestinal side effects, hepatotoxicity, lipodystrophy and PR interval 
prolongation (Echecopar-Sabogal et al., 2018). Atazanavir and darunavir are probably the 
most well-tolerated PIs. However, atazanavir can cause renal toxicity and 
hyperbilirubinemia (Voshavar, 2019). Drug-drug interactions are also common with PIs. For 
instance, absorption is decreased with co-administration of stomach acid lowering drugs.  
Standard ART usually consists of a combination of two NRTIs, referred to as the “backbone”, 
and a third agent. Currently the preferred third agent is an InSTI (dolutegravir), which has 
replaced NNRTIs or PIs from first-line options (DHHS, 2018). Therapy choice depends on 
pharmacological and pharmacodynamic properties (e.g. PIs have high genetic barrier to 
resistance), individual circumstances (e.g. PIs are preferred if adherence is an issue), 
virological characteristics (e.g. NNRTI mutations causing drug resistance are frequent), 
tolerability (e.g. patients may become intolerant to efavirenz due to neurological toxicity) 
and ease of use (e.g. single tablet once daily formulations) (Yombi and Pozniak, 2016) . 
Since ART is life-long, minimising drug exposure, risk of toxicity and cost are paramount 
aspects which make dual therapy appealing (Achhra et al., 2016). A meta-analysis of 
randomised controlled trials comparing dolutegravir/lamivudine with triple agent regimes 
for ART initiation revealed similar virological efficacy over a period of 48 weeks (Radford et 
al., 2019b). Two-drug combinations have also been tested as a simplification strategy in 
stably suppressed patients on triple ART (Achhra et al., 2016, Llibre et al., 2018). 
Dolutegravir/rilpivirine has been shown to be a good alternative for maintenance of 
suppression while lamivudine in combination with dolutegravir, boosted atazanavir or 
boosted darunavir is also supported by good evidence (Calza et al., 2018, Llibre et al., 2018, 
Radford et al., 2019a). European and North American guidelines have adapted 
dolutegravir/lamivudine and dolutegravir/rilpivirine for first line therapy and treatment 
switch, respectively, in selected adults (DHHS, 2018, EACS, 2018). Nonetheless, long-term 
data and larger studies are required to confirm the efficacy of various 2-drug combinations. 
ART can successfully suppress viral replication, but it cannot eradicate HIV.  A significant 
decrease in plasma HIV-1 RNA levels is noted to a level below 50 copies/mL within six 
months after ART initiation, with subsequent immune reconstitution (Maldarelli et al., 2007, 
Perelson et al., 1997). However,  virus rebound to pre-treatment levels occurs nearly always 
in case of ART discontinuation (Bailey et al., 2006, Chun et al., 2010, Harrigan et al., 1999, 
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Jubault et al., 1998, Maggiolo et al., 2012, Palmer et al., 2008). The reason is that latently 
infected reservoirs established early during infection are not targeted by ART (Chun et al., 
2011, Chun et al., 1997, Finzi et al., 1997, Palmer et al., 2011, Ruggiero et al., 2015, Shen and 
Siliciano, 2008b, Siliciano et al., 2003). Proliferation of HIV-harbouring cells maintains the 
reservoirs and it can be antigen-driven, homeostatic through cytokine pathways or due to 
activation of genes controlling cell cycle progression by integrated HIV sequences (Chomont 
et al., 2009, Maldarelli et al., 2014, Simonetti et al., 2016, Wagner et al., 2014, Wang et al., 
2018). 
ART preserves and partly restores immune functions, reducing chronic T cell activation and 
inflammation. As a result, the risk of both AIDS-defining and non-AIDS illnesses (e.g., 
cardiovascular disease) is minimised (Appay and Kelleher, 2016, Nou et al., 2016, Younas et 
al., 2016). Moreover, the absence of seroconversion among HIV discordant couples where 
the positive partner is under treatment indicates the important role of early ART initiation 
in transmission and control of the HIV pandemic (Anglemyer et al., 2011, Rodger et al., 
2019). HIV infection in countries with widely available access to ART is a chronic, usually 
well-controlled disease, as long as compliance with therapy is maintained. In 2017, the 
United Kingdom (UK) met the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-
90-90 target with 92% of infected people being diagnosed, 98% of people diagnosed with 









LTR: long terminal repeat; gag: group-specific antigen; p: protein; pol: DNA polymerase; vif: 
virion infectivity factor; vpr: viral protein R; tat: trans-activator of transcription; rev: 
regulator of expression of virion proteins; env: envelope; vpu: viral protein unique; gp: 








During the eclipse phase HIV-1 is replicating at the mucosal tissue and draining lymph nodes 
causing an increase in acute phase proteins. Around day 10 (T0) HIV-1 RNA can be detected 
in the plasma and there is an interferon response to the spread of the virus. As HIV-1 RNA 
levels increase exponentially antibody and CD8 cytotoxic T lymphocyte responses take place 
which can control viral replication only partially due to rapid viral escape. Eventually complex 
virus-host interactions create a steady level of viraemia. 
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Table 1.1: Anti-retroviral classes and drugs (AIDSinfo, 2019). 
 









abacavir (abacavir sulfate, ABC) Ziagen 
emtricitabine (FTC) Emtriva 
lamivudine (3TC) Epivir 
tenofovir disoproxil fumarate (tenofovir DF, TDF) 
tenofovir alafenamide (TAF) 
Viread 
Vemlidy1 






doravirine (DOR) Pifeltro 
efavirenz (EFV) Sustiva 
etravirine (ETR) Intelence 
nevirapine (NVP) Viramune 




atazanavir (atazanavir sulfate, ATV) Reyataz 
darunavir (darunavir ethanolate, DRV) Prezista 
fosamprenavir (fosamprenavir calcium, FOS-APV, FPV) Lexiva  
lopinavir (LPV) Kaletra2  
ritonavir (RTV, r)3 Norvir 
saquinavir (saquinavir mesylate, SQV) Invirase 
tipranavir (TPV) Aptivus 
Fusion inhibitors enfuvirtide (T-20) Fuzeon 
CCR5 
antagonists 





bictegravir (bictegravir sodium, BIC) Biktarvy4 
dolutegravir (dolutegravir sodium, DTG) Tivicay  
elvitegravir (EVG) Vitekta  













cobicistat (COBI, c) Tybost 
 
1: Stand-alone TAF is not FDA approved for HIV but is approved for treating chronic HBV 
infection 
2: Lopinavir in combination with ritovavir 
3: Ritonavir is a PI which is used as a pharmacokinetic enhancer for other protease inhibitors 




1.2 Viral load monitoring 
 
1.2.1 Viral load 
Viral load, defined as HIV-1 RNA copies per mL of plasma, was early identified as a 
measurable predictor of clinical outcomes including rate of CD4 decrease, progression to 
AIDS and risk of death (Mellors et al., 1997). Viral load, in conjunction with CD4 counts, was 
originally used for prognosis and guided ART initiation and monitoring (Saag, 1997, Wei et 
al., 1995, Young et al., 2015). The target was to suppress viral load at levels below the assay 
quantification limits which were around 400 copies/mL for first generation assays (Churchill 
and Weber, 1999, Saag et al., 1996). Quantification of HIV-1 RNA levels in plasma can predict 
treatment failure earlier than CD4 count and it is not required to be performed more than 
twice annually in stable patients (BHIVA, 2019, DHHS, 2018, EACS, 2018, Geretti, 2009, 
Young et al., 2015). Eventually viral load became the gold standard and only surrogate 
marker for monitoring long-term clinical response to therapy (BHIVA, 2019, DHHS, 2018, 
EACS, 2018) and CD4 count measurements are performed less frequently. Viral load serves 
as an indicator of virus control and risk of transmission (Quinn et al., 2000, Rodger et al., 
2019, Rodger et al., 2016).  
Samples can be easily obtained, transported and processed on automated platforms. The 
half-life of HIV in plasma at body temperature is two days, but this increases at lower 
temperatures (Moudgil and Daar, 1993). Hence, transport of whole blood in 
ethylenediamine tetraacetic acid (EDTA) tubes allows 72 hours of RNA stability at room 
temperature with minimal degradation (Bonner et al., 2014). However, samples from 
patients with viraemia <200 copies/mL should be processed within 4-8 hours after collection 
to avoid cell lysis. Blood cells infected with HIV-1 can release viral DNA upon lysis and if the 
assay employs total nucleic acid extraction method, contaminant HIV-1 DNA can be 
measured along with RNA during the amplification step (Fernandes et al., 2010).  
Technical characteristics and accuracy of clinical assays has improved significantly over time 
with lower limits of quantification reducing from 400 copies/mL with first generation assays 
to 50 copies/mL with second generations assays and to 40 and 20 copies with the most 
popular third generation assays traded by Abbott (RealTime HIV-1 Viral Load assay, which 
will be referred to as RealTime in this work) and Roche (COBAS® AmpliPrep/COBAS® 
TaqMan® HIV-1 Test, v2.0, which will be referred to as TaqMan v2), respectively (Doyle and 
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Geretti, 2012). Four major technologies have been developed for viral load measuring: RT-
PCR, nucleic acid sequence-based amplification (NASBA), branched-chain DNA (bDNA) and 
the most recently FDA approved transcription-mediated amplification (TMA). Currently real-
time RT-PCR and TMA remain in commercial use and will be described in more details below, 
whereas NASBA and bDNA are phased out. Overall commercial viral load assays have similar 
accuracy, quantitation range and technical characteristics (Wang et al., 2010). Studies 
comparing the two most widely used third-generation assays (the RealTime and TaqMan 
v2.0) show good correlation for all HIV-1 subtypes. However, discordances occur for low 
level viraemia and around the lower quantitation limit (Doyle and Geretti, 2012). 
 
1.2.2 Commercial assays used in clinical settings 
1.2.2.1 RT-PCR 
FDA approved the Roche Amplicor HIV-1 Monitor Test (referred to as Amplicor) for 
quantitation of viral load in the summer of 1996 (FDA, 2018). Since then RT-PCR for HIV-1 
RNA detection and quantitation is the gold standard clinical tool for viral load monitoring in 
a two-step enzymatic process (RT and PCR step). Primers, nucleotides, enzymes and 
template RNA are mixed together and undergo one thermal cycle of annealing and 
extending that derives the cDNA. Purified HIV-1 RNA is used as template to be converted to 
a more stable form of cDNA. Then cDNA is amplified through recurrent thermal cycles (30-
40) of template denaturation (temperature (T) >900C), primer annealing (T: 50-750C) and 
elongation (T: 72-780C) to exponentially produce the amplicon of a DNA region (Mackay et 
al., 2002).  Primers choice is probably the most important aspect in design, as they should 
achieve template specificity, thermodynamic stability and functional agreement in the 
mixture (Farrell, 2010). Quantitation of the amplicon happens as a fluorescence signal 
accumulates with nucleotide consumption (real-time).  Meaningful results accrue from 
absolute or relative quantitation, where a standard curve or a control sample are used as 
reference, respectively (Farrell, 2010b). Assays report a lower limit of quantitation (LLoQ) 
and a limit of detection (LoD) (CLSI, 2012). LLoQ is the lowest concentration of HIV-1 RNA 
that can be reliably quantified within a total error of usually 1 log copies/mL. The LLoQ is 
determined by testing serial dilutions of the 3rd HIV-1 World Health Organisation (WHO) 
International Standard (subtype B) and it is verified across subtypes and groups. The highest 
LLoQ for all subtypes and groups is chosen. The LoD is the concentration of HIV-1 RNA that 
is detected with at least 95% probability and it is determined in a similar way as the LLoQ 
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through Probit analysis. A value is reported for samples with HIV-1 RNA levels equal or above 
the LLoQ and a qualitative result (“target detected”) is returned for samples with viral load 
between the LLoQ and LoD. Viral load is reported as “target not detected” if it is below the 
LoD. Real-time RT-PCR reduces process time, has good sensitivity and precision and 
minimises contamination risk (Mackay et al., 2002).  
The Amplicor assay utilised end-point RT-PCR technology by targeting the gag region of HIV-
1 genome with a single enzyme for both the conversion and amplification steps (Mulder et 
al., 1994). It had an upper limit of quantitation at 10,000,000 copies/mL and a LLoQ at 400 
copies/mL with version 1.5 or 50 copies/mL with the ultrasensitive assay (Sun et al., 1998). 
The introduction of the COBAS® AmpliPrep instrument upgraded the assay (COBAS® 
AmpliPrep/COBAS® Amplicor HIV-1 Monitor Test, version 1.5) by performing a fully 
automated HIV-1 RNA extraction and purification from plasma samples (COBAS AmpliPrep 
platform) (Germer et al., 2007). End-point assays dominated at clinical laboratories for over 
a decade until 2008 when the replacement by real-time RT-PCR started (de Mendoza and 
Soriano, 2009, Holodniy, 2006). Yet, most data demonstrating ART efficacy and the 
predictive role of viral load suppression accrued with the utilisation of the Amplicor 
technology. 
The COBAS® rival AmpliPrep/TaqMan® HIV-1 Test utilised real-time RT-PCR technology with 
earlier versions targeting highly conserved regions within the gag gene and a LLoQ at 40 
copies/mL. However, studies showed significant bias in reported values with mean 
differences exceeding 1 log10 copies/mL when compared with viral load testing by other real-
time platforms such as the RealTime (Wirden et al., 2011). Roche identified that genetic 
variability for group M and non-B subtypes resulted in primer or probe mismatches and 
underestimation. Hence, they upgraded to version 2.0 which incorporates a dual target 
strategy amplifying highly conserved gag and LTR sequences and achieving a LLoQ at 20 
copies/mL (Roche Molecular Systems, 2018, Schumacher et al., 2007). TaqMan probes (25-
30 nucleotides) are single stranded and carry a fluorescence reporter at 5’ end and a 
quencher absorber at 3’ end. The probe hybridizes with its complimentary DNA sequence 
and it is cleaved by a DNA polymerase which disassociates the fluorescence reporter from 
the quencher with signal emission. During an effective process the signal aggregates with a 
rate proportional to the amount of the original target RNA and the machine records the 
cycle at which it overcomes background (CT). The CT values are used in a calculation with the 
CT values from internal standards (and competitive control as indicator of PCR inhibition) to 
report viral load in copies/mL (Liegler TJ and RM, 2009). 
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Abbott entered commercial competition with the RealTime which also adapts a fully 
automated extraction process to purify RNA from whole blood samples (m2000sp platform). 
The principle in methodology is similar to Roche assays with conversion of RNA to cDNA, 
amplification and fluorescent detection. However, Abbott technology targets a highly 
conserved integrase region within the pol gene. Abbott probe is also partially double 
stranded with reporter and quencher being on each strand and signal emission occurring 
upon uncoupling. The rationale is to allow hybridization at lower temperatures with 
tolerance to mismatches and genetic variability (Johanson et al., 2001). Also, Abbott uses a 
non-competitive internal control (hydroxypyruvate reductase of pumpkin) to indicate PCR 
inhibition events. As to method of quantitation, a stored standard curve, calibrated at each 
run, is used in a linear regression model with the input of the CT value for each sample to 
return the quantity of HIV-1 RNA in copies/mL. The LLoQ is 40 copies/mL (Abbott, 2018, 
Tang et al., 2007). 
The Versant HIV-1 RNA kinetic PCR assay by Siemens Diagnostics (referred to as Versant 
kPCR) employs a real-time (or kinetic) PCR method to target a highly conserved region within 
the pol gene utilising TaqMan probes which emit signal upon unfolding during the 
amplification step. It involves automated sample preparation, an internal control and two 
external quantitation standards. LLoQ is 37 copies/mL (Ruelle et al., 2009). 
The Xpert® HIV-1 Viral Load assay by Cepheid (referred to as Xpert) prequalified by WHO in 
2017.  Xpert is based on real-time RT-PCR targeting a region within LTR and it detects group 
M (subtypes A, B, C, D, AE, F, G, H, AB, AG, J, and K) and groups N and O. Its LLoQ is 40 
copies/mL and its upper limit is 10,00,000 copies/mL. It requires minimal training (fully 
automated) and moderate infrastructure (single cartridge containing all reagents and 
internal controls) to provide rapid (within 90 minutes) and accurate results. The same 
platform can also be used for testing for a variety of infections including tuberculosis and 
hepatitis B and C. A systematic review (12 studies included) showed good performance of 
the Xpert assay compared to current reference tests (Nash et al., 2018). It is a reliable tool 
for viral load monitoring and detection of treatment failure in the clinic including resource-
limited settings (Sacks et al., 2019, Villa et al., 2020). 
1.2.2.2 TMA 
The Hologic Aptima HIV-1 Quant Dx assay (referred to as Aptima) received FDA approval for 
viral load monitoring in 2016. It is a fully automated process (Panther system) involving 
target capture, TMA and fluorescent detection. With the exception of the TMA step the rest 
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of the process has many similarities with RT-PCR methods. TMA is also a transcription-
mediated nucleic acid amplification method, but with some important differences. HIV-1 
RNA is isolated from plasma samples and captured by oligonucleotides targeting a highly 
conserved region of the HIV-1 genome. The hybridised RNA is separated with magnetic 
microparticles and a magnetic field. Purified viral RNA is converted to DNA by a reverse 
transcriptase, which is used as template for the production of multiple RNA copies by a T7 
RNA polymerase. Two target regions within pol and LTR are amplified. Single-stranded 
nucleic acid torches hybridise to the RNA amplicon in real-time and as result the quencher 
moves away from the fluorophore allowing for the signal to emit. An internal control is 
present at each reaction to ensure amplification efficiency and quantitation of target RNA. 
The concentration of the HIV sample and the internal control are determined on a 
calibration curve. The linear range of quantitation is between 30 and 10,000,000 copies/mL 
and LoD is around 12 copies/mL with some variation across subtypes and groups (e.g. 17 
copies/mL for subtype G). Equally the LLoQ is 10 copies/mL for B subtypes and from 10 to 
30 copies/mL for non-B subtypes (Hologic, 2017). Contrary to RT-PCR, the whole process 
takes place at the same temperature. Comparative studies have shown that the Aptima 
assay is precise, accurate, sensitive and concordant with widely used assays including the 
RealTime and the TaqMan v2.0 (Longo et al., 2018, Wiesmann et al., 2018).  
 
1.2.3 Historical assays 
1.2.3.1 NASBA 
NASBA methodology comprises of iso-thermal amplification of RNA and detection of target 
sequences (gag originally and then LTR) based on electro-chemiluminescence (end-point) or 
molecular beacon (real-time) technologies (Deiman et al., 2002). The NucliSens HIV-1 QT 
assay was commercialised by bio Mérieux in 1995. A second generation assay with a 
quantitation range of 176 to 3,470,000 copies/mL received FDA approval in 2001 (Ginocchio 
et al., 2003). The NucliSens EasyQ HIV-1 version 2.0 was an update incorporating an 
automated process and molecular beacons for target quantitation (Xu et al., 2010). 
According to literature the NASBA technology is as accurate as PCR, if not more sensitive, 
for the quantitation of HIV-1 RNA levels (Ginocchio et al., 2003, Mourez et al., 2015, 
Notermans et al., 2000, Shepard et al., 2000). However, interlaboratory variability has been 
reported more frequently than other assays probably due to free choice of extraction 





The representative of bDNA technology was the Versant HIV-1 RNA 3.0 assay by Siemens 
Medical Solutions (previous versions known as Quantiplex). HIV RNA is not purified but 
released with a lysis step and captured on a microwell coated with oligonucleotides with 
homology to conserved regions of the pol gene. Another set of nucleotides target HIV RNA 
and amplify the signal by binding at multiple sites. There is no transcription of viral RNA. 
Detection is by chemiluminescence and determined from a standard curve. The range of 
quantitation is 75 to 500,000 copies/mL (Collins et al., 1997, Liegler TJ and RM, 2009). Under-
quantification has been shown with the Siemens bDNA assay and reports demonstrate 
consistently lower values compared to other technologies (Senechal and James, 2012). 
1.2.3.3 ELISA 
Enzyme-linked immunosorbent-based assays (ELISA), such as ExaVir RT (Cavidi) were 
inexpensive and simple assays used at resource limited settings  (Boni et al., 1997, Labbett 
et al., 2009, Pascual et al., 2002, Stevens et al., 2005). The ExaVir RT assay measured RT 
activity on a poly-A oligonucleotide template with an incorporated alkaline phosphatase 
colorimetric assay. RT activity correlated with signal intensity. Version 3.0 had a LLoQ 
corresponding to viral load of 200 copies/mL (Labbett et al., 2009).  
 
1.2.3 Ultrasensitive HIV-1 RNA assays used in research settings 
Ultrasensitive assays with a cut-off as low as a single copy, or near single copy, of HIV-1 RNA 
per mL of plasma have been developed for research purposes (Palmer et al., 2008). They 
require large volumes of sample which is either concentrated or tested in replicates. 
Samples are usually intensively processed before quantitation and operator-led over 
automated steps analogy varies (Table 1.2). Commercial platforms or in-house RT-PCR 
technology targeting highly conserved regions of the HIV-1 genome are usually utilised to 
measure residual virus presence (Amendola et al., 2011, Hatano et al., 2009, Margot et al., 
2018, Palmer et al., 2003, Yukl et al., 2011). 
Ultrasensitive assays attempt to shed light on viral kinetics during suppressive ART and 
predict the risk of virological failure in patients with residual levels of virus presence in the 
blood or other compartments which are not detected with commercial assays (Palmer et al., 
2008). First-generation single copy assays (SCA) targeted HIV-1 gag with higher rates of 
primer mismatch and larger volumes of sample (7 mL). A subsequent SCA targeted a highly 
37 
 
conserved region of integrase (iSCA) in x3 concentrated samples from an original volume of 
3 mL (Cillo et al., 2014). Based on the iSCA a clinical study showed that all samples from 
patients on suppressive ART reported as “target not detected” with the TaqMan v2.0 had at 
least 1 copy of HIV RNA. Interestingly, samples with viral loads above 20 copies/mL appeared 
to measure lower with the iSCA indicating some overestimation with the Roche platform 
(Margot et al., 2018). An update version of iSCA (v2.0), which uses a greater proportion of 
total extracted nucleic acid for HIV-1 RNA quantitation, increased the number of samples 
with detected HIV-1 RNA by almost one third and more than doubled the amount of 
copies/mL (Tosiano et al., 2019). Automated platforms testing multiple replicates with single 
copy sensitivity are currently under development (Bakkour et al., 2019). 
Lack of standardisation of SCA results in significant variation in methodology, input plasma 
volume and detection limit. Hence, findings may be conflicting and non-comparable. Of 
note, commercial assays report discrepant results towards their LLoQ even within the same 
platform (Doyle and Geretti, 2012, Ruelle et al., 2012). Nevirapine compared to efavirenz 
and lopinavir/ritonavir appeared to have a virological advantage in patients with HIV-1 RNA 
in plasma less than 2 copies/mL as measured with a modified protocol of the Amplicor v1.5 
(Bonora et al., 2009). A SCA-based study also supported the claim that nevirapine may be 
better than efavirenz in suppressing virus replication (Haim-Boukobza et al., 2011). No such 
correlation, though, was found in a study comparing nevirapine with PI-based therapy 





Table 1.2: Characteristics of representative single copy assays. 
 
Reference (Palmer et al., 2003) (Yukl et al., 2011) 
(Hatano et al., 
2009) 
Type of sample Plasma Plasma Plasma 
Input sample 
volume, mL 
7 30 2 
Method of sample 
concentration 
Ultracentrifugation 
(170,000 ×g, 30 
min, 4°C, Sorvall T-
1270 rotor) 
Centrifugation 
(47,810 xg, 3 hrs, 
4°C, Sorvall RC6 







N/A N/A 4 





Automated Semiautomated  









Target region on 
HIV genome 




generate a standard 
curve at each run 
Abbott calibrator 
kit generate and 
store a standard 
curve which is 











Interpolation of Ct 
values from x3 
Interpolation of Ct 
values from x1 
Matching of S/Co 




Reference (Palmer et al., 2003) (Yukl et al., 2011) 
(Hatano et al., 
2009) 
replicates in a linear 
regression model 
replicate in a linear 
regression model 
predefined viral 
load values derived 




RCAS: replication-competent avian sarcoma; N/A: not applicable; IC: internal control; LTR: 
long terminal repeat 
1: (Giachetti et al., 2002)  
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1.3 HIV-1 RNA presence in plasma during effective therapy 
 
1.3.1 Viral kinetics during suppressive antiretroviral therapy 
ART suppresses viral replication to plasma HIV-1 RNA levels below the LLoQ of commercial 
assays (20 and 40 copies/mL) within 3-6 months of therapy initiation (Boender et al., 2015, 
Doyle et al., 2012, Tanner et al., 2016). However, ART does not eradicate HIV-1 from latently 
infected cells. Viral decay following ART initiation occurs in 4 phases (Palmer et al., 2008, 
Riddler et al., 2016). Phase one and two are very dynamic stages during which turnover of 
virus population and productively infected cells is suppressed and plasma HIV-1 RNA 
decreases below 50 copies/mL (Wei et al., 1995). First there is a rapid decline in plasma 
viraemia with a half-life of 1-2 days, which is the effect of a significant reduction in infected 
activated CD4 T cells. A second phase of slower decay (half-life 2-3 weeks) follows because 
of clearance of long-lived cells harbouring and producing HIV. Phase three and four are more 
stochastic and the cellular source associated with them involves latently infected cells with 
self-renewal capacity. The third phase is dominated by a very slow decay (39 weeks half-life) 
due to decrease of latently infected cells that become sporadically activated, such as resting 
memory CD4 T-cells. During the fourth phase viraemia declines at an extremely low rate 
(0.026 log10 per year) with a half-life of at least 11.5 years (95% CI 6.2-83 years) (Riddler et 
al., 2016). Although a similar half-time (t1/2) (13 years) has been estimated for the decay of 
the total cell-associated HIV-1 DNA (Gandhi et al., 2017), the half-life of productively 
infected cells is not known (Jacobs et al., 2019). 
Residual viral RNA in the plasma between 1 and 3 copies/mL is quantified with ultra-
sensitive assays in the majority of patients despite optimal ART (Cillo et al., 2014, Maggiolo 
et al., 2012, Margot et al., 2018, Palmer et al., 2008). It has been previously reported that 
patients on a boosted lopinavir based regimen and with suppressed viral loads less than 50 
copies/mL for 7 years have at least one sample with detectable HIV-1 RNA measured with a 
SCA (Palmer et al., 2008). Although most patients on stable ART experience at least 
intermittently quantifiable HIV-1 RNA levels, the exact proportion of patients with 
detectable levels with SCAs varies among different studies (Cillo et al., 2014, Gandhi et al., 
2010, Hofstra et al., 2014, Kiselinova et al., 2015, Margot et al., 2018, Tosiano et al., 2019). 
It is unclear if the reason for these discrepancies lies with study population demographics, 
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viral characteristics, immune system capacity to control viral replication along with ART, SCA 
complexity and technical limitations or a combination of the above. 
The exact mechanism of residual HIV-1 RNA presence in the plasma is unclear. Ongoing 
cycles of viral replication may supply circulation with viruses (Lorenzo-Redondo et al., 2016, 
Rothenberger et al., 2019, Sahu, 2015). This model is supported by evidence showing that 
drug concentrations vary among tissues and ART penetration may be sub-optimal at sites 
which are rich in reservoirs such as lymph nodes (Di Mascio et al., 2009, Estes et al., 2017, 
Fletcher et al., 2014, Lee et al., 2020). Alternatively, clone-specific T cell activation triggered 
by antigen recognition or local inflammatory processes may cause small bursts of viral 
production which are immediately suppressed by ART (Shen and Siliciano, 2008b). Of note, 
phylogenetic studies have not revealed genetic evolution which is a hallmark of viral 
replication (Bailey et al., 2006, Josefsson et al., 2013, Kearney et al., 2014, Kieffer et al., 
2004). Hence, ongoing viral replication should be rare and residual virus should not derive 
from new infection cycles (Bachmann et al., 2019, Bozzi et al., 2019, Joos et al., 2008, Palmer 
et al., 2011, Rosenbloom et al., 2017, Sigal et al., 2011). Moreover, integration sites were 
identical in infected cells, whereas integration during new infections occurs at different sites 
of the host genome (Cohn et al., 2015, Wagner et al., 2014).  
Pharmacological interventions also argue that intermittent clonal-driven virus production is 
the main mechanism of residual viraemia. Analytical treatment interruption studies have 
demonstrated that viral rebounds are populated by genetically identical viruses (De 
Scheerder et al., 2019, van Zyl et al., 2018). On the other end of the spectrum, ART 
intensification by the addition of one or more potent drugs such as raltegravir, maraviroc, 
efavirenz or a boosted PI, did not have an effect on residual HIV-1 RNA levels implying that 
current treatment regimens achieve maximal efficiency in suppressing viral replication 
(Chaillon et al., 2018, Dinoso et al., 2009, Gandhi et al., 2010, Hatano et al., 2011, Hatano et 
al., 2013, McMahon et al., 2010, Puertas et al., 2014, Rasmussen et al., 2018). Interestingly, 
though, measurement of different outcomes in intensification studies shows a decrease in 
immune activation and transient increase in viral episomal DNA (Buzon et al., 2010, Yukl et 
al., 2010). Pharmacological features and immune functions, yet to be revealed, may be the 
reason for these seemingly conflicting findings. Although bursts of viral production appear 
to be the most prevalent view on presence of residual HIV-1 RNA in plasma, ongoing viral 
replication may also be relevant in some patients depending on host and virus 
characteristics (Darcis and Moutschen, 2017, Nightingale et al., 2016). 
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1.3.2 Low level viraemia and residual viraemia 
Plasma viral load is undoubtedly the most accurate surrogate marker of ART efficacy as 
indicated by viral suppression (HIV-1 RNA <50 copies/mL). Although guidelines recommend 
a definition for viral rebound as viral load above 200 copies/mL on two occasions, new 
evidence suggests that this threshold may need revision (BHIVA, 2019). There is no 
consensus on the definition  of residual viraemia, and subsequently low level viraemia  
(Doyle and Geretti, 2012). In this work we have adapted the cut-off at 10 copies/mL and we 
defined residual viraemia when HIV-1 RNA levels in the plasma are less than 10 copies/mL 
and low level viraemia when HIV-1 RNA levels are between 10 and 200 copies/mL. 
It is common clinical practice to use a threshold of 50 copies/mL to define viral suppression 
However, viral load between 50 and 200 copies/mL is also acceptable in selected patients 
and the North American guidelines use 200 copies/mL as cut-off of therapy success (BHIVA, 
2019, DHHS, 2018). These thresholds are based on the risk for viral rebound which is 
stratified by the level of viraemia. A quarter of patients who have achieved suppression with 
first-line ART will experience viral rebound with at least one viral load between 50 and 400 
copies/mL in the first year after suppression. Almost a quarter of them will have persistent 
viraemia (median 162 copies/mL) with a two-fold increase in the risk of virological failure 
(>400 copies/mL) (Geretti et al., 2008). In another study patients on ART for at least one 
year were stratified according to their level of persistent viraemia in three categories 
including patients who did not achieve suppression. Authors demonstrated that the risk of 
virological failure (>1,000 copies/mL) was increased by five times with viraemia 500-999 
copies/mL and doubled with viraemia 50-199 and 200-499 copies/mL compared to patients 
with suppressed viral loads (<50 copies/mL) when adjusting for date of HIV infection and 
use of tenofovir, emtricitabine, and efavirenz. Although almost half patients with viraemia 
50-199 copies/mL did not achieve virological suppression before their viraemic episode, 
findings remained interesting (HR 1.52 from 2.61) when the analysis was restricted to only 
those with previous suppression (Laprise et al., 2013). HIV-1 RNA levels less than 50 
copies/mL have also been shown to favour virological rebound in stably treated patients 
(Doyle et al., 2012, Gianotti et al., 2015, Hofstra et al., 2014, Maggiolo et al., 2012). Doyle 
and colleagues were first to suggest a revisit of clinical thresholds as to treatment efficacy 
since they observed an increased risk for viral rebound >50 and >400 copies/mL in patients 
with viraemia between 10 and 40 copies/mL and between 40 and 50 copies/mL, 
respectively.  Hence, a cut-off at 10 copies/mL is the most appropriate relevant threshold 
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not associated with viral rebound (Doyle et al., 2012, Gianotti et al., 2015, Hofstra et al., 
2014, Maggiolo et al., 2012). 
Residual viraemia less than 10 copies/mL is non-dynamic and does not predict further 
increases in viraemia. Viruses appear to have a clonal origin with no genetic evolution over 
time (Bailey et al., 2006, Hermankova et al., 2001, Kieffer et al., 2004, Nettles et al., 2005, 
Tobin et al., 2005, Shen and Siliciano, 2008a). Lack of genetic evolution also precludes 
emergence of drug resistance (Doyle and Geretti, 2012). Fully reconstructed viruses from 
the plasma of a patient under suppressive ART revealed that half of them were replication 
competent and the other half carried mutations corresponding to decreased viral fitness 
due to defects of the replication machinery (Sahu et al., 2010). However, replication-
competent virions may not necessarily infect new cells due to their very low levels and ART 
pressure (Wang et al., 2018).  
The impact of residual viraemia on the balance of immune activation and tolerance is not 
clear. Chronic antigenaemia drives immune exhaustion following recurrent cycles of 
immune proliferation and activation (Kuchroo et al., 2014). The immune system has 
acquired memory to HIV antigens and even small amounts of HIV particles during effective 
ART may activate immune mechanisms. Effective clearance of the antigen results in 
undetectable levels of HIV-1 RNA in plasma (Hatano, 2013, Younas et al., 2016). Immune 
activation is expected to be proportional to antigenaemia and current methods may not be 
able to measure it in cases of residual viraemia (Yukl et al., 2010). Instead the focus should 
be on HIV-1 specific immunity, as in elite controllers who are able to suppress viraemia at 
the absence of ART and maintain normal immune activation but increased HIV-1 specific 
immunity (Bello et al., 2009). Indeed, HIV-specific CD8 T cell responses in elite controllers 
demonstrate increased antiviral efficacy compared to progressors (Collins et al., 2020).  
Determinants of residual viraemia are elusive with potential unknown host and virological 
factors influencing frequency and size of viral presence in plasma. Previously, latent 
reservoir size, ART duration, pre-ART viraemia and age have been associated with residual 
viraemia but literature may be contradictory for some parameters (Chun et al., 2011, 
Kiselinova et al., 2015, Palmer et al., 2008, Zheng et al., 2013). Large scale studies and new 
techniques are required to clarify the field of sustained residual viraemia despite ART. 
Third-generation assays have a LLoQ between 20 and 40 copies/mL, but their LoD is even 
lower and down to ~3.5 and 10 copies/mL with the TaqMan v2.0 and RealTime, respectively 
(Abbott, 2018, Amendola et al., 2014, Doyle and Geretti, 2012). However, there is lack of 
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concordance the lower the detection limit is set (Amendola et al., 2014, Karasi et al., 2011). 
Due to remarkable assay variability at low levels of viraemia, study outcomes should be 
treated with caution and in the context of the method of measurement applied. For 
instance, findings based on the TaqMan v2.0 imply that viraemia between 20 and 50 
copies/mL was not associated with virological failure (Charpentier et al., 2012). A recent 
study, though, re-tested samples (stored aliquot) with viral load between 50 and 200 
copies/mL and found that 42% of them had a repeat viral load less than 50 copies/mL 
underscoring intra-assay variability (White et al., 2018). Assay characteristics and evidence 
from comparison studies should be considered to interpret these reports. 
 
1.3.3 Source of residual viraemia  
HIV can effectively infect activated cells, a small fraction of which escape the cytopathic 
effect of viral replication and revert to resting memory cells within a very short time window 
from the original transmission event (Siliciano et al., 2003, Swiggard et al., 2005, Zhou et al., 
2005). This long-lived reservoir is established early after transmission and it is maintained 
despite pharmacological and immune pressure (Archin et al., 2012, Bukrinsky et al., 1991, 
Chun et al., 1998).  However, only a small fraction of this reservoir (2-10%) contains full-
length, intact proviruses which are replication competent (Bruner et al., 2019, Ho et al., 
2013, Hiener et al., 2017). This small subset has the potential to cause viral rebound upon 
treatment discontinuation and remains the supreme obstacle for a cure. During suppressive 
ART, the majority of these proviruses is localised in T follicular helper cells (Tfh) at the 
germinal centres of lymph nodes (Banga et al., 2016, Estes et al., 2017). 
Two mechanisms have been suggested to maintain the HIV-1 reservoir during ART: 
homeostatic CD4 T cell proliferation and residual viral replication (Chomont et al., 2009, 
Fletcher et al., 2014, Frenkel et al., 2003, Grossman et al., 1999, Kearney et al., 2014, 
Lorenzo-Redondo et al., 2016, McManus WR et al., 2018, Rosenbloom et al., 2017). We have 
already discussed that new infections are very rare in patients with residual viraemia. 
HIV-1 DNA is mainly found in resting CD4 T cells in suppressed patients. Other cells such as 
monocytes, macrophages and haematopoietic stem cells contain HIV-1 DNA to a lesser 
extend (Mitchell et al., 2019). Cells harbouring HIV-1 DNA circulate throughout the body and 
may reside at lymph nodes, gut-associated lymphoid tissue (GALT), cerebrospinal fluid, 
adipose tissue and the urethra (Chun et al., 2008, Couturier et al., 2015, Ganor et al., 2019, 
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Nightingale et al., 2016, Perreau et al., 2013b). Residual viraemia is sourced from some of 
these cells and tissues which may vary between patients and over time within an individual 
(Jacobs et al., 2019). Intensive sampling and single genome sequencing suggested that 
residual viraemia originates from memory CD4 T cells which reside in lymphoid-rich tissues 
or traffic in circulation (Bailey et al., 2006). It has been demonstrated that effector and 
transitional memory CD4 T cells (CD4+/CD45RA-/CCR7-/CD27- and CD27+, respectively) 
accommodate proviral sequences which are closely related with viral sequences in residual 
viraemia (Puertas et al., 2016). However, there are also predominant identical sequences 
that are underrepresented in resting CD4 T cells. These probably derive from clonal species 
of virus which do not undergo any changes in their sequence for up to 3 years. The type of 
cell harbouring these viruses should have proliferative capacity regardless of activation 





1.4 Programmed death 1 in the pathogenesis of HIV infection 
 
1.4.1 Immune response and HIV escape 
HIV remains “invisible” in the 10 days after transmission, as demonstrated by the absence 
of viraemia and HIV-specific immune responses (eclipse phase) (Fiebig et al., 2003, 
McMichael et al., 2010). According to findings from the simian model, in the first week post 
transmission the first cells to become infected are mucosal resting memory CD4 T cells along 
with submucosal dendritic cells. The latter transfer HIV to local lymph nodes where activated 
T cells and follicular dendritic cells secrete pro-inflammatory cytokines such as interleukin-
1 (IL-1), IL-6 and tumour necrosis factor α (TNFα) offering an ideal environment for host cell 
infection and spread of virus particles in great numbers (Perreau et al., 2013a). Vigorous 
replication results in apoptosis of infected and bystander cells with release of 
immunosuppressive microparticles such as TNF-related apoptosis-inducing ligand (TRAIL) 
(Gasper-Smith et al., 2008). Although acute phase cytokines peak towards the end of the 
eclipse phase and before viraemia, the first HIV-specific CD8 T cell response is recorded to 
coincide with the peak of viral RNA in the plasma about 3 weeks post infection (Borrow et 
al., 1994, Stacey et al., 2009). The exact timing of the onset of HIV-specific CD4 T cell 
responses is unclear and probably precede CD8 activation, but their function is impaired 
with the predominance of inhibitory pathways triggered by HIV (D'Souza et al., 2007, Gloster 
et al., 2004, Perreau et al., 2013b). 
Plasma viraemia at the end of the eclipse phase assists HIV spread to distant lymphoid-rich 
tissues such as the GALT, where the rate of CD4 T cell depletion is four times higher than the 
rate of CD4 infection (Brenchley et al., 2004). Around 3 weeks post infection plasma viraemia 
peaks, viral reservoirs have been established and HIV-specific CD8 responses are triggered 
(Figure 1.2). It is only later that humoral immunity with broadly neutralising antibodies 
(bNAbs) develops (Huber and Trkola, 2007). However, under the selective pressure of 
antibodies, HIV rapidly evolves by mutating the env gene to escape neutralisation. 
Moreover, gp120 and gp41 demonstrate conformational changes and their regions are 
heavily glycosylated protecting them from interactions with circulating antibodies. Yet, over 
the course of infection, potent bNAbs with cross-reactivity are developed in “elite 
neutralizers”. These have unusual specifics such as somatic hypermutation and very short 
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or long antigen-binding loops making their adaptation for a vaccine challenging (Landais and 
Moore, 2018, Richman et al., 2003, Wei et al., 2003). 
Cytotoxic CD8 T cell driven immunity appears to be the most important function to control 
HIV dissemination. The initial CD8 response against key targets such as the env and nef HIV 
proteins is effective with reduction in viraemia. However, virus escape mutants occur rapidly 
under immune pressure, with sequentially mutated epitopes triggering recurrent cycles of 
CD8 activation (Arcia et al., 2016, Goonetilleke et al., 2009, Keele et al., 2008b). Continued 
epitope recognition and lack of CD4 T cell help, due to their depletion and functional 
impairment, cause exhaustion of cytotoxic T lymphocytes (CTL) allowing virus persistence 
(Blattman et al., 2009, Petrovas et al., 2006, Wherry, 2011, Zhang et al., 2007). 
Immune escape is achieved via multiple pathways which affect the interactions between 
MHC-I/HIV-1 epitope/T cell receptor (TCR) complex. First the antigenic epitope on gp120 
has a variable region with significant diversity among strains. Transformation of RNA to DNA 
produces antigenic diversity due to the innate tendency of RT to create single-nucleotide 
mutations and strand recombination. Furthermore, HIV proteins, such as nef and vpu, and 
presence of non-immunogenic glycans on epitopes have a direct effect on host recognition 
through down-regulation of MHC-I expression  (Oldstone, 1997, Wei et al., 2003). Escape 
variants are not always effective to produce cell infection. Defects that impair replication 
and cell invasion have a significant impact on their fitness to survive (Kent et al., 2005). 
Latent infection is also an escape mechanism from both immunological and pharmacological 
clearance. Latency is characterised by a resting state of the infected cell and increased 
expression of immune checkpoints, such as the programmed death 1 (PD1) and cytotoxic T 
lymphocyte-associated protein 4 (CTLA-4) (Chomont et al., 2009). Indeed, virus production 
requires HIV-1 DNA transcription which largely depends on an increase of host transcription 
factors in the nucleus following T cell activation. These pathways are suppressed by immune 
checkpoints (Deeks et al., 2016).  
 
1.4.2 Structure, genome, ligands and role of PD1 
In 1992, the RNA of a novel inducer of programmed cell death was isolated from apoptotic 
murine cell lines and was named PD1 (or CD279) (Ishida et al., 1992). Further studies 
revealed that PD1 and its ligands play a pivotal immunoregulatory role by inducing T cell 
anergy (Jin et al., 2011). 
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PD1 is a 55-kDa monomer cell surface protein of the CD28 superfamily expressed in CD4 and 
CD8 T cells, B cells, natural killer (NK) cells, monocytes and dendritic cells. It has an 
extracellular Ig-like variable domain, a transmembrane region and a cytoplasmic tail 
containing an immunoreceptor tyrosin-based inhibitory motif (ITIM) and an 
immunoreceptor tyrosine-based switch motif (ITSM) (Figure 1.3). PDCD1 on chromosome 2 
is the gene that encodes PD1 and consists of 5 exons. Alternative splicing results in 4 variants 
with similar properties as the full length isoform except from the PD1Δex3 transcript that 
lacks the transmembrane region and thus is in soluble form (Ishida et al., 1992, Jin et al., 
2011, Nielsen et al., 2005). 
PD1 ligands are PD-L1 (B7-H1 or CD274) and PD-L2 (B7-DC or CD273). PD-L1 is constitutively 
expressed on a variety of non-lymphoid tissues including parenchymal organs, such as the 
heart, lung and placenta. T and B cells also express negligible amounts of PD-L1 which are 
significantly increased upon activation (Dong et al., 1999). On the other hand, PD-L2 
expression is confined to professional antigen-presenting cells (APC), such as macrophages, 
dendritic cells, bone-marrow derived mast cells and resting peritoneal B1 cells, and it is 
interferon-γ dependant. The binding affinity of PD-L2 to PD1 is two to six folds higher than 
that of PD-L1, and it appears to have an additional receptor with a costimulatory role for T 
cell activation (Shin et al., 2003, Tseng et al., 2001, Youngnak et al., 2003). PD-L1 and PD-L2 
induced effects appear to be distinct (Dyck and Mills, 2017a). A murine model of malaria 
demonstrated a protective role of PD-L2 in preventing PD-L1 induced exhaustion and 
establishing effective CD4 T cell immunity with better pathogen clearance (Karunarathne et 
al., 2016). Also, mice lacking PD-L2, but not PD-L1, developed an excessive immune response 
to cutaneous leishmaniasis with marked production of pathogen-specific antibodies, while 
PD-L1(-/-) mice were resistant to disease (Liang et al., 2006). 
Immune activation begins with a primary signal generated from an antigen (Ag) binding to 
a TCR. The primary response will be either enhanced or suppressed depending on accessory 
signals derived from co-receptors such as the B7-recognising immunoreceptors (CD28, 
CTLA-4, ICOS, PD1 and BTLA). The balance between a positive (CD28 and ICOS) and a 
negative (CTLA-4, PD1 and BTLA) stimulation ensures a controlled immune response and 
determines the fate of the cell (Bretscher, 1999, Freeman et al., 2000, Ishida et al., 1992, 
Nielsen et al., 2005, Okazaki et al., 2013). Clonal expansion is enhanced or diminished 
depending on the original signal and immune checkpoints, maintaining a balance between 
activation and tolerance (Fife and Bluestone, 2008, Wang et al., 2018).  
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PD1 and CTLA-4 are the most well described immune checkpoints and are targeted with 
inhibitors in cancer therapy with the aim to boost cytotoxic effector T cell responses (Dyck 
and Mills, 2017b). PD1 expression plays a central role in an inhibitory regulatory pathway 
on both recently activated and memory T cells (Figure 1.4). A similar effect but less 
prominent is observed on naïve T cells during a primary immune response (Agata et al., 
1996, Cai et al., 2004). The PD1 pathway regulates a broad spectrum of immune functions 
including immunological tolerance, regulation of T cell, B cell and NK cell proliferation and 
effector functions. TCR or B cell receptor (BCR) mediated cell activation induces PD1 
expression. During chronic infection there is increased expression of PD1 on virus-specific T 
cells. Its ligands are also expressed at high levels by various tumour cells implying that cancer 
and viruses exploit PD1 pathway properties to their survival benefit (Jin et al., 2011). 
 
1.4.3 Molecular mechanism 
TCR-mediated calcium influx activates the nuclear factor of activated T cells calcineurin-
dependent 1 (NFATc1) which initiates expression of PD1 (Oestreich et al., 2008). In addition, 
γ-chain associated cytokines (e.g. IL-2) and type I interferons (e.g. IFN-α) synergistically up-
regulate PD1 transcription. It has been reported that cytokine-stimulated expression of PD1 
may be antigen-independent during chronic infection (Cho et al., 2008, Kinter et al., 2008, 
Terawaki et al., 2011). Once PD1 integrates in the cell membrane it sustains its position 
making it an easy target for quantification with flow cytometry. 
PD1 interaction with its ligands results in phosphorylation of its intracellular tyrosines and 
their association with Src homology 2 (SH2) domain-containing tyrosine phosphatase 1 and 
2 (SHP-1, SHP-2). SHP-1 and -2 inactivate key signalling molecules of the antigen recognition 
cascade. Dephosphorylation of phosphoinositide-3 kinase (PI3K) inhibits Akt 
phosphorylation (Parry et al., 2005, Sheppard et al., 2004) and the secretion of cytokines 
(IFN-γ, TNFα, IL-2, Bcl-xL) implicated in effector cell functions, cell expansion, differentiation 
and survival.  While inhibition of Erk by binding SHP-2 results in decreased proliferation  
(Butte et al., 2007, Keir et al., 2008). 
 
1.4.4 Function 
The PD1 pathway inhibits the effector functions of lymphocytes and preserves survival of 
target cells such as infected or cancerous cells. This signifies two sides of the same coin: 
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immunotolerance and immunopathology. PD1 plays a crucial role in prevention of immune 
over-activation securing balanced immune responses and peripheral tolerance. It has been 
demonstrated that PDCD1 knockout mice develop autoimmunity and PDCD1 
polymorphisms in human are associated with autoimmune diseases such as systemic lupus 
erythematosus (SLE), type 1 diabetes, Grave’s disease and multiple sclerosis (MS) (Okazaki 
and Honjo, 2007). Cancerous and infected cells exploit the physiological inhibition to escape 
immunity and establish malignancies and chronic infections, respectively. Antigen-specific T 
cells during chronic viral infections suffer an impaired function and PD1 is implicated to play 
a pivotal role in the establishment of this state of anergy (Barber et al., 2006, Boni et al., 
2007, Day et al., 2006, D'Souza et al., 2007, Okazaki et al., 2013, Radziewicz et al., 2007). 
Virus-specific CD8 T cells become gradually exhausted originally by loss of their cytotoxicity 
and IL-2 production which is followed by loss of TNFα production and their proliferative 
potential (Freeman et al., 2006). Models of lymphocytic choriomeningitis virus (LCMV) 
infection have indicated that knock down of PD1 expression may result in a rapid clearance 
of the pathogen preventing chronic infection, but the effect of excessive T cell activation on 
healthy tissue is deleterious (Barber et al., 2006). 
High and persistent expression of PD1 has been observed in virus-specific immune cells 
during chronic infection as a result of demethylation in the promoter region of the PDCD1 
gene (Youngblood et al., 2011). Hence, a state of phenotypic and functional senescence 
persists. Although cells are seemingly too “exhausted” to proliferate or produce cytokines, 
their transfer to an infection-naïve murine recipient experiencing acute infection triggers 
cell expansion and control of infection (Utzschneider et al., 2013). These data imply that at 
least a fraction of the exhausted virus-specific CD8 T cells is not terminally differentiated 
and retains unaffected memory properties of proliferation and cytokine production upon 
antigen presentation. Virus-infected cells seem to express PD1 to prevent an overwhelming 
chronic immune response (Utzschneider et al., 2013). 
Similarly, some tumours ensure their survival by expressing high levels of PD-L1 which 
interacts with PD1 on cytotoxic T cells inhibiting their effector function. PD-L1 is also 
upregulated in various chronic viral infections. For instance, increased PD-L1 expression is 
demonstrated on bronchial and alveolar epithelial cells after their infection with respiratory 
syncytial virus, human hepatocytes infected with adenovirus, hepatocytes and circulating 
monocytes of patients with hepatitis B virus (HBV) infection, dendritic cells infected with 
rhinoviruses and macrophages infected with the herpes simplex virus (HSV) type 1. In 
agreement PD1 expression was increased at the acute phase of hepatitis C virus (HCV) 
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infection and either decreased in patients with virus clearance or persisted in those with 
chronic infection (Trautmann et al., 2007). Murine models also imply that the same strategy 
of immune escape, by increased expression of PD-L1, is adapted by HIV-infected cells 
(Akhmetzyanova et al., 2015).  
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1.4.5 PD1/PD1 ligand blockade 
Interferon α, β and γ increase PD-L1 expression during early innate immune responses to 
infection (Freeman et al., 2006). Early data showed that transient blockade of PD1/ligand 
interaction restored the normal functions of LCMV-specific CD8 T cells (Barber et al., 2006). 
Similarly, monoclonal antibodies targeting the PD1/PD-L1 pathway are employed 
successfully in cancer therapy because they have shown to enhance cytotoxic T lymphocyte 
responses resulting in tumour regression (Hirano et al., 2005, Ohigashi et al., 2005). 
Although PD-L1 blockade overall improves cytotoxic functions, most experiments were 
conducted on T cell lines and replication of findings in primary T cells is required (Trautmann 
et al., 2007). 
Checkpoint inhibitors have shown to suppress viral load in chronic infections with HBV, HCV 
and HIV by reversing exhaustion in virus specific T cells (Cox et al., 2017). Nivolumab, an 
anti-PD1 monoclonal antibody, was shown to reduce significantly viraemia in a chimpanzee 
model and a small subset of patients with HCV (Fuller et al., 2013, Gardiner et al., 2013). 
Responses were enhanced when two different inhibitory pathways were blocked. Liver-
derived CD8 T cells from chronically infected HCV patients had their functionality effectively 
restored once both the PD1 and CTLA-4 pathways were pharmacologically inhibited 
(Nakamoto et al., 2009). Studies in humanised mouse models and macaques have reported 
lymphocyte reconstitution with regard to both T and B cell functions and decrease in viral 
load with PD1 blockade (Finnefrock et al., 2009, Seung et al., 2013, Velu et al., 2009). 
Immune checkpoint inhibitors have been used in HIV positive patients with advanced 
malignancies and a recent systematic review has demonstrated their safety and efficacy 
(Cook and Kim, 2019). However, reports on virological and immunological parameters of the 
HIV reservoir were inconsistent. Nivolumab in lung cancer patients has been shown to cause 
a decrease in HIV-1 DNA and an increase in viral-specific CD8 T cell activity (Guihot et al., 
2018, Le Garff et al., 2017), whereas there was no effect in other studies (Gay et al., 2017, 
Lavolé et al., 2018, Scully et al., 2018). Administration of a single dose of nivolumab to an 
HIV-infected patient with metastatic melanoma on ipilimumab (anti-CTLA-4) increased cell-
associated HIV RNA in CD4 T cells, but there were no changes to total HIV-1 DNA or viraemia 
(Evans et al., 2018). Of note, the sample sizes of these studies were small and their 
methodologies differed. Currently there a few ongoing clinical trials that will shed more light 
on the efficacy of checkpoint inhibitors in HIV infection (Chen et al., 2020). Combination 
therapy may also improve outcomes (Van der Sluis et al., 2020, Wykes and Lewin, 2018). 
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1.4.6 PD1 and HIV 
A hallmark of HIV infection is chronic immune activation which is coupled with increases in 
checkpoint molecules. Antigen presence and persistence consist the main drives for the 
upregulation of several checkpoint receptors in T cell populations. PD1 expression is 
increased during HIV-1 infection on specific CD4 and CD8 T cells, Tfh cells, follicular CD8 T 
cells and HIV-1 infected CD4 T cells (Chen et al., 2020). 
Chronic persistent infection results in the unresponsiveness of cytotoxic CD8 T cells to 
infected cells. Exhausted CD8 T cells first lose their ability to produce IL-2 and be cytotoxic 
and then TNFα and IFN-γ production. Studies based on the LCMV model of infection 
demonstrated that epitope-specific CD8 T cells seem to have a phenotype of chronic 
activation with indefinitely impaired antigen-effector functions. This status of anergy was 
found predominately in CD4 (-/-) knockout mice implicating the critical role of CD4 T-helper 
cells in the function of cytotoxic CD8 T cells during infection clearance. Moreover, they were 
incapable of producing long lived memory subsets which persist at the absence of antigen 
(Wherry and Ahmed, 2004, Zajac et al., 1998). This functional impairment is also 
demonstrated in HIV infection (Sperk et al., 2018). 
The PD1 pathway suppresses cytokine driven T cell proliferation and induces apoptosis 
during later stages of activation (effector phase) by inhibiting TCR-induced signals (Fife and 
Bluestone, 2008, Keir et al., 2008). Lack of CD4 helper cells and prolonged immune activation 
(both present in HIV infection) result in increased PD1 expression (Buchbinder and Desai, 
2016). PD1 expression prior to ART commencement correlated with viral DNA levels and it 
was a predictor of time to rebound after treatment suspension (Hurst et al., 2015). 
Therefore, inhibitory pathways such as the PD1 have been proposed as responsible for 
suboptimal immune reconstitution in chronic HIV infection. 
Day et al. and Trautmann et al. showed that PD1 expression on HIV-specific CD8 T cells was 
higher than on CMV-specific CD8 T cells and the degree of expression varied among HIV 
epitope-specific CD8 T cells from a single individual. Moreover, antigenaemia positively 
correlated with PD1 expression on HIV-specific or total CD8 T cells and total CD4 T cells. 
Further characterisation of HIV-specific CD8 T cells revealed that they were pre-terminally 
differentiated, with additional high expression of CD27 and low expression of CD28, CCR7 
and CD45RA. Their cytotoxic (TNFα and IL-2 production) and proliferative functions were 
impaired, but restored with blockade of the PD1/PD-L1 axis (Day et al., 2006, Trautmann et 
al., 2006). Petrovas et al. took one step further and demonstrated that decreased cytokine 
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production was an indirect effect of high PD1 expression on CD8 T cells which resulted from 
a defect in their proliferative capacity. Increased levels of PD1 expression can induce cell 
apoptosis independently of other factors (Petrovas et al., 2006). During chronic untreated 
infection PD1 expression on HIV-specific CD4 cells is up-regulated in strong correlation with 
viral load and it is twice higher than on HIV-specific CD8 cells. The same study also observed 
that viral suppression with ART causes a more prominent decrease of PD1 expression on 
HIV-specific CD4 T cells, but still the expression remains higher than on HIV-specific CD8 T 
cells. Simultaneous measurements in lymph node derived T cells demonstrated similar 
findings except from that PD1 expression is much higher compared to blood circulating T 
cells. This is related with increased expression of PD-L1 on APC reflecting the high levels of 
viral replication and antigen presence.  PD-L1 blockade increased HIV-specific CD4 T cell 
proliferation, but not cytokine production. Interestingly, IFN-γ-producing cells 
demonstrated higher levels of PD1 expression compared to IL-2 producing cells (D'Souza et 
al., 2007). 
Eradication strategies focus on the clearance of quiescent virus harboured in resting cells. 
Blockade of checkpoint pathways appears to reverse latency, as indicated by enhancement 
of immune responses against HIV and changes in markers of reservoirs, raising promises for 
a functional cure (Fromentin et al., 2019, Sperk et al., 2018). Based on the principles of 
chimeric antigen receptor (CAR) T-cell therapy for cancer treatment, viral reservoirs can be 
potentially reduced with ex vivo expansion and re-introduction of HIV-specific CD8 T cells 
which are negative for PD1 and other markers of impaired effector function (Chapuis et al., 
2011, Miliotou and Papadopoulou, 2018, Porter et al., 2011, Terme et al., 2008). Similarly, 
but in vivo, a strategy called “shock and kill” involves stimulating activation of resting 
reservoirs in order to induce an immune response sufficient to clear them (Shan et al., 2012). 
This approach may be assisted by the blockage of inhibitory pathways such as PD1 (Amancha 
et al., 2013, Finnefrock et al., 2009, Freeman et al., 2006). Achieving a HIV cure is likely to 










The cytoplasmic tail of PD-1 contains two tyrosines: the immunoreceptor tyrosin-based 
inhibitory motif (ITIM) and the immunoreceptor tyrosine-based switch motif (ITSM). Ligation 
of T cell receptor (TCR) and PD-1 can lead to tyrosine phosphorylation (P) and activation of 
Src homology 2-containing phosphotyrosine phosphatase (SHP-2), resulting in 
dephosphorylation of signalling molecules and reduced cytokine mRNA synthesis  
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1.5 Aims and objectives 
 
1.5.1 Aim  
This work aims to investigate factors associated with residual viraemia defined as HIV-1 RNA 
in plasma less than 10 copies/mL during ART. 
 
1.5.2 Objectives 
1.5.2.1 Predictors of the presence of HIV-1 RNA in plasma between 10 and 200 copies/mL 
(low level viraemia) despite effective ART will be identified through a systematic review of 
current literature.  
1.5.2.2 We will measure virological (total HIV-1 DNA in peripheral blood mononuclear cells 
(PBMC)) and immunological (PD1 expression on circulating memory CD4 and CD8 T cells) 
parameters and determine their association with residual viraemia, defined as HIV-1 RNA in 
plasma less than 10 copies/mL in successfully treated patients. 
1.5.2.3 HIV-1 RNA in plasma, total HIV-1 DNA in PBMC and drug levels will be measured 






A systematic review of factors 
associated with low level viraemia in 





Low level viraemia (LLV) is the presence of HIV-1 RNA in plasma despite effective ART which 
is detected by commercial assays and may reach a few hundred copies (Geretti et al., 2008). 
After a sharp decline in viral load (VL) following ART commencement and in the absence of 
treatment interruptions, VL remains suppressed (<50 copies/mL) in most patients. Inability 
to achieve VL suppression or virological rebound after an initial response may indicate 
treatment failure and a possible requirement for ART modification. VL thresholds defining 
virological failure vary from 50 to 1,000 copies/mL with most recommendations adapting a 
cut-off at 200 copies/mL (Table 2.1). Although guidelines suggest switch of treatment for 
confirmed viraemia above 200 copies/mL, some authors recommend considering regimen 
changes in cases of persistent VL results between 50 and 200 copies (Thompson et al., 2012). 
It remains unclear whether LLV ranging from a “target detected” result to 200 copies/mL is 
associated with an increased risk of resistance mutations (Gallien et al., 2011, Jordan et al., 
2013, Malet et al., 2012, Swenson et al., 2014b, Taiwo et al., 2011) and immune activation 
(Schuler et al., 2013, Stephan et al., 2013, Zheng et al., 2014). Discordances in study design 
and definitions are main reasons for the conflicting findings. 
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Intermittent episodes of LLV which are preceded and followed by an undetectable VL 
measurement are referred to as viral blips (Di Mascio et al., 2003, Grennan et al., 2012, 
Greub et al., 2002, Mira et al., 2002, Nettles and Kieffer, 2006, Sklar et al., 2002). In a cohort 
from the Netherlands, episodic LLV between 50 and 1,000 copies/mL did not instigate 
therapy changes or clinical deterioration, whereas viraemia above 1,000 copies/mL was 
linked with drug resistance (van Sighem et al., 2008). At least one fifth of fully suppressed 
patients experience viral blips (Greub et al., 2002, van Sighem et al., 2008). Blips of low 
magnitude, such as less than 500 copies/mL as suggested by Grennan et al. (2012), do not 
predispose to virological failure or rebound. They may represent normal biological variation 
in patients with viraemia below or around the assay LLoQ, statistical variation due to assay 
variability at lower HIV-1 RNA levels, or methodological artefacts. On the contrary, viral blips 
of higher magnitude have been associated with virological failure (Easterbrook et al., 2002, 
Grennan et al., 2012, Moore et al., 2002, Nettles and Kieffer, 2006, Nettles et al., 2005).  
Persistent LLV, confirmed with at least two consecutive measurements, has been related 
with an increased risk for virological failure when above 200 copies/mL (Bernal et al., 2018, 
Boillat-Blanco et al., 2015). However, some studies reported an association between 
virological failure and any level or frequency of confirmed LLV identified with commercial 
assays (Laprise et al., 2013, Leierer et al., 2016, Pernas et al., 2016). 
The range of LLV varies in literature depending on the assay used and the country of study 
(Appendix, Table A.1). Current commercial assays are based on the technologies of real-time 
RT-PCR and TMA achieving a LLoQ between 20 and 40 copies/mL. Introduction over time of 
more sensitive real-time assays increased the number of patients experiencing LLV on 
suppressive treatment who had previously undetectable VL  (Do et al., 2011). Nevertheless, 
ultra-sensitive experimental methods have revealed that the effect of ART is suppressive 
and not eliminatory with residual HIV-1 RNA around 3 copies/mL persisting in patients with 
undetectable VL (Shen and Siliciano, 2008b, Bailey et al., 2006). 
More than three quarters of stably suppressed patients with viral load below 50 copies/mL 
experience residual viraemia when tested with an ultrasensitive single copy assay (Palmer 
et al., 2008). Although the mechanism of this residual viraemia is unclear, it has been 
suggested that virus is primarily produced upon activation of chronically infected cells and, 
to a lesser or even negligible extent, during cycles of viral replication (Anderson et al., 2011, 
Palmer et al., 2011, Shen and Siliciano, 2008b). As to the significance of residual viraemia, it 
has been demonstrated that the risk for viral rebound is gradually increasing with levels of 
HIV-1 RNA above approximately 10 copies/ml (Doyle and Geretti, 2012, Doyle et al., 2012, 
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Gianotti et al., 2015, Hofstra et al., 2014, Maggiolo et al., 2012). Current commercial VL 
assays have a LoD of around 10 copies/mL, reporting a qualitative “target detected” signal 
between the LLoQ and the LoD. In several studies, patients with “target detected” results 
by such commercial assays, were found to be at increased risk of virological rebound 
compared to those with “target not detected” (Doyle and Geretti, 2012, Doyle et al., 2012, 
Gianotti et al., 2015, Henrich et al., 2012, Hofstra et al., 2014, Pugliese et al., 2013). In 
contrast, HIV-1 RNA levels below this threshold appear to be stable and non-evolving (Shen 
and Siliciano, 2008b, Shen and Siliciano, 2008a).  
LLV is a grey area causing confusion and nervousness as to clinical management. Our 
knowledge of probable predictors of LLV is even more limited since most studies adapt a 
cross-sectional observational design rather than an investigation of pre-defined causal 
relationships. Pre-ART conditions, ART-related factors and microbial translocation, as well 
as assay technical characteristics are proposed to contribute to LLV. We conducted a 
systematic review in order to summarise our current knowledge of clinical, virological and 
immunological factors associated with viral rebound post original suppression. Considering 
the LoD of commercial assays and the threshold of virological failure recommended by most 
guidelines, we defined LLV in treated patients as VL between 10 and 200 copies/mL.   
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Table 2.1: Definitions of virological failure according to current guidelines. 
 
Guidance Definition of virological failure Reference 
WHO >1,000 copies/mL on two consecutive 
measurements (3-6 months apart) 
(WHO, 2017) 
DHHS >200 copies/mL1 (DHHS, 2018) 
EACS • >200 copies/mL 6 months post first-line ART1 
• >50 copies/mL on two consecutive 
measurements (1-2 months apart) in previously 
suppressed patients 
(EACS, 2018) 
BHIVA >200 copies/mL on two consecutive measurements (BHIVA, 2019) 
BC-CfE >250 copies/mL on two consecutive measurements (British Columbia 
Centre for Excellence 
in HIV/AIDS, 2015) 
 
1: Although the definition of virological failure does not specify the number of measurements 
required, it is recommended that treatment switch is considered with confirmed virological 
failure implying that a second measurement is needed. 
WHO: World Health Organisation; DHHS: U.S. Department of Health and Human Services; 
EACS: European AIDS Clinical Society; BHIVA: British HIV Association; BC-CfE: British 









2.2.1 Search strategy and review methodology 
Three main databases, Medline (interrogated with Ovid and PubMed), Cochrane Library and 
Scopus were searched from 1st January 2008 to 16th August 2018 for studies identifying 
factors associated with LLV. We included work that adapted a definition for LLV as VL 
rebound between “target detected” and 200 copies/mL or 20 and 200 copies/mL for studies 
using a qualitative or quantitative lower cut-off, respectively. We also screened studies with 
broader definitions for subgroup analysis and we considered including those which reported 
that 95% of subjects with LLV had a VL within our pre-defined range. We used the median 
(or mean) and confidence interval (or standard deviation) of VL where the percentage was 
not mentioned. We chose 2008 as a starting point to capture mainly studies utilizing third 
generation assays which report VL values below 50 copies/mL. Our search strategy was 
developed using Medline and adapted for the other databases (Table 2.2). It was based on 
five main terms and their alternative keywords: HIV, viral load, ART, low level viraemia and 
predictors.  
Virological blips were excluded as long as they were confirmed with the acquisition of three 
consecutive measurements, whereas studies using single measurement of VL and not 
providing confirmation of LLV were included (Table 2.3). Abstracts from meetings would be 
included if they contained sufficient information and their findings were not published in 
another work. Scripts in English were checked for eligibility. The references listed in the 
articles from the final selection were also queried for relevant records. 
 
2.2.2 Data extraction and quality assessment 
Citations were exported to EndNote X7 manager and the results from the three databases 
were merged. An EndNote command identifying duplicates (or triplicates) was followed by 
manual recognition and extraction of the same articles appearing in more than one 
database. Then titles and abstracts were carefully reviewed for relevance and eligibility 
(Table 2.3). In most cases the information on LLV was inadequate and a search of the main 
text was performed focusing on the 200 copies/mL cut-off (first stage of selection). A 
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detailed read of the remaining articles followed (second stage of selection). Only studies 
showing positive associations between a factor and LLV were included.  
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
checklist was followed except from the points referring to meta-analysis conduct as this is a 
qualitative review. Being part of a thesis, abstract is not provided, but we will consider 
adding one in case of publishing in a peer reviewed journal. This work is registered with the 
PROSPERO international database (registration No: CRD42019132516). 
 
2.2.3 Data analysis and synthesis 
Studies were summarised according to study design. We extracted all factors demonstrating 
positive association with LLV from each publication. A template was created in excel to 
contain key characteristics of the selected studies including time period, country, primary 
outcome, sample size, definition of LLV, VL assay, ART regimen and suggested predictors. A 
second template was populated with information on each potential predictor including 
patient groups, descriptive statistics and test or model. Common categories and 
subcategories were identified to include relevant factors. For each factor we presented the 
number of studies reporting a significant association with LLV and details on the analysis 
performed by authors. The templates were also used to determine study heterogeneity and 
if a quantitative synthesis could be performed. 
A detailed description of findings within the context of the selected studies was generated. 
We presented factors associated with LLV in author-reported multivariate models with odds 
ratios (OR) and 95% confidence intervals (CI), as well as the co-variates that the models were 
adjusted for. Medians and interquartile ranges (IQR) or means and standard deviations (SD) 
were used for continuous parameters which were identified with less robust statistical 
methods than multivariate analysis. Categorical variables were presented with percentages. 
The statistical information for each factor was extracted from the publications based on the 
most robust method used. For instance, if a parameter was significant in the multivariate 
analysis, we did not include the univariate analysis. We generated tables reporting study 
characteristics including definition of LLV, assay for VL measurement, factors associated 
with LLV and statistical methods. Factors identified by author-reported multivariate models 





MeSH: Medline subject headings; ab.ti: abstract.title; ART: anti-retroviral therapy; cART: 




Table 2.2: Search strategy. 
 
Search Query 
#1: MeSH (HIV/ OR HIV-1/) AND (RNA, viral/ OR Viral Load/ OR Viremia/) AND (Anti-
retroviral Agents OR Anti-HIV Agents OR Antiretroviral Therapy, Highly 
Active OR HIV Integrase Inhibitors OR HIV Protease Inhibitors OR Reverse 
Transcriptase inhibitors) AND (Risk Factors/) 
#2: ab.ti (HIV) AND (anti?retroviral therapy OR ART OR cART OR HAART) AND (low 
level vir?emia) AND (predictors OR determinants OR factors) 
#3: mp (HIV) AND (low level vir?emia) AND (anti?retroviral therapy) 
#4 #1 OR #2 OR #3 
#5 Limit #4 to (humans AND yr= “2008-Current”) 
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Table 2.3: Eligibility criteria. 
 
Inclusion criteria Exclusion criteria 
1. HIV-1 infected adult patients (≥18 
years of age) 
2. Treated with ART for at least 6 
months and achieving original 
suppression 
3. VL measured with commercial 
assays 
4. LLV clearly defined as VL between 
20 and 200 copies/mL or “target 
detected” and 200 copies/mL or at 
least 95% of the LLV group having 
VL within these ranges 
5. Original publications dated from 
01/01/2008 to 16/08/2018 
1. Not specifying VL assay, LLV range 
or ART duration 
2. Not achieving suppression within 6 
months of ART commencement 
3. Utilisation of experimental in-
house or modified assays 
4. LLV >200 copies/mL 
5. Isolated viral blips (VL sequence: 
ND -> 20-200 copies/mL -> ND) 
6. Reviews and poster abstracts if 
original studies published in peer-
reviewed journal already included 
 






2.3.1 Study characteristics and heterogeneity 
Term search returned 639 publications including 165 duplicates which were removed 
(Figure 2.1). An original screening of 474 unique articles was conducted to review their 
relevance to the objective of this work and their eligibility as to the predefined 
inclusion/exclusion criteria. The original language of nine papers was not English but their 
titles and abstracts being in English contained adequate information to satisfy our exclusion 
criteria, such as defining LLV above 200 copies/mL and being reviews. A detailed 
examination of all sections (stage two) identified that more than half of records (28/43) were 
ineligible. The majority of excluded studies at the second review stage failed to fulfil our 
definition of LLV with less than 95% of patients ranging within 20 and 200 copies/mL (n = 7) 
or lack of clarity in reporting the portion of patients with VL within our range (n = 3). The 
second most frequent reason for exclusion was the utilisation of a modified protocol of a 
commercial assay aiming to increase sensitivity (n = 6).  Other less frequent reasons were 
the allowance of isolated blips (n = 3), poor virological response to ART at 6- or 12-months 
post therapy commencement (n = 3) and a review. Query of references contributed 3 
papers. In total 15 relevant publications are presented in this systematic review which are 
grouped as studies identifying patient parameters associated with LLV (n=8) (Table 2.4) and 
work comparing commercial assays (n=7) (Table 2.5). 
Several factors have been associated with LLV in published multivariate and univariate 
models. These can be categorised as pre-ART, ART-related, virological, immunological and 
methodological due to assay variability. There were differences among authors in the way 
that a factor was treated (e.g. ordinal vs. continuous variable) and these were outlined 
under each category. Factors were presented along with the statistical method which was 
used by authors and differences in study design if they were identified in more than one 
work. 
Definition of LLV, as to the VL range and confirmation on repeated measurements, varied 
significantly. Only two studies used our definition of LLV (20-200 copies/mL) with a single 
measurement of VL, while three adapted a VL range between 20 and 50 copies/mL as 
determined at one or multiple occasions. Three studies adapted a definition of LLV of 
detected HIV-1 RNA but less than the LLoQ of the assay used. Most authors (5 out of 8 
articles) compared the group with LLV to a group of patients with reported VL as “target not 
67 
 
detected” (Table 2.4). All parameters that were associated with LLV in published 
multivariate models are presented in Figure 2.2. Articles comparing the performance of 
commercial platforms identified variability around a cut-off (Table 2.6). This threshold varied 
between the LLoQ of assays and 50 copies/mL (Table 2.5). The definition of some variables 
was also different among authors. Hence, heterogeneity did not allow pooling of data and 
performance of meta-analysis. Instead a realist synthesis has been adapted (Bearman and 
Dawson, 2013). 
 
2.3.2 Patient parameters associated with low level viraemia 
 
2.3.2.1 Pre-ART factors  
Three studies reported that a higher VL prior to ART initiation was a predictor of LLV post 
therapy commencement. Pre-ART VL was treated as both ordinal and continuous variable. 
As ordinal there were two thresholds applied at 100,000 (or 5 log10) copies/mL (Martin-
Blondel et al., 2012) and at 10,000 (or 4 log10) copies/mL (Leierer et al., 2015). Pre-ART VL 
higher than 100,000 copies/mL was strongly associated with LLV between 20 and 200 
copies/mL in the published (Leierer et al., 2015) multivariate analysis (Table 2.7). VL 
between 9,999 and 100,000 copies/mL also exhibited a significant, but weaker, association 
with LLV (Table 2.7).  As a continuous variable, the median VL (IQR) for the group with LLV 
and the group with undetected VL was 5.13 (4.87-5.70) and 4.97 (4.65-5.29) log10 copies/mL, 
respectively (Pascual-Pareja et al., 2010). 
Patients with LLV between 20 and 200 copies/mL (single measurement of VL) had a diagnosis 
of HIV for a median of 18 years (median, IQR: 14-20) compared to 10 years (IQR: 6-16) in 
patients with undetected VL (Table 2.7). Charpentier and colleagues reported that 53% of 
patients with confirmed LLV between 20 and 50 copies/mL had a diagnosis of CDC stage B/C 
at the time of first-line ART initiation compared to 30% in patients with undetectable VL. 
The difference was significant in a univariate, but not in the multivariate analysis. The same 
study also reported that the LLV group had an older age (median: 47, IQR: 43-53) compared 
to undetectable controls (median 44 years; IQR: 38-50) (Table 2.7). 
 
2.3.2.2 ART-related factors 
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Two groups demonstrated that PI-based ART combinations were independently associated 
with LLV between 20 and 50 (confirmed LLV) or 20 and 200 copies/mL (Table 2.7). Falasca 
et al. reported a positive association between confirmed LLV up to 200 copies/mL and use 
of InSTI (Table 2.7). The authors added that half their patients receiving an InSTI were also 
on a PI. NRTI-sparing combinations were associated with LLV between 20 and 200 copies/mL 
in a study by Reus and colleagues (Table 2.7).   
Shorter ART duration was associated with LLV in two published multivariate logistic 
regressions adjusting for different co-founding factors as shown in Table 2.7. One study 
treated ART duration as an ordinal variable (<9 and >18 months), whereas the other study 
as a continuous (median: 15 months in the group with LLV and median: 25 months in the 
group with undetected VL). LLV was also associated with shorter duration of viral 
suppression (<50 copies/mL) less than 1 year (Table 2.7). Difference in ART duration was not 
significant in studies with treatment duration for more than one and a half years. 
Previous ART interruption longer than 8 days and at least 6 months prior to study inclusion 
was associated with LLV between 20 and 200 copies/mL as determined with a single 
measurement in a multivariate model (Table 2.7). The presence of clinical symptomatology 
or AIDS-defining conditions (CDC stage B/C) during stable ART was also related to LLV 
between 20 and 50 copies/mL (Table 2.7). 
 
2.3.2.3 Virological factors 
Infection with HIV non-B subtype (40% AG, 20% A, 17% G, 7% AE, 3% AB, 3% CRF & 3% F) 
was a predictor of LLV less than 50 copies/mL in a study from France (Table 2.7). 
A study found that higher levels of HIV-1 DNA in PBMC were associated with confirmed LLV 
below 200 copies/mL. This work stratified LLV into measurable VL between the LLoQ (37 
copies/mL) and 200 copies/mL and very low level viraemia (VLLV) reported as “target 
detected” below 37 copies/mL. Total HIV-1 DNA in PBMC was higher in the group with LLV 
(median: 3.05 log copies/106 PBMC; IQR: 3.0–3.36) than VLLV (median: 2.87 log copies/106 
PBMC; IQR: 2.53–3.18) and undetectable VL (median: 2.59 log copies/106 PBMC; IQR: 2.25–
2.88). A logistic regression model adjusting for several clinical and immunological co-
founding factors, as shown in Table 2.7, confirmed the relation between HIV-1 DNA load and 
LLV or VLLV.  
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Charpentier and colleagues demonstrated that more frequent episodes of transient 
viraemia (blip) between 50 copies/mL and 1,000 copies/mL were an independent predictor 
of persistent LLV from 20 to 50 copies/mL. Similarly, higher levels of HIV-1 RNA during earlier 
ART regimens were significantly associated with LLV during current ART, but this factor was 
not tested in the multivariate model (Table 2.7). Of note, only 6% (n=38) of their study 
population experienced LLV. 
 
2.3.2.4 Immunological factors 
Immune activation and microbial translocation are potential determinants or consequence 
of LLV. Lower CD4 count prior to initiation of current regimen and current CD4 count were 
significantly associated with LLV between 20 and 50 copies/mL and below 200 copies/mL, 
respectively, but did not maintain significance in the multivariate analysis (Table 2.7). 
Immune activation was also observed in a group of patients with detectable but 
unquantifiable VL <37 copies/mL. CD14+/CD16+/CD163+, indicating activated monocytes, 
were expressed with higher frequencies in the LLV group compared to patients with 
undetectable VL. The same work also reported an association of LLV with higher levels of 
lipopolysaccharide-binding protein (LBP) (Table 2.7). A similar study, setting a higher limit 
for LLV at 200 copies/mL, demonstrated a significant association between soluble CD14, a 
marker of microbial translocation, and LLV in a logistic regression model. The same work 
also revealed a relation between the inflammatory marker TNFα and LLV, which did not 
reach statistical significance in the model (Table 2.7). Moreover, Reus et al. showed that 
increased bacterial ribosomal DNA circulated in the blood of patients with VL from 20 to 200 
copies/mL. An analysis of variance indicated IL-6 levels were also higher in the group of 
patients with LLV compared to undetectable controls (Table 2.7). 
 
2.3.3 Assay variability  
Current knowledge as to LLV is founded on second and third generation assays the 
performance of which is compared in 7 studies (Tables 2.5 and 2.6). VL was measured in 
parallel with three real-time assays and the Amplicor v1.5 assay in a large cohort (n=391) of 
HIV-positive patients with a wide range of viraemia from target not detected (TND) to 
>100,000 copies/mL. The frequencies of LLV between 50 and 200 copies/mL with the 
RealTime, TaqMan v2.0 and TaqMan v1.0 were 11.5%, 8.2% and 9.5%, respectively, 
compared to 6.4% reported with the Amplicor v1.5 (Do et al., 2011). Overall agreement at 
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the cut-off of 50 copies/mL between the Amplicor v1.5 and the two assays currently in use 
(RealTime and TaqMan v2.0) was reported between 87% and 92% and kappa statistics (0.14) 
showed only slight agreement for LLV between the LLoQ and 200 copies/mL (Table 2.8). The 
most discrepant results were demonstrated in the comparison of the TaqMan v1.0 and 
Amplicor v1.5 with 73% (598/819) of samples being discordant at the cut-off of 50 copies/mL 
and kappa coefficients less than 0.20 (Table 2.8). 
Higher level of discordance has been observed between current and previous versions of 
real-time assays. In one study, 27% (63/230) of samples that were measured as <50 
copies/mL with the RealTime assay, were above 50 copies/mL with the TaqMan v1.0 (Table 
2.8). Yan et al. reported fair agreement of the two methods (kappa coefficient = 0.38) for 
LLV between the LLoQ and 200 copies/mL (Table 2.8). Comparing the TaqMan v1.0 and v2.0 
in 69 paired clinical samples with VL <200 copies/mL, 41% were quantified with a mean 
difference of 1 copy/mL and 9% were undetectable with both assays (Table 2.8). One study 
compared the Versant kPCR v1.0 with the RealTime and TaqMan v2.0 and found that 9.9% 
(6/61) and 8.2% (5/61) of samples, respectively, were discordant at the cut-off of 50 
copies/mL (Table 2.8). 
Discrepancies are reported with currently used real-time assays around their LLoQ. Leierer 
et al. conducted a multi-centre study with 78% of VL samples measured using the TaqMan 
v2.0 and 22% with the RealTime. In a multivariate analysis they found that the probability 
of having LLV between 20 and 200 copies/mL vs VL <20 copies/mL was lower if the RealTime 
was utilised (Table 2.7). Karasi et al. tested 328 clinical specimens with VL <200 copies/mL, 
including samples with TND, with both methods. They demonstrated 91% overall agreement 
(95% CI: 88-93) at the threshold of 50 copies/mL and 2 copies/mL mean difference of 
quantifiable VL. Overall, 60% (196/328) and 46% (150/328) of samples were undetectable 
with the RealTime and TaqMan v2.0 assay, respectively (Table 2.8). Two studies showed that 
around 13% (73/569 and 7/59) of samples that were <50 copies/ml by RealTime were above 






























Literature search: 16/08/2018 
Databases: Medline/Ovid, Medline/PubMed), Cochrane Library and Scopus 
Terms: HIV, viral load, ART, low level viraemia and predictors  
639 records 
identified 
163 duplicates removed 
476 records  433 studies excluded on initial screening (LIST REASONS) 
• LLV defined above 200 copies/mL 
• Non-clinical experimental studies or animal models 
• VL not measured with commercial assays 
• Reviews 
43 records  28 studies excluded on secondary screening 
• 7: LLV definition not within 20-200 copies/mL with 
<95% having a VL 20-200 copies/mL 
• 3: LLV definition not within 20-200 copies/mL and 
median/mean VL not mentioned 
• 6: Modified protocol of a commercial assay 
• 3: inability to achieve virological suppression 6 months 
post ART commencement 
• 3: allowing isolated blips in the control or case group 
• 1: no clear definition of LLV or accessible 95% of 
determinant VL 
• 1: <6 months on ART 
• 1: review study (references screened)  
• 1: abstract from an included study 
• 1: abstract not specifying the assay used 
• 1: 8 case studies not powered to report associations 
 
15 records: 









ART: anti-retroviral therapy; LLV: low level viraemia; VL: viral load 
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Figure 2.2: Factors associated with low level viraemia in published multivariate models1 
  
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Pre-ART VL >100,000 copies/Ml vs VL ≤9,999 copies/mL
Pre-ART VL >100,000 copies/Ml vs VL ≤100,000 copies/mL
Higher pre-ART VL, log10 copies/mL (continuous)
Pre-ART VL 100,000-99,999 copies/mL vs VL ≤9,999 copies/mL
PI vs NNRTI or InSTI -based regimen
PI vs NNRTI -based regimen
PI vs InSTI -based regimen
NNRTI-based regimen vs InSTI
ART duration <9 months vs >18 months
ART duration <12 months
Shorter ART duration, months (continuous)
One or more ART interruptions vs uninterrupted ART
CDC stage B/C vs A at study inclusion
Lower blip ratio 2 (continuous)
Non-B subtype
Higher soluble CD14, μg/ml (continuous)




1: Only variables that remained associated with LLV after adjustment are presented 
2: Blip ratio was defined as the proportion of VL values >50 copies/mL to the number of VL measurements for the period from initiation of current ART until 
study inclusion 
 
ART: anti-retroviral therapy; VL: viral load; PI: protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; InSTI: integrase strand transfer 
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TaqMan v2.0 (20) 
RealTime (40) 









TaqMan v2.0 (20) 
Target not 
detected  
20-50 (LLV) and 
target detected 









































TaqMan v2.0 (20) Below the LLoQ 20-49 1 












< 50 including target 




(median = 8 in both 
groups) 





(67); PI-based triple 
therapy (33) 





below the LLoQ 
1 





PI-, NNRTI- & INI- 
based and other 
(not specified) 




37-200 (LLV) and 
target detected 















Definition of LLV, 
copies/mL 
VL determinants1 
(Reus et al., 2013) 
Cross-sectional 
(Spain; 2011) 
PI (52); NNRTI (67); 
NRTI (86) Other 
(19) 
TaqMan v2.0 (20) 




1: Number of VL measurements required to define the groups 
2: This study also has a prospective follow-up period (2010-2011) aiming to assess virological outcomes, such as virological failure, which is not included in this 
analysis. 
3: The study objective is to present the impact of ritonavir-boosted PI monotherapy (darunavir or lopinavir) on immune activation, inflammation and microbial 
translocation compared to PI-based triple therapy. In this review we include a sub-analysis comparing activated monocytes (CD14+CD16+CD163+ cells) and 
lipopolysaccharide-binding protein (LBP) as a marker of microbial translocation in the LLV and control group. 
ART: anti-retroviral therapy; LLoQ: lower limit of quantitation; LLV: low level viraemia; VL: viral load; PI: protease inhibitor; NNRTI: non-nucleoside reverse 
transcriptase inhibitor; InSTI: integrase strand transfer inhibitor; TaqMan v2.0: Roche COBAS AmpliPrep/COBAS TaqMan version 2.0; RealTime: Abbott 
RealTime HIV-1 Viral Load assay; VLLV: very low level viraemia; NRTI: nucleoside reverse transcriptase inhibitor; Versant kPCR v3.0:  Siemens Versant HIV-1 
RNA v3.0; Versant kPCR v1.0:  Siemens Versant HIV-1 RNA kPCR v1.0 
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Table 2.5: Characteristics of studies comparing the performance of commercial assays. 
 
Reference Study type (country; period) Assays (LLoQ, copies/mL) Definition of LLV, copies/mL (VL determinants1) 
(Do et al., 2011) 
Cross-sectional multi-centre (x3) 
(USA; 2007-2008) 
TaqMan v1.0 (40) 
TaqMan v2.0 (20) 
RealTime (40) 
Amplicor v1.5 (50) 
 <50 measured using the Amplicor v1.5 (1) 
(Lima et al., 2009) Retrospective (Canada; 2006-2008) 
TaqMan v1.0 (40) 
Amplicor v1.5 (50) 
No definition 
(Swenson et al., 
2014) 
Multi-site (x14) cross-sectional 
(International) 
TaqMan v1.0 (40) 
TaqMan v2.0 (20) 
RealTime (40) 
Amplicor v1.5 (50) 
<1,000 (1) 
(Yan et al., 2010) 
Cross-sectional (Australia; 2008-
2009) 
TaqMan v1.0 (40) 
RealTime (40) 
Amplicor v1.5 (50) 
0-200 (not specified) 
(Wojewoda et al., 
2013) 
Cross-sectional (USA) 
TaqMan v1.0 (48)2 




Reference Study type (country; period) Assays (LLoQ, copies/mL) Definition of LLV, copies/mL (VL determinants1) 
(Karasi et al., 2011) 
Cross-sectional (Luxembourg & 
Rwanda; 2009) 
RealTime (40) 
TaqMan v2.0 (20) 
Amplicor v1.5 (50) 
<200 including unquantifiable samples and 
target not detected (1) 
(Ruelle et al., 2012) Cross-sectional (Belgium) 
Versant kPCR v1.0 (37) 
TaqMan v2.0 (20) 
Realtime (40) 
<50 and target detected below the LLoQ (1) 
 
1: Number of VL measurements required to define the groups 
2: Wojewoda et al. report a LLoQ for the TaqMan v1.0 of 48 copies/mL in their publication. 
LLoQ: lower limit of quantitation; LLV: low level viraemia; VL: viral load; TaqMan v1.0: Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v1.0; TaqMan v2.0: 
Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v2.0; Abbott: Abbott RealTime HIV-1 Viral Load assay; Amplicor v1.5: Roche COBAS Amplicor HIV-1 





Table 2.6: Characteristics of commercial assays utilised by the selected studies.  
 
Assay 
Lower limit of 
quantitation, 
copies/mL 
Assay characteristics Reference 
Roche COBAS AmpliPrep/ 
COBAS TaqMan HIV-1 
Test v2.0 (RT) 
20 
Dual-target of gag and LTR regions 
Quantitation based on an internal standard 
Group M (A-H & CRF01-AE) and O subtypes 
(Roche Molecular Systems, 2018) 
Abbott RealTime HIV-1 
Viral Load (RT) 40 
Targets the pol integrase region 
Quantitation based on a calibration curve 
Group M (A-G, CFR01-AE & CRF02-AG), O and N subtypes 
(Abbott, 2018) 
Roche COBAS AmpliPrep/ 
COBAS TaqMan HIV-1 
Test v1.0 (RT) 
40 
Targets a highly conserved gag region 
Quantitation based on an internal standard 
Group M (A-H & CRF01-AE) subtypes 
(Roche Molecular Systems, 2007, 
Swenson et al., 2014) 
Roche COBAS Amplicor 
HIV-1 Monitor Test v1.5 
(end-point)  
50 
Targets a highly conserved gag region 
Quantitation based on an internal standard 
Non-B subtypes amplified with reduced efficiency 
(Roche Diagnostic Systems, 1996) 
Siemens Versant HIV-1 
RNA 1 - 3 (kPCR) 
37 
Targets a highly conserved pol integrase region 





Lower limit of 
quantitation, 
copies/mL 
Assay characteristics Reference 
Group M (A-H & CRF02-AG) and O subtypes 
 





Table 2.7: Patient factors associated with low level viraemia. 
 
Reference Groups (n) Statistical method used by authors 
Parameters associated with 
LLV 
Reported OR (95% CI) or median 
(IQR) or mean (SD) or as otherwise 
stated and p-value 
(Martin-Blondel 




Multivariate logistic regressions (x2) 
Outcome: TND vs LLV (1) or VLLV (2) 
Co-variates: time since HIV diagnosis, 
duration of ART, zenith VL, duration of 
suppression (<50 copies/mL), current CD4 
count, zenith VL and NNRTI-based regimen 
(ref: PI).  
Zenith VL <5 log10 copies/mL (1): 2.48 (1.75–3.50); p <0.001 
(2): 1.51 (1.15–1.99); P = 0.003 
NNRTI-based regimen (1): 1.45 (1.03–2.04); P = 0.03 
(2): N/K 3 
Current CD4 count <500 
cells/mm3 
(1): 1.25 (0.86-1.80); P = N/K3 
(2): 1.44 (1.08–1.92); P = 0.01 
Duration of viral suppression 
>1 year 
(1): 3.33 (1.66–6.66); P = 0.0006 
(2): 1.56 (0.83-2.94); P = N/K3 
Duration of viral suppression 
>2 years 
(1): 3.23 (1.64-6.67); P = not 
reported 
(2): 2.33 (1.20–4.54); P = 0.01 
Analysis of variance (ANOVA) Time since HIV diagnosis LLV: 14 years (7) 
VLLV: 13 years (7) 
TND: 15 years (7) 
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Reference Groups (n) Statistical method used by authors 
Parameters associated with 
LLV 
Reported OR (95% CI) or median 
(IQR) or mean (SD) or as otherwise 
stated and p-value 





Multivariate regression with a forward 
stepwise selection 
Outcome: LLV 
Co-variates: pre-ART VL and duration of ART 
Pre-ART VL 4.24 (1.28–13.97) 
P = 0.018 
ART duration 0.987 (0.974–1) 
P = 0.044 









Multivariate logistic regressions x2: VL 
measured with the TaqMan v2.0 or RealTime 
assay and VL measured with the TaqMan 
v2.0 assay only (S) 
Outcome: LLV 
Co-variates (ref): age (>50 years), HIV 
transmission mode (MSM), ART interruptions 
(no interruptions), VL assay (TaqMan v2.0), 
ART duration (>18 months), ART regimen 
Pre-ART VL ≥ 100,000 (a) and 
10,000-99,999 copies/mL (b) 
(a): 4.19 (2.07–8.49); p = N/K 
(S)(a): 3.95 (1.94-8.04); p = N/K 
(b): 2.52 (1.23–5.19); p = N/K 
(S) (b): 2.38 (1.15-4.94); p = N/K 
Female heterosexuals 0.62 (0.41–0.95); p = N/K 
(S): 0.67 (0.43-1.04); p = N/K 
PI-based ART 1.54 (1.15–2.06); p = N/K 
(S): 1.60 (1.18-2.18); p = N/K 
ART duration < 9 months 2.59 (1.38–4.86); p = N/K 
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Reference Groups (n) Statistical method used by authors 
Parameters associated with 
LLV 
Reported OR (95% CI) or median 
(IQR) or mean (SD) or as otherwise 
stated and p-value 
(NNRTI- or InSTI- based regimens) and pre-
ART VL (≤9,999 copies/mL) 
(S): 2.54 (1.32-4.90); p = N/K 
ART interruptions 1.69 (1.22–2.34); p = N/K 
(S): 1.66 (1.17-2.35); p = N/K 






Multivariate logistic regression using a 
backward elimination 
Outcome: LLV 
Co-variates: age at inclusion, CDC stage at 
inclusion (B/C vs A), CDC stage at initiation of 
first-line ART (B/C vs A), VL at initiation of 
current ART, CD4 count at initiation of 
current ART, duration of current ART and blip 
ratio2. 
CDC stage B/C at study 
inclusion 2.9 (1.4–5.9) 
P = 0.003 
Blip ratio2 
0.9 (0.9–1.0) 
P = 0.001 
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Reference Groups (n) Statistical method used by authors 
Parameters associated with 
LLV 
Reported OR (95% CI) or median 
(IQR) or mean (SD) or as otherwise 
stated and p-value 
Wilcoxon Age at study at study 
inclusion 
LLV: 47 years (43-53) 
TND: 44 years (38-50) 
P = 0.04 




P = 0.006 
Wilcoxon VL at initiation of current ART LLV: 2.0 log10 copies/mL (1.7-4.5) 
TND: 1.7 log10 copies/mL (1.7-3.4) 
P = 0.02 
Wilcoxon CD4 count at initiation of 
current ART 
LLV: 254 cells/mm3 (142-583) 
TND: 402 cells/mm3 (262-587) 
P = 0.02 
(Reus et al., 2013) LLV (13) 
BLQ (39) 
Mann-Whitney Time since HIV diagnosis LLV: 18 years (14-20) 
BLQ: 10 years (6-16) 
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Reference Groups (n) Statistical method used by authors 
Parameters associated with 
LLV 
Reported OR (95% CI) or median 
(IQR) or mean (SD) or as otherwise 
stated and p-value 
P < 0.01 
χ2 NRTI-sparing regimens LLV: 69% 
BLQ: 92% 
P < 0.05 
Mann-Whitney IL-6 LLV: 90 pg/mL (81–154) 
BLQ: 79 pg/mL (61–105) 
P <0.05 
χ2 Ribosomal bacterial DNA (16S 









Multivariate logistic regression 
Outcome: LLV or combined LLV and RV 
Co-variates: age, sex, therapy combination 
(ref: INI-based regimens), duration of 
therapy, CDC stage (ref: A), years since 
diagnosis, co-infection with HBV and HCV, 
PI-based regimens 0.26 (0.08-0.88)1 
P = 0.030 
NNRTI-based regimens 0.11 (0.03-0.43)1 
P = 0.001 
HIV-1 DNA in PBMC 1.01 (1.00–1.02)1 
P = 0.003 
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Reference Groups (n) Statistical method used by authors 
Parameters associated with 
LLV 
Reported OR (95% CI) or median 
(IQR) or mean (SD) or as otherwise 
stated and p-value 
HIV-1 DNA in PBMC, soluble CD14, IL-6 and 
TNFα. 
Soluble CD14 1.66 (1.32–2.08)1 
P < 0.001 
Mann-Whitney with Bonferroni correction 
for LLV vs TND (1) and LLV vs TND (2) 
TNFα LLV: 25.6 pg/mL (22.7–30.1) 
VLLV: 23 pg/mL (18.2-26.2) 
TND: 15.5 pg/mL (13.1-21) 
P = 0.02 (1) and P = 0.046 (2) 
Kruskal-Wallis for VLLV vs TND CD4 count LLV: 565 cells/mm3 (356-925)  
VLLV: 565 cells/mm3 (303-795) 
TND: 641 cells/mm3 (523-888) 
P = 0.017 




Multivariate Cox regression model 
Outcome: TND 2 years post virological 
suppression 
Co-variates: age at HIV diagnosis and non-B 
subtype 
B subtype 
HR (95% CI): 3.98 (1.08–14.7) 
P = 0.037 
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Reference Groups (n) Statistical method used by authors 
Parameters associated with 
LLV 
Reported OR (95% CI) or median 
(IQR) or mean (SD) or as otherwise 
stated and p-value 




Mann-Whitney Activated monocytes in blood 
(CD14+/CD16+/CD163+) 
LLV: 13.65% (4.02-22.17) 
TND: 7.65 (4.21-13.31) 
P = 0.029 
Mann-Whitney Lipopolysaccharide-binding 
protein (LBP) 
LLV: 9,964 ng/mL (8,452-13,213) 
TND: 8,574 ng/mL (7,820-9,548) 
P = 0.025 
 
1: Proportional odds ratio of LLV vs combined RV and TND and combined LLV and RV vs TND. 
2: Blip ratio was defined as the proportion of VL values >50 copies/mL to the number of VL measurements for the period from initiation of current ART until 
study inclusion 
3: Not presented because not statistically significant or p >0.05. 
LLV: low level viraemia; 95% CI: 95% confidence interval; IQR: interquartile; SD: standard deviation; VLLV: very low level viraemia; TND: target not detected; 
VL: viral load; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; BLQ: below limit of quantitation; ART: anti-retroviral therapy; 
TaqMan v2.0: Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v2.0; Abbott: Abbott RealTime HIV-1 Viral Load assay; MSM: men who have sex with men; 
InSTI: integrase strand transfer inhibitor; CDC: Centers for Disease Control; NRTI: nucleoside reverse transcriptase inhibitor; HBV: hepatitis B virus; HCV: 
hepatitis C virus; PBMC: peripheral blood mononuclear cells; IL-6: interleukin 6; TNFα: tumour necrosis factor aplha  
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VL range of 
samples, 
copies/mL 
Comparison strategy Results 
(Do et al., 
2011) 
Amplicor v1.5 vs: 
TaqMan v1.0 (1) or 
TaqMan v2.0 (2) or 
RealTime (3) 
391 TND - >100,000 Concordance analysis at 50 
copies/mL cut-off with 
percent agreement and 
McNemar’s test (p-value) 
Overall agreement % (95% CI); p-value: 
(1): 91.8 (88.6-94.3); 0.0004 
(2): 92.1 (88.9-94.5); 0.0196 





50-200 Mean difference log10 copies/mL (SE); 95% CI: 
(1): 0.225 (0.0931); 0.030-0.421 
(2): 0.303 (0.1307); 0.030-0.577 
(3): 0.316 (0.1074); 0.084-0.548 
(Lima et al., 
2009) 
TaqMan v1.0 vs 
Amplicor v1.5 
159 40-100 Analysis at 50 copies/mL cut-
off with percent agreement 
and Cohen’s Kappa 
- 45% overall agreement 
- kappa statistic 0.19 (95% CI: 0.10-0.29) indicating 
slight agreement 







VL range of 
samples, 
copies/mL 
Comparison strategy Results 
-0.46 sensitivity, 0.88 specificity, 0.94 positive 





TaqMan v1.0 (1) 
RealTime vs 
TaqMan v2.0 (2) 
Amplicor v1.5 vs 
TaqMan v1.0 (3) 
Amplicor v1.5 vs 





< 50 measured 
using the 
RealTime, (1)-
(2) or Amplicor 
v1.5, (3)-(4) 
Discordance at 50 copies/mL 
with presentation of 
percentages and absolute 
numbers 
% (n) of samples with VL >50 copies/mL measured 
using the TaqMan v1.0 or v2.0 
 (1): 27 (63) 
 (2): 13 (73) 
 (3): 73 (598) 
 (4): 6 (10)  
 
(Yan et al., 
2010) 
Amplicor v1.5 vs 
TaqMan v1.0 (1) 
Amplicor v1.5 vs 
RealTime (2) 





LLoQ - 200 Cohen’s kappa coefficient Kappa coefficient (degree of agreement; 95% CI) 
 (1): = 0.16 (slight: -0.03-0.35) 
 (2): 0.14 (slight; 0.06-0.38) 







VL range of 
samples, 
copies/mL 




TaqMan v2.0 vs 
TaqMan v1.0 





Frequencies - 49% (n = 34) were quantifiable with TaqMan 
v1.0 and 54% (n = 37) with TaqMan v2.0 
- 41% (n = 28) were quantifiable with both assays 
with mean difference -0.096 log10 copies/mL 
- 9% (n = 6) were TND with both assays 
(Karasi et 
al., 2011) 
TaqMan v2.0 vs 
RealTime (1) 
TaqMan v2.0 vs 
Amplicor v1.5 (2) 
RealTime vs 






Concordance analysis at 50 
copies/mL with percent 
agreement and Wilsons 
efficient-score method (95% 
CI) 
Overall agreement, % (95% CI): 
 (1): 90.9% (87.9-93.1) 
 (2): 88.3 (N/A) 




RealTime (1) vs 
TaqMan v2.0 (2) vs 
Versant kPCR v1.0 
(3) 
61 Detected VL <50 
copies/mL 
Frequencies of VL >50 
copies/mL 
% (n) 
(1): 3.3 (2) 
(2): 14.8 (9) 




VL: viral load; TaqMan v2.0: Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v2.0; RealTime: Abbott RealTime HIV-1 Viral Load assay; Amplicor v1.5: Roche 
COBAS Amplicor HIV-1 Monitor Test, v1.5; TaqMan v1.0: Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v2.0; TND: target not detected; 95% CI: 95% 








Higher pre-ART VL, particularly above 5 log10 copies/mL, time since HIV diagnosis and CDC 
stage B/C have been associated with LLV in the published literature. The most consistent 
association was with pre-ART VL, which was identified as a strong predictor in three 
independent multivariate models that adjusted for variables including time since HIV 
diagnosis, duration of ART, ART combination, CD4 count, age, HIV mode of transmission and 
ART interruptions  (Leierer et al., 2015, Martin-Blondel et al., 2012, Pascual-Pareja et al., 
2010). Pre-ART VL has also been described as a predictor of the level of residual viraemia 
(Maldarelli et al., 2007, Palmer et al., 2008). These findings seem to reflect a larger cellular 
compartment harbouring integrated virus which was established prior to therapy 
commencement. 
Falasca and colleagues measured HIV-1 DNA in PBMC and they found that they were 
independently and positively associated with LLV in a multivariate analysis (Falasca et al., 
2017). However, it was unclear whether viral replication drove the increase in total HIV-1 
DNA or higher proviral load caused LLV. The frequency of HIV infection in CD4 T cells residing 
in the periphery, such as the GALT, was higher than in circulating CD4 T cells and cross-
infection between the two compartments was recorded (Chun et al., 2008). Virus 
production may take place in the GALT with virus shedding in the blood. Parallel 
measurement of the size of reservoirs and HIV-1 RNA level in the periphery is important, but 
also more challenging. 
Shorter duration of viral suppression also related with LLV in three independent multivariate 
analysis (Leierer et al., 2015, Martin-Blondel et al., 2012, Pascual-Pareja et al., 2010). A rapid 
decline in VL post ART initiation (first and second phase of viral decay) is followed by a third 
and fourth phase of viral decay (Palmer et al., 2008). The third phase represents a cellular 
compartment with a half-life of 39 months causing a decrease in HIV-1 RNA levels below 50 
copies/mL during the first couple of years of ART. The fourth phase reflects a stable reservoir 
with proliferative capacity that replenishes residual viraemia. Indeed, in one study using two 
cut-offs for ART duration one year of suppressive ART was less strongly associated with LLV 
below the LLoQ than 2 years (Martin-Blondel et al., 2012). 
Patients on PI-based regimens also appeared to be more likely to experience LLV (Leierer et 
al., 2015, Martin-Blondel et al., 2012). PIs have a high genetic barrier to resistance and they 
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are preferred by clinicians in cases of suspected non-adherence issues. Although the 
selected studies did not report or adjust their models for adherence, a sensitivity analysis 
revealed that groups of patients at higher risk of non-compliance, such as intravenous drug 
users, were more likely to be on PI-based ART (Leierer et al., 2015). Similarly, NRTI-sparing 
regimens and use of InSTI were associated with LLV (Falasca et al., 2017, Reus et al., 2013). 
These combinations were not first-line options at the time of recruitment for most studies 
and they were possibly used to target mutated viruses that were either transmitted or 
evolved during periods of treatment interruptions.  As to the association of LLV with non-B 
subtypes it is likely to reflect factors other than the actual virus sequence and subtype. 
Socio-economic considerations, health care access and delays in HIV diagnosis may cluster 
with non-B subtypes in some settings  (Saison et al., 2013). Moreover, most patients (51 out 
of 57) were on PI-based ART which was not accounted for in the analysis.  A review 
investigating LLV up to 500 copies/mL reported poor adherence as a risk factor (Ryscavage 
et al., 2014). Adherence is difficult to quantify, because it is a parameter based on patient-
reporting and its accuracy may be questioned. However, it is an obvious cause of LLV and 
virological failure in a similar way as ART interruptions were independently associated with 
subsequent LLV (Leierer et al., 2015). 
Markers of microbial translocation including soluble CD14, ribosomal bacterial DNA in 
blood, LBP and activated monocytes, were positively associated with LLV (Falasca et al., 
2017, Reus et al., 2013, Torres et al., 2014). Increased levels of the inflammatory markers IL-
6 and TNFα in patients with LLV may also be the result of increased microbial translocation 
(Falasca et al., 2017, Reus et al., 2013). CD4 depletion in the GALT during early infection 
causes microbial translocation, which declines with the reduction of VL following therapy 
initiation, but does not normalise (Jiang et al., 2009). Residual viral replication at the 
intestinal mucosa may cause compromisation of the GALT and microbial translocation. 
Alternatively, early events during the infection may have significant structural effects on 
GALT, which do not reverse with ART, resulting in chronic microbial translocation and 
immune activation with subsequent virus production. As to circulating CD4 counts, they 
were significantly lower in patients with LLV, but adjusting for co-founding factors such as 
duration of ART and CDC stage made their difference insignificant (Martin-Blondel et al., 
2012). 
We report that current literature varies remarkably as to the definition of LLV and study 
design. We applied strict eligibility criteria in an attempt to collect comparable data. Despite 
the small number of relevant studies (n=15) included, methodology strategies adopted by 
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authors differed significantly making impossible to conduct of a collective approach and 
comparison, such as a meta-analysis. For instance, two studies with similar design utilised 
different  definitions for LLV with one adapting a VL between 20 and 200 copies/mL as 
determined from a single measurement and the other using a VL range between 20 and 50 
copies/mL as measured on one or two occasions  (Leierer et al., 2015, Martin-Blondel et al., 
2012). Moreover, the control group in the former probably (but not clearly stated) included 
patients with detected VL below the LLoQ, whereas patients with detected but not 
quantified (VLLV) VL shaped a separate category in the latter. The same model was applied 
to the VLLV group and the same associations as the LLV group were identified with the only 
exception of treatment combination that was not different.  Yet, both studies identified 
higher pre-ART VL, shorter ART duration and PI-based regimens as factors associated with 
LLV. 
The same factors were also demonstrated in a work by Vancoillie et al., but isolated blips 
were allowed in the “aviraemic” control group (Vancoillie et al., 2014). In literature isolated 
viral blips are generally accepted as insignificant clinical events reflecting random biological 
or statistical variation (Nettles et al., 2005). Blips were reported in 10% of chronically 
suppressed patients during routine follow-ups with a median VL of 78 and 116 copies/mL 
with the TaqMan v1.0 and TaqMan v2.0, respectively (Garrett et al., 2012). Also, 38% of LLV 
may also evolve in future blips and vice versa, more frequent blips may predict future LLV 
(Charpentier et al., 2012, Wojewoda et al., 2013). Hence, viral blips are different from LLV 
and as a result we decided to exclude them from this work. However, we included studies 
that defined LLV based on a single measurement and in this scenario a proportion would 
represent isolated blips and not persistent LLV. Only 2 studies used strict criteria in their 
definition of persistent LLV including at least two consecutive measurements of VL. As a 
result, the size of the case group is smaller compared to the control group. Of note, we 
report that the proportion of patients with LLV ranges in selected studies from 6% to 77%. 
We utilised a time frame beginning in 2008, which is the transition year from a decade of 
use of the Amplicor method in clinical settings to third generation assays. The rationale was 
to reduce under-reporting of LLV <200 copies/mL as demonstrated in five selected studies 
(Do et al., 2011, Karasi et al., 2011, Lima et al., 2009, Swenson et al., 2014, Yan et al., 2010). 
Third generation real-time assays detect nucleic acids during the exponential phase of each 
amplification cycle producing faster results and reducing the risk of contamination. The main 
representatives of real-time platforms, the TaqMan v2.0 and RealTime, show good 
correlation of results within their entire range of reporting values (Do et al., 2011, Paba et 
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al., 2011, Swenson et al., 2014, Yan et al., 2010). However, concordance is getting poorer 
close to their LLoQ. Percent agreement at the 50 copies/mL cut-off was reported around 
90% (Karasi et al., 2011, Swenson et al., 2014). Intra-assay variability of the RealTime and 
TaqMan v2.0 was significant with over half of clinical samples being discordant as to their 
detection status at the 50 copies/mL cut-off for at least one out of three replicates (Ruelle 
et al., 2009). Discordant results around the assay LLoQ differed between the two methods 
and were more pronounced for the TaqMan v2.0 compared to the RealTime. Leierer et al. 
observed that patient samples tested with the TaqMan v2.0 had higher frequency of LLV 
between 20 and 200 copies/mL compared to the RealTime (Leierer et al., 2015). However, 
more than half of them (57%) had a VL between 20 and 50 copies/mL for which both inter- 
and intra- assay repeatability is poor. Non-B HIV subtypes and sample handling may have 
affected reported results in the past, but they are less of an issue with new fully automated 
assays (Ndiaye et al., 2015, Parekh et al., 2018). 
A main drawback of this systematic review is that it is based on a qualitative synthesis. We 
tried to present the data accurately within the context of the selected studies. Yet, there is 
an element of subjectivity. In addition, only one reviewer conducted the search and 
selection of studies as part of the original work presented by the student in this thesis. 
Moreover, all selected studies have a cross-sectional design and causality is not proven but 
assumed for factors preceding LLV. 
Current literature addressing the issue of LLV is subject to variability due to lack of a broadly 
accepted definition which would specify range of HIV-1 RNA levels and duration. We 
propose that the factors identified in literature to be associated with LLV between 10 and 
200 copies/mL reflected a larger size of cellular reservoirs, adherence issues and enhanced 
microbial translocation. Due to assay limitations, we need to treat with caution any findings 
regarding viraemia between 20 and 50 copies/mL. Further work is required to confirm 
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Combination ART effectively suppresses viral replication, which is reflected in a steep 
decline in VL, but it cannot eradicate HIV as indicated by persistence of a latent reservoir 
and residual viraemia (Dornadula et al., 1999, Havlir et al., 2005, Maggiolo et al., 2012, 
Maldarelli et al., 2007, Palmer et al., 2008, Palmisano et al., 2005). Moreover, treatment 
cessation results in viral rebound with new cycles of viral production and infection (Wen et 
al., 2018). Replication-competent virus resides as integrated provirus mainly in resting CD4 
T cells, a latent reservoir which is established early after infection and persists at stable 
levels in spite of effective ART (Ho et al., 2013, Hosmane et al., 2017, Ruggiero et al., 2015, 
Shen and Siliciano, 2008b, Siliciano et al., 2003, Siliciano and Siliciano, 2004). Ability to 
propagate via cell proliferation without requiring virus production and potential for 
generating intermittent bursts of virus production upon cell activation are key features of 
the HIV reservoir (Ananworanich et al., 2016, Bachmann et al., 2019, McManus WR et al., 
2018, Pitman et al., 2018, Wang et al., 2018).   
Residual viraemia is the presence of HIV-1 virus in the plasma at levels below the LoD of 
commercial assays. Residual viraemia is stable with a mean of 3 copies/mL and it is detected 
with ultrasensitive methods in the majority of ART-suppressed patients (Amendola et al., 
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2011, Hatano et al., 2009, Margot et al., 2018, Palmer et al., 2008, Yukl et al., 2011). Palmer 
and colleagues found that all of their suppressed patients who were sampled longitudinally 
had at least one specimen with residual viraemia quantified with a SCA. Residual viraemia 
confirms the existence of an active, or intermittently active, HIV-1 reservoir. Yet, it remains 
to be elucidated which are the particular cell types or the circumstances that drive virus 
release.  It has been proposed that direct or bystander activation of resting memory CD4 T 
cells harboring HIV-1 may result in intermittent virus shedding identified by SCA (Anderson 
et al., 2011, Hermankova et al., 2001, Kieffer et al., 2004). The clonal character of sequences 
found in residual viraemia indicate production of virus by a single type of cell with 
proliferative capacity (Sahu, 2015). The lack of occurrence of new drug resistance mutations 
following ART initiation and the inability of intensification strategies to clear residual virus 
in plasma are substantial arguments against ongoing cycles of viral replication and infection 
(Bailey et al., 2006, Brennan et al., 2009, Buzon et al., 2010, Hatano et al., 2011, McMahon 
et al., 2010). 
Eradication of this cellular reservoir by the immune system appears unattainable. HIV-
specific cytotoxic lymphocytes, although abundant during chronic infection, are unable to 
clear cellular reservoirs harboring integrated viral DNA (Lieberman et al., 2001). Antigen 
presentation to naïve T cells (CD45RA+) drives their differentiation to antigen-specific 
effector cells (CD45RA-) which reverse to a memory state, either as central (CCR7+) or 
effector (CCR7-), upon pathogen clearance (Ahmed and Gray, 1996, Bevan and Goldrath, 
2000, Parish and Kaech, 2009, Seder and Ahmed, 2003, Wherry and Ahmed, 2004). Antigen 
persistence during chronic infection, on the other hand, results in functional impairment 
characterised by reduced cytokine production, proliferation and cytotoxicity (Wherry et al., 
2003). Functional impairment appears to be associated with increased expression of PD1 
(Barber et al., 2006, Freeman et al., 2006), which is also a marker of latency in HIV infection 
(Ghosn et al., 2018). PD1 binds to its ligands (PD-L1 and PD-L2) and approximates TCR while 
TCR interacts with antigens. The complex is a negative regulator of lymphocyte activation 
by downsizing intracellular signals (Freeman et al., 2000, Greenwald et al., 2005, Latchman 
et al., 2001, Okazaki and Honjo, 2007). PD1 overexpression on HIV-specific memory T cells 
has been observed and associated with cell exhaustion and apoptosis (Day et al., 2006, 
Petrovas et al., 2006).  
We conducted a study in a strictly defined population of HIV-1 positive patients on first line 
ART experiencing consistent VL suppression since treatment commencement. Our aim was 
to identify virological and immunological factors associated with residual viraemia. We 
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focused on HIV-1 DNA load in PBMC, which is a good indicator of HIV-1 reservoirs and PD1 







3.2.1 Study population 
To circumvent heterogeneity and identify a highly stable on treatment population we 
applied strict eligibility criteria (Table 3.1). We screened the records of all patients attending 
the HIV clinic at the Royal Liverpool University Hospital between October 2013 and August 
2014. Eligible patients were on first line combination ART with two NRTIs and either a NNRTI 
or a PI. We allowed a single switch of PI to another PI and modifications of the NRTI 
backbone for tolerability reasons. ART was commenced at least 6 months prior to 
recruitment and VL was regularly monitored with commercial assays at a minimum of two 
routine visits per year. VL was suppressed below 50 copies/mL within 6 months of ART 
commencement and remained persistently suppressed since and until all samples were 
collected. Patients on PIs were allowed single blips up to 200 copies/mL which were 
confirmed with suppressed VL preceding and following the isolated events of viraemia. 
Eligible patients had to report good adherence with no missed doses and no recorded 
treatment interruptions.   
The study complied with the Standard Operating Procedures for Research Ethics 
Committees (REC) in the UK and received approval by the National Research Ethics Service 
(NRES) committee and local Research Development and Innovation (RD&I) department 
(REC: 10/H0808/75). All patients were provided with an information leaflet and signed a 
consent form. This project is funded by the Engineering and Physical Sciences Research 
Council (EPSRC) and it is included in the National Institute for Health Research Clinical 
Research Network (NIHR CRN) portfolio.  
 
3.2.2 Sampling 
Up to 36mL of whole blood was collected in EDTA tubes and processed within 1.5 hours of 
venipuncture to maximise yield and cell viability. Samples underwent centrifugation at 2,500 
rpm for 10 min at 180C and plasma was immediately stored at – 800C. The remaining 
fractions were mixed with equal volume of Roswell Park Memorial Institute (RPMI) medium 
(80% RPMI 1640 and 20% fetal bovine serum [FBC]) and used to isolate PBMC by density 
gradient centrifugation. Briefly, 20mL of diluted sample was layered on 15mL of Ficoll-Paque 
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medium and centrifuged at 500 xg for 30 min with no break at 180C. The PBMC layer was 
harvested and washed twice to remove Ficoll-Paque and platelet contaminants. The 
washing steps included resuspension in RPMI medium up to a total volume of 50 mL and 
centrifugation at 300 xg for 10 minutes (180C). 
Cells were resuspended in 10 mL of RPMI medium and the number of viable cells was 
counted with the haematocytometer. Tryptan Blue stain 0.4% was mixed with the cells at a 
dilution 1:10 (10 μL of specimen and 90 μL of stain). Using a hand tally counter the number 
of live cells (unstained by Tryptan Blue) were counted in all four corner squares (a). The total 
number of cells was calculated from the formula: (a/4)*10*(10^4)*10. The viability 
requirement was set at >90%. If less than 90% of cells were viable, another aliquot was 
tested. In cases of viability <90% in the repeated aliquot, the sample was discarded and a 
new sample from the patient was sought. However, cell viability was above 97% in all 
samples and none of the above was required. Cells for freezing were centrifuged and 
resuspended in cold sterile freezing medium made up of 80% FBS and 20% 
dimethylsulphoxide (DMSO).  Aliquots were then placed in Mr Frosty, a container with 
isopropyl alcohol, which was kept for at least 2.5 hours at -800C. This way the temperature 
was gradually decreased to -800C at cooling rate of about 10C/min to avoid osmotic 
intracellular dehydration. Aliquots were transferred to liquid nitrogen the following day. 
Fresh PBMC aliquots (10x106) were used immediately for flow cytometry. Aliquots of 5x106 
were stored in 1mL freezing medium at -800C or liquid nitrogen. This process was carried 
out by three colleagues, Yufei Wang (post-doctoral researcher), Alessandra Ruggiero 
(doctoral student) and me. 
 
3.2.3 Ultrasensitive quantification of plasma HIV-1 RNA  
HIV-1 RNA levels were measured with a validated in-house ultrasensitive assay that applied 
a modified version of the RealTime assay on the Abbott m2000 (sp/rt) platform 
(Maidenhead, UK) (Kiselinova et al., 2015, Ruggiero et al., 2015). A total of 8 mL of plasma 
was ultra-centrifuged at 35,000 rpm (209,490.6 xg) for 15 min at 40C with a centrifuge rotor 
Beckman SW41. The pellet was resuspended in 1 ml of basematrix (SeraCare, USA) and 
processed on the Abbott m2000 platform as per the manufacturer’s instructions. The assay 
employs automated RNA extraction, followed by cDNA transcription and amplification using 
internally controlled real-time PCR. Three types of results were reported: (i) HIV-1 RNA 
copies/mL if the level was above the LLoQ, (ii) target detected if below the LLoQ but above 
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the LoD and (iii) target not detected if less than the LoD. For samples reported in (i) and (ii) 
the output Ct value was used in a formula with the run intercept and slope values to 
estimate the number of copies per mL of plasma (VL = 10^[(Ct-Intercept)/Slope]/8). Results 
were reported in copies/mL. 
The assay was previously validated by spiking HIV-negative plasma with four serial dilutions 
of the WHO 3rd International HIV-1 RNA Standard in quadruplicates (Palmer et al., 2003). 
The assay detection rates for 5, 3 and 1 HIV-1 RNA copies/mL were 100%, 80% and 60%, 
respectively (Ruggiero et al., 2015). 
 
3.2.4 Quantitation of cellular HIV-1 DNA  
3.2.4.1 DNA extraction 
HIV-1 DNA load was measured using cryopreserved PBMC. For each patient, an aliquot of 5 
x 106 PBMC stored at -800C was thawed to room temperature. DMSO-containing freezing 
solution was immediately removed with two washing steps by adding phosphate-buffered 
saline (PBS) and centrifugation at 800 xg for 10 min on a bench microcentrifuge. Cell death 
and release of viscous DNA causing cell clumping was expected to be minimal only from 
thawing, as cells were frozen gradually with Mr Frosty. Cells were resuspended in 200 μL of 
PBS. The QIAamp® DNA Mini and Blood Mini kit (Thermo Fisher Scientific) was used to 
isolate DNA as described by Geretti et al. (Geretti et al., 2013a). In brief, cell lysis was 
performed with addition of Proteinase K (20 μL) and lysis buffer (200 μL) and incubation at 
560C for 30 min and 1000C for 30 min. DNA was then purified with QIAamp Mini spin columns 
following the manufacturer’s instructions to yield a 100 μL DNA eluate which was stored at 
-200C until DNA quantification. 
 
3.2.4.2 DNA quantitation 
Total DNA concentration in extracts was determined by a spectrophotometer (Thermo 
Scientific NanoDropTM 1000) at an optical density of 260 nm. DNA concentration was 
adjusted to 50 ng/μL in a volume of 50 μL, which corresponds to 1 μg of double stranded 
DNA per PCR input volume (20 μL) and 150,000 cells (Dib et al., 1996). The same buffer as 
the eluate (Buffer AE, Qiagen) was used as blank before measurements and to dilute DNA. 
DNA purity was assessed with the 260/280 and 260/230 ratios. Any ratio lower than 1.8 
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indicated contamination (e.g. protein) and extraction was repeated. Diluted samples were 
checked for concentration and readings were recorded, or further dilutions were performed 
if required. 
Total HIV-1 DNA load in PBMC was quantified by a quantitative real-time PCR using the 
Applied Biosystems 7500 Real-Time PCR platform.   A standard curve incorporating four 
quantities of HIV-1 DNA (6,000, 600, 60 and 6 copies/reaction) was produced for every run 
using the Generic HIV DNA CELL kit (Biocentric Laboratories, France) (Avettand-Fenoel et al., 
2009). A 50 μL volume per reaction contained 1 μg of DNA extract. The target was a 
conserved LTR region. Thermal cycles included 2 minutes at 500C (uracil-DNA glycosylases 
incubation), 10 minutes at 950C (polymerase activation) and 50 cycles of 15 seconds at 950C 
(denaturation/melting step) and 1 minute at 600C (hybridisation/annealing step). The 
software reported HIV-1 DNA copies/μg (b) which was converted into HIV-1 DNA copies/106 
PBMC using the formula: b * 10^6 / 150,000.  
 
3.2.5 PD1 expression on CD4 and CD8 T cell subsets 
A post-doctoral researcher in the group (Yufei Wang) performed all immunophenotyping on 
fresh PBMC isolated from whole blood within 2 hours of collection1. Immunophenotyping 
was part of a separate project and I was given access to the final data only. An aliquot of 10 
million PBMC was used. PBMCs were stained for markers of differentiation (CD3, CD4, CD8, 
CD45RA, CCR7) and exhaustion (PD1) with directly conjugated antibodies purchased from 
Biolegend (CD3/4/8-PE, CD45RA-perCP, CCR7-FITC, PD1-APC). Markers co-expression was 
measured on the BD FACSCalibur platform as per manufacturer instructions and raw data 
were processed with the accompanying software. 
 
3.2.6 Statistical analysis 
Statistics were conducted with SPSS version 25 (IBM). Continuous variables that were 
normally distributed are presented as means with SD whereas continuous variables that did 
not have normal distribution are presented as medians and IQR. Normality of continuous 
variables was assessed through Shapiro-Wilk test (Shapiro and Wilk, 1965). Categorical 
1: All experiments were performed by myself, unless otherwise stated. 
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variables are presented with frequencies and percentages.  We assigned the value of 0.5 
copies/mL to undetectable HIV-1 RNA with the SCA to use in descriptive statistics and 
further analysis. A comparative analysis between patients with detectable and undetectable 
HIV-1 RNA below 50 copies/mL was conducted using the chi-square or Fisher’s exact test for 
categorical variables. Student’s t-test and Mann-Whitney test were applied to continuous 
variables that were normally and non-normally distributed, respectively. Levene test was 
applied to confirm the assumption of equal variance between groups before proceeding 
with comparison of means. Univariate and multivariate logistic regression models were used 
to explore factors associated with residual viraemia. The outcome (dependent) variable was 
detectable HIV-1 RNA with the SCA. A stepwise model selection process was used for the 
adjusted analysis; initially every variable from the univariate analysis with a p value of less 
than 0.20 was added in the model and then the non-significant ones were removed 
sequentially with the “Backward: LR” method in SPSS. Predictor variables were tested for 
multicollinearity before included in the model with the variance inflation factor (VIF) being 
less than 5. The analysis was performed under the kind guidance of Eftychia Psarelli, a senior 





Table 3.1: Eligibility criteria for inclusion in the study. 
 
Eligibility criteria 
Adult (>16 years old) HIV-1 positive patients 
First line ART with two NRTIs and either an NNRTI or a PI 
No changes of the NNRTI 
Changes from one PI to another PI allowed 
Changes of the NRTI arm allowed within the same drug class 
ART commenced at least 6 months prior to recruitment 
Viral load suppression <50 copies/mL documented within 6 months of starting ART  
No recorded viral load rebound1   
No treatment interruption  
At least two viral load measurements documented per year 
 
 
1: Episodes of viral rebound were defined as VL >50 copies/mL for the NNRTI-based group 
and VL >200 copies/mL for the PI group. Isolated blip events between 50 and 200 copies/mL 
were permitted in patients on PIs. 
ART: anti-retroviral therapy; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-





3.3.1 Study population 
A total of 59 HIV-1 positive patients were recruited. Three moved to another region before 
sampling and we had inadequate blood volume for both virological and immunological 
experiments for three, yielding 53 patients for analysis.  Their characteristics are shown in 
Table 3.2.  In brief, all subjects were receiving ART with either an NNRTI (n=42, 79%) or a 
ritonavir-boosted PI (n=11, 21%). At sampling patients were on ART for a median duration 
of 5.1 years (IQR: 1.7-7.2) with VL suppression (<50 copies/mL) for a median of 4.8 years 
(IQR: 1.5-7.0). The shortest duration of ART was almost a year (34 weeks) and the longest 
16.5 years. The most commonly used ART combination was TDF/emtricitabine (FTC) plus 
efavirenz (EFV) or darunavir/ritonavir (DRV/r) (Table 3.2).  In the PI group, only 2 subjects 
changed from the initial PI (lopinavir/ritonavir and saquinavir/ritonavir were switched to 
DRV/r and atazanavir/ritonavir due to diarrhoea and hypercholesterolaemia, respectively). 
There were 15 cases of NRTI changes in 12 patients (Appendix, table A.2). 
 
3.3.2 Virological parameters 
Residual HIV-1 RNA in plasma was detected in 19 patients. Almost two thirds (n=34, 64.2%) 
of all patients had undetectable HIV-1 RNA in the plasma. Although almost one third (n=13, 
31%) experienced detectable HIV-1 RNA in the group of patients receiving NNRTI-based 
regimens, more than half (n=6, 54.5%) of patients on a PI-based regimen had residual 
viraemia quantified with our SCA. Reflecting these findings, the median was an undetectable 
HIV-1 RNA (assigned an arbitrary level of 0.5 copies/mL, IQR: 0.5-2) overall, and 2 copies/mL 
(IQR: 0.5-3) in patients on PI-based regimens (Table 3.2). Residual HIV-1 RNA which was 
quantified with our SCA had a median of 3 copies/mL (IQR: 2-7). Only three patients had 
viraemia quantified above 10 copies/mL. The highest value of 38 copies/mL was measured 
in a subject who at the time of sampling had been receiving TDF/FTC/DRV/r for 45 weeks 
and had shown a suppressed VL (<50 copies/mL) for 23 weeks, which was the shortest 
duration of suppression in our cohort. 
Total HIV-1 DNA had a median of 2.6 log10 copies/106 PBMC (IQR: 2.4-3.1) and a range 
between 1.74 and 3.59 log10 copies/106 PBMC. 
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We first explored differences between groups with undetectable (n=34) and detectable HIV-
1 RNA in plasma (n=19) combining the NNRTI and PI group together (Table 3.3). HIV-1 DNA 
load in PBMC, PD1 expression on effector memory CD4 T cells and on central and effector 
memory CD8 T cells differed significantly among the two groups (Figure 3.1). We noted that 
duration of suppression below 50 copies/mL and ART duration were shorter in the group 
with detected HIV-1 RNA in plasma, although that was not statistically significant.  
 
3.3.3 Immunological parameters 
CD4 and CD8 were balanced with a ratio of 1. The highest PD1 expression was observed on 
effector memory CD4 T cells (CD4+/CD45RA-/CCR7-) and the lowest on naive CD4 T cells 
(CD4+/CD45RA+) as shown in Table 3.2. CD4+ and CD8+ cells had similar expression levels 
of PD1. However, PD1 expression was higher on the effector memory CD4 subset compared 
to CD8 and naïve CD8 subset. PD1 expression on all CD4 and CD8 subsets was higher in 
patients receiving NNRTI-based ART compared to PI-based ART with the differences being 
more prominent for CD8 than CD4 cells. 
PD1 expression on total and memory CD4 and CD8 subsets was consistently higher in 
patients with undetectable HIV-1 RNA compared to the group with detectable HIV-1 RNA 
(Figure 3.2). The highest PD1 expression was observed on effector memory CD4 cells in both 
undetected and detected groups. There was a consistent 5% difference between the two 
groups for total and central memory CD4 cells and this difference more than tripled for 
effector memory CD4 cells (17%). A similar trend was demonstrated among CD8 subsets 
with PD1 expression on effector memory CD8 cells being also the highest, but the difference 
between the two groups of patients remained stable around 10% for all memory subsets 
(Figure 3.2).   
 
3.3.4 Factors associated with residual viraemia 
Factors independently associated with the detection of residual HIV-1 RNA were first 
explored by univariate logistic regression analysis and the results are summarized in Table 
3.4. There was an association between the detection of HIV-1 RNA and total HIV-1 DNA in 
PBMC, and PD1 expression on effector memory CD4 cells and central and effector memory 
CD8 cells.  More specifically, for every unit increase in the log10 DNA copies, the odds of 
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detectable HIV-1 RNA were increasing 9 times, although with 95% assurance this estimate 
could have been between 1.8 to 45 times greater (p = 0.007). Similarly, for every unit 
increase in the % of PD1 expression on CD4+/CD45RA-/CCR7-, the odds of residual viraemia 
as quantified with our SCA were decreased by 4%, although with 95% assurance this 
estimate could have been between 1% and 8% (p=0.034). 
Age, third agent, total HIV-1 DNA in PBMC, time from suppression to recruitment, CD8%, 
PD1 on CD8+ (%), PD1% on CD8+/CD45RA-/CCR7+ (%), PD1 on CD8+/CD45RA-/CCR7- (%) 
and PD1 on CD4+/CD45RA-/CCR7- (%) had a p-value less than 0.2 in the univariate analyses 
and passed the multicollinearity check allowing for inclusion as predictor variables in the 
logistic regression (VIF for PD1 on CD8+/CD45RA- was 7.38 and the variable was excluded). 
The relation between total HIV-1 DNA and residual viraemia remained significant adjusting 
for PD1 expression on effector memory CD4 T cells and age in the final model (Table 3.5). 
The steps to the final model are shown in Appendix, Table A.3.    
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Figure 3.1: Factors associated with residual viraemia in the univariate analysis.  
   
 
(a) median total HIV-1 DNA in the group with undetectable and detectable HIV-1 RNA in plasma and (b) median PD1 expression on CD4 and CD8 subsets 
in the group with undetectable and detectable HIV-1 RNA in plasma. P-value <0.05 
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Table 3.2: Baseline characteristics of the study population overall and stratified by therapy 
as non-nucleoside reverse transcriptase inhibitor and protease inhibitor -based regimens. 
 
Characteristic Total (n=53) NNRTI (n=42) PI (n=11) 
Age (years), mean (SD) 43.5 (9.9) 44.4 (10.1) 40.2 (8.5) 




























Time from diagnosis to start of 
ART), median months (IQR) 
9.9 (1.9 – 44.2) 10.0 (2.0 – 42) 4.9 (3.3 – 5.9) 




























Nadir CD4 count (cells/mm3), 
mean (SD)* 
198 (108) 191 (109) 222 (109) 
Nadir CD4 count (cells/mm3), 
median (IQR)* 
183 (124-276) 179 (125-239) 233 (139 – 313) 
Pre-ART VL (log10 copies/mL), 
median (IQR) 
4.8 (4.5 – 5.2) 4.8 (5 – 5.2) 4.9 (0.8) † 
Calendar year for ART 
commencement, median (IQR) 





















































No of PI changes, n 1 2 N/A 2 
Duration of ART (years), 
median (IQR) 
5.1 (1.7 – 7.2) 5.9 (2.5 – 7.8) 2.8 (1.3 – 5.2) 
Duration of viral load 
suppression (years), median 
(IQR) 
4.8 (1.5 – 7.0) 5.2 (3.3) † 1.9 (0.8 – 4.8) 
Residual HIV-1 RNA, median 
copies/mL (IQR) 
0.5 (0.5-2) 0.5 (0.5-1.8) 2 (0.5-3) 
Total HIV DNA, median log10 
copies/106 PBMC (IQR) 
2.6 (2.4 – 3.1) 2.6 (0.4) † 3.1 (0.4) † 
CD4 count mean cells/mm3, 
(SD) 
650 (223) 637 (220) 695 (241) 
CD4 (%), mean (SD) 37.5 (8.2) 37.6 (8.3) 37 (8.5) 
CD8 (%), mean (SD) 38.5 (11.3) 38.4 (10.6) 39 (14.0) 
CD4/CD8 ratio, median (IQR) 1.0 (0.7 – 1.4) 1.0 (0.7 – 1.4) 1.1 (0.5) † 
PD1 on CD8+ (%), median 
(IQR) 
17.1 (10.2 – 
24.0) 
19.1 (9.0) † 12.1 (6.1) † 
PD1 on CD8+/CD45RA- (%), 
median (IQR) 
28.0 (18.9 – 
39.0) 
32.3 (14.9) † 22.5 (14.6) † 
PD1 on CD8+/CD45RA-/CCR7+ 
(%), median (IQR) 
22.6 (14.3 – 
35.8) 
25.7 (13.9) † 19.5 (13.2) † 
PD1 on CD8+/CD45RA-/CCR7- 
(%), median (IQR) 
32.3 (20.7 – 
48.0) 
36.7 (16.9) † 20.8 (15.1) † 
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Characteristic Total (n=53) NNRTI (n=42) PI (n=11) 
PD1 on CD8+/CD45RA+ (%), 
median (IQR) 
6.4 (3.9 – 11.9) 7.2 (4.0 – 13.6) 5.7 (3.1) † 
PD1 on CD4+ (%), median 
(IQR) 
17.6 (11.5 - 
25.1) 
18.5 (11.8 – 
25.2) 
16.6 (7.4) † 
PD1 on CD4+/CD45RA- (%), 
median (IQR) 
25 (18.9 – 31.9) 26.8 (21.9 – 33) 23.4 (10.7) † 
PD1 on CD4+/CD45RA-/CCR7+ 
(%), mean (SD) 
21.3 (9.0) 22.1 (8.8) 18.0 (9.3) 
PD1 on CD4+/CD45RA-/CCR7- 
(%), mean (SD) 
40.2 (16.3) 42.5 (16.2) 31.3 (13.9) 
PD1 on CD4+/CD45RA+ (%), 
median (IQR) 
2.4 (1.0 – 4.7) 2.5 (1.0 – 5.9) 2.4 (1.7 – 2.7) 
 
 
*Shapiro Wilcoxon test indicated a normal distribution for nadir CD4 count (P >0.05). Here 
we present both mean and median as per Shapiro Wilcoxon test and as frequently 
encountered in literature, †: mean (SD)  
NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; VL: viral load; 
SD: standard deviation; MSM: men who have sex with men; IQR: interquartile; TDT: 
transmitted drug resistance; ART: anti-retroviral therapy; VL: viral load; EFV: efavirenz; NVP: 
nevirapine; RPV: rilpivirine; DRV/r: darunavir/ritonavir; LPV/r: lopinavir/ritonavir; ATV/r: 






Table 3.3: Comparative analysis of the group with undetected HIV-1 RNA in plasma vs. 








Age (years), mean (SD) 44.9 (9.9) 40.9 (9.7) 0.162* 





















Time from diagnosis to start of 
ART), median months (IQR) 
9.5 (1.8 – 37.1) 16.1 (1.9 – 54.3) 0.711** 







Nadir CD4 count (cells/mm3), 
mean (SD)¥ 
195 (119) 202 (89) 0.818* 
Nadir CD4 count (cells/mm3), 
median (IQR)¥ 
172 (114-242) 203 (147-288) 0.565** 
Pre-ART VL (log10 copies/mL), 
median (IQR) 
4.7 (4.6 – 5.2) 4.9 (4.5 – 5.0) 0.857** 







Duration of ART (years), 
median (IQR) 
5.9 (2.4-8.0) 3.9 (1.6-6.0) 0.111** 
Duration of viral load 
suppression (years), median 
(IQR) 
5.6 (1.5-7.8) 3.5 (1.4-5.9) 0.097** 
Total HIV DNA, median log10 
copies/106 PBMC (IQR) 









CD4 count mean cells/mm3, 
(SD) 
627 (223) 691 (224) 0.359* 
CD4 (%), mean (SD) 38.4 (7.7) 35.9 (9.0) 0.297* 
CD8 (%), mean (SD) 36.7 (10.5) 41.7 (12.2) 0.124* 
CD4/CD8 ratio, median (IQR) 1.0 (0.8 – 1.5) 1.0 (0.6 – 1.4) 0.250** 
PD1 on CD8+ (%), median 
(IQR) 
18.5 (12.7 – 
27.6) 
12.1 (9.2 – 18.2) 0.064** 
PD1 on CD8+/CD45RA- (%), 
median (IQR) 
31.0 (2.07 – 
41.9) 
21.3 (15.3 – 
32.4) 
0.097** 
PD1 on CD8+/CD45RA-/CCR7+ 
(%), median (IQR) 
24.9 (17.8 – 
37.3) 
15.7 (10.3 – 
25.2) 
0.034** 
PD1 on CD8+/CD45RA-/CCR7- 
(%), median (IQR) 
37.5 (23.9 – 
52.0) 
23.0 (16.5 – 
34.8) 
0.022** 
PD1 on CD8+/CD45RA+ (%), 
median (IQR) 
9.6 (3.9 – 13.8) 5.1 (3.9 – 9.0) 0.179** 
PD1 on CD4+ (%), median 
(IQR) 
19.0 (2.6 – 27.9) 13.6 (2.1 – 22.8) 0.383** 
PD1 on CD4+/CD45RA- (%), 
median (IQR) 
25.2 (3.7 – 33.9) 22.6 (6.7 – 27.8) 0.105** 
PD1 on CD4+/CD45RA-/CCR7+ 
(%), mean (SD) 
22.4 (8.8) 19.2 (9.1) 0.219* 
PD1 on CD4+/CD45RA-/CCR7- 
(%), mean (SD) 
43.9 (16.0) 33.7 (15.2) 0.028* 
PD1 on CD4+/CD45RA+ (%), 
median (IQR) 
12.0 (1.0 – 22.0) 11.6 (1.4 – 17.5) 0.809** 
 
*Student’s t-test (normally distributed continuous variables), †: Chi-squared test (categorical 
variables), **: Mann-Whitney test (non-normal continuous variables), ‡: Fisher’s Exact test 
(categorical variables with at least one expected frequency cell ≤5), ¥: Shapiro Wilk test 
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indicated a normal distribution for nadir CD4 count (P >0.05). Here we present both mean 
and median as per Shapiro Wilcoxon test and as frequently encountered in literature 
VL: viral load; SD: standard deviation; MSM: men who have sex with men; IQR: interquartile; 
TDT: transmitted drug resistance; ART: anti-retroviral therapy; VL: viral load; TDF: tenofovir; 
FTC: emtricitabine; EFV: efavirenz; ABC: abacavir; 3TC: lamivudine; RPV: rilpivirine; NVP: 




Table 3.4: Univariate logistic regression of clinical, virological and immunological factors on 
the outcome of residual viraemia detection.  
 
Factor Odds Ratio 95% CI p-value 
Age (years) 0.96 [0.90 – 1.02] 0.163 
Gender (F vs. M) 0.73 [0.23 – 2.25] 0.581 
Ethnicity (Black vs. White) 0.94 [0.29 – 3.00] 0.920 
Risk group (MSM/Other vs. Hetero) 1.65 [0.53 – 5.17] 0.390 
Time from diagnosis to start of ART 
(months) 
1.01 [0.99 – 1.02] 0.533 
HIV-1 clade (B vs. A/C) 0.80 [0.17 – 3.69] 0.775 
TDR (Yes vs. No) 1.83 [0.48 – 6.95] 0.373 
Nadir CD4 count (ln cells/mm3) 1.26 [0.59 – 2.72] 0.547 
Pre-ART VL (log10 copies/mL) 1.02 [0.45 – 2.32] 0.957 
Third agent (PI vs. NNRTI) 2.68 [0.69 – 10.38] 0.154 
Time from suppression to recruitment 
(years) 
0.84 [0.70 – 1.01] 0.068 
Total HIV-1 DNA (log10 copies/106 
PBMC) 
9.15 [1.85 – 45.4] 0.007 
CD4 count (ln cells/mm3) 2.45 [0.42 – 14.4] 0.319 
CD4 (%) 0.96 [0.90 – 1.03] 0.293 
CD8 (%) 1.04 [0.99 – 1.10] 0.126 
CD4/CD8 ratio 0.50 [0.15 – 1.60] 0.243 
PD1 on CD8+ (%) 0.94 [0.87 – 1.01] 0.071 
PD1 on CD8+/CD45RA- (%) 0.97 [0.93 – 1.01] 0.119 
PD1 on CD8+/CD45RA-/CCR7+ (%) 0.95 [0.91 – 0.99] 0.049 
PD1 on CD8+/CD45RA-/CCR7- (%) 0.96 [0.92 – 0.99] 0.029 
PD1 on CD8+/CD45RA+ (%) 0.92 [0.83 – 1.02] 0.117 
PD1 on CD4+ (%) 0.97 [0.91 - 1.4] 0.374 
PD1 on CD4+/CD45RA- (%) 0.96 [0.90 – 1.01] 0.142 
PD1 on CD4+/CD45RA-/CCR7+ (%) 0.96 [0.89 – 1.03] 0.218 
PD1 on CD4+/CD45RA-/CCR7- (%) 0.96 [0.92 - 0.99] 0.034 
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Factor Odds Ratio 95% CI p-value 
PD1 on CD4+/CD45RA+ (%) 1.02 [0.94 – 1.12] 0.575 
 
 
CI: confidence interval; F: female; M male; MSM: men who have sex with men; Hetero: 
heterosexual; TDT: transmitted drug resistance; ART: anti-retroviral therapy; VL: viral load; 
NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; PBMC: 




Table 3.5: Multivariate logistic regression model of factors associated with detection of 
residual viraemia in plasma. 
 
Factor Odds Ratio 95% CI p-value 
Total HIV-1 DNA, log10copies/106 PBMC 3.42 [1.32 – 8.83] 0.011 
PD1 on CD4+/CD45RA-/CCR7- 0.97 [0.93 – 1.00] 0.05 
Age 0.95 [0.89-1.01] 0.072 
 





This study investigated a cohort of successfully treated HIV-1 patients on first line ART and 
no evidence of virological failure for a duration of around 5 years. HIV-1 RNA in plasma was 
detected and quantified with a SCA in almost one third of patients and the median was 3 
copies/mL. Previous studies have shown that residual viraemia of this level has identical HIV 
sequences implying that the source is a clonally expanded infected cell (Bailey et al., 2006, 
Bozzi et al., 2019, Jacobs et al., 2019, Rosenbloom et al., 2017). Hence, ongoing virus 
replication is probably rare, if not absent at all, in our cohort of patients. Antigen or cytokine 
triggered activation of cells harboring HIV-1 DNA is responsible for  production of virus  
(McManus WR et al., 2018, Wang et al., 2018). Reservoirs are maintained by proliferation 
and escape clearance by cytotoxic cells (Shen and Siliciano, 2008b, Zheng et al., 2014). 
Immune checkpoints such as the PD1 play a critical role in responses which are pivotal in 
controlling HIV-1 replication and viraemia (Schmitz et al., 1999, Zheng et al., 2014) and 
appear to be a mechanism of short-term latency (Boyer and Palmer, 2018).  
Patients on a PI-based regimen demonstrated some trends different from the group of 
patients on NNRTI-based ART. Subjects on PIs were allowed to have changes of the PI arm 
and isolated VL measurements up to 200 copies/mL post suppression. The rationale was 
that PI-based regimens exhibit increased toxicity and pharmacokinetics which make drug 
switches and isolated episodes of viraemia (viral blips), respectively, more frequent than 
NNRTIs. Moreover, blips of this magnitude have not been associated with virological failure 
(Grennan et al., 2012, Raffi et al., 2017). Regardless, the number of patients on PIs was very 
small and only one fifth of our population. Although our study lacked sufficient statistical 
power to find differences by regimen, we observed some trends. Subjects receiving PI-based 
ART compared to NNRTI-based ART appeared to have a distinct virological profile with a 
higher frequency of transmitted drug resistance mutations, detectable HIV-1 RNA in plasma 
and total HIV-1 RNA in PBMC, shorter duration of ART and lower PD1 expression on CD4 and 
CD8 subsets compared to the NNRTI group. These observations agree with previous studies 
suggesting that PI-based ART is less suppressive than NNRTI and InSTI based regimens 
(Bonora et al., 2009, Darcis et al., 2020, Geretti et al., 2019, Gianotti et al., 2018, Gianotti et 
al., 2012, Maggiolo et al., 2012, McKinnon et al., 2016, Sarmati et al., 2012). PIs have 
insufficient tissue penetration and even small decreases in their plasma concentration can 
cause significant reduction in their activity (Shen et al., 2008, Yeh et al., 2009). These 
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pharmacological features coupled with shorter ART duration in our cohort may imply that 
ongoing viral replication may occur more frequently in the PI group. Yet, the level of residual 
viraemia was the same as in the NNRTI group and except for one sample, which also had the 
shortest duration of suppression in the study (23 weeks), all the rest were below 5 
copies/mL.  
This study found that successfully treated patients had their total HIV-1 DNA in PBMC 
strongly associated with residual viraemia. HIV-1 DNA load in blood was a strong predictor 
of detectable HIV-1 RNA in plasma when adjusting for PD1 expression on effector memory 
CD4 T cells (CD4+/CD45RA-/CCR7-) and age. This should be interpreted with caution due to 
the wide 95% confidence interval (1.2 – 31). Two previous studies reported a positive 
correlation between residual viraemia (<10 copies/mL) and HIV-1 DNA in circulating CD4 T 
cells or total HIV-1 DNA in PBMC (Chun et al., 2011, Hong et al., 2018). Indeed, we may 
speculate that a larger reservoir may increase the probability of bursts of virus production 
upon cell activation. The argument is that only a small proportion of the reservoir (~5%) can 
produce intact viruses without defects and this subset appears to lack the capacity to 
clonally expand in response to TCR stimulation ex vivo (Bruner et al., 2019). On the contrary, 
cells harboring defective viruses proliferate with the potential to produce residual viraemia 
upon activation (Imamichi et al., 2016). Our group has previously reported no association 
between residual viraemia and integrated or total HIV-1 DNA (Ruggiero et al., 2018, 
Ruggiero et al., 2015). This finding accrued from a very similar population, but on NNRTI-
based ART exclusively, while in this cohort we have included patients on PI-based regimens. 
The characteristics of the PI group may reflect a more active and bigger cellular reservoir 
which could have strengthened the association between HIV-1 DNA in PBMC and HIV-1 RNA 
in plasma. From a technical perspective, it has been demonstrated that co-amplification of 
cellular HIV-1 DNA along with HIV-1 RNA results in increased HIV-1 RNA values (Wan et al., 
2010). However, the Abbott m2000sp platform employs an RNA-centric extraction method 
with the use of purification reagents specific for RNA. It has been shown that co-
amplification of HIV-1 DNA is minimal with the RealTime assay compared to the TaqMan 
v2.0 (Fernandes et al., 2010).  
Surprisingly, residual viraemia did not associate with increased PD1 expression on CD4 and 
CD8 subsets. On the contrary, PD1 expression on effector memory CD4 and CD8 T cells and 
central memory CD4 T cells was significantly increased in patients with undetectable HIV-1 
RNA in a univariate model. Moreover, PD1 expression was consistently higher on all CD4 
and CD8 subsets in the group with undetectable HIV-1 RNA compared to the group with 
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residual viraemia with the biggest difference seen on effector memory CD4 T cells. PD1 is 
expressed on activated CD4 and CD8 T cells to orchestrate the balance between immune 
stimulation and inhibition (Sharpe et al., 2007). PD1 regulatory and inhibitory roles are 
evident in two models of acute and chronic LCMV infection. Transient expression of PD1 on 
early effector CD8 T cells precedes acute infection clearance contrary to persistent PD1 up-
regulation during chronic infection which attenuates a constant TCR signaling from antigen 
presence (Barber et al., 2006). PD1 has been associated with immune exhaustion and T cell 
dysfunction in HIV-1 infection (Day et al., 2006, D'Souza et al., 2007, Trautmann et al., 2006). 
High PD1 expression on T cells during chronic HIV infection is epitope-dependent driving 
functional inactivation and facilitating HIV persistence (Blattman et al., 2009, Day et al., 
2006, Gilboa, 1999, Oldstone, 1997, Petrovas et al., 2006, Trautmann et al., 2006). However, 
the interaction of HIV-specific CD8 cells with mutated epitopes does not result in increased 
PD1 expression (Blattman et al., 2009, Conrad et al., 2011). Indeed, RNA viruses escape 
cytotoxicity and establish chronic infection with the acquisition of mutations at the sites of 
interaction with TCR receptors or by impairing important helper CD4 functions disabling 
their communication with CD8 cells (Blattman et al., 2009, Oldstone, 1997). Assuming that 
residual viraemia is clonal and bears mutations at the antigenic regions, it would not trigger 
PD1 expression. This would not explain the increased expression in patients with 
undetectable HIV-1 RNA in plasma, though. 
Studies blocking the PD1-PD-L1/2 pathway in vitro and in vivo during SIV infection 
demonstrated immunological recovery with potential clinical benefit (Finnefrock et al., 
2009, Freeman et al., 2006, Velu et al., 2009). Contrary to these promising findings, a model 
of rhesus macaques failed to show any VL suppression with PD1-PD-L1 inhibition in vivo 
(Amancha et al., 2013). These reports underscore the complex interplay of immune-
regulatory mechanisms. Our group and others have provided evidence of immune activation 
during long-term suppressive ART (Ruggiero et al., 2018, Ruggiero et al., 2015, Zaidan et al., 
2019). As a result, PD1 may increase to control an immune response that effectively clears 
residual virus production in patients with undetectable HIV-1 RNA in plasma. For instance, 
the interaction of PD1 with PD-L2 on APC exhibits a costimulatory role for T cell activation 
and prevents PD-L1 induced exhaustion in murine models (Dyck and Mills, 2017b, 
Karunarathne et al., 2016). PD1 is also normally expressed on Tfh which comprise around 
20% of circulating CD4 T cells (CD4+/CD45RA-/CXCR5+/PD1+) and trigger B cells to produce 
antibody responses in secondary lymphoid tissues (Eivazi et al., 2016, Kawamoto et al., 2012, 
Tangye et al., 2013). Frequency of Tfh cells in HIV positive subjects correlates positively with 
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the capacity to develop bnAbs and stronger immune responses (Locci et al., 2013). Hence, 
PD1 expression in patients with undetectable HIV-1 RNA may reflect the activation of 
protective immune mechanisms. 
Our study has limitations. The main disadvantage is our small sample size due to the rarity 
of the population we targeted to recruit. For this reason, we combined data from patients 
on NNRTI and PI based regimens and we allowed single episodes of viral rebound up to 200 
copies/mL in the latter. Moreover, we included the three patients with LLV in our group with 
detectable HIV-1 RNA. Multi-centre studies are required to achieve larger numbers of 
participants on each type of therapy. We also focused on the PD1 pathway to address 
immune exhaustion and impairment of the cytotoxic machinery. A future approach would 
be to measure additional markers on CD4 and CD8 T cells, such as the exhaustion markers 
Tim-3 and CD160 (Kuchroo et al., 2014) and Tfh cell markers with mass cytometry. It would 
also be useful to have longitudinal immunological data to demonstrate the dynamics of PD1 
expression. 
Our findings imply that residual viraemia in successfully treated patients can be predicted 
by the size of circulating reservoirs when adjusting for PD1 expression on effector memory 
CD4 T cells and age. To the best of our knowledge there is no previous work on PD1 
expression on CD4 and CD8 T cells in patients with residual viraemia. In this work it was 
demonstrated that patients with undetectable HIV-1 RNA express PD1 at increased levels 
compared to those with residual viraemia. Further work is required to investigate this 













Residual viraemia persists despite 




ART initiation causes decay of HIV-1 RNA in plasma in four phases (Palmer et al., 2008). A 
very rapid decrease in VL during the first and second phase (t1/2 = 1.5 and t1/2 = 28 days, 
respectively) is followed by a slower decay in the third phase (t1/2 = 39 weeks). Eventually, 
the fourth phase is established during which HIV-1 RNA in plasma persists indefinitely in 
most patients on successful ART (Hatano et al., 2009, Havlir et al., 2005, Palmer et al., 2008, 
Ruggiero et al., 2018). Accumulating evidence suggests that residual viraemia at the level of 
around 3 copies/mL has an archival character and derives from clonally expanded cells 
harbouring HIV-1 DNA (Bailey et al., 2006, Hosmane et al., 2017, Lorenzi et al., 2016, 
Simonetti et al., 2016, Wang et al., 2018). Some of these clones persist longitudinally while 
others disappear with residual viraemia remaining stable (Wang et al., 2018).  
However, sub-optimal drug levels at sanctuary sites may allow ongoing cycles of viral 
replication and virus detection in plasma (Fletcher et al., 2014, Nightingale et al., 2016). At 
the same time, modest lapses in adherence may result in low level HIV-1 replication which 
may not be detected with commercial assays (Konstantopoulos et al., 2015, Pasternak et al., 
2012); consistent with this view, adherence levels have been associated with persistent HIV-
1 RNA detection below 50 copies/mL as measured with ultra-sensitive assays (Li et al., 2014). 
Yet, patients with optimal adherence can also have detectable HIV-1 RNA in plasma (Li et 
al., 2014, Maggiolo et al., 2017). 
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Here, we investigated whether detection of residual plasma HIV-1 RNA at levels below 10 
copies/mL during suppressive first-line ART remains stable in subsequent measurements 






4.2.1 Study population 
Methods have been described in Chapter 3. In brief, we recruited HIV-1 infected individuals 
on first-line ART comprising of two NRTI and either a NNRTI or a PI. ART regimen 
modifications were allowed for the NRTI and PI arm and within the same drug class. Eligible 
patients were on therapy for at least 6 months. Their VL was consistently suppressed below 
50 copies/mL. Patients on PI based regimens were allowed blips up to 200 copies/mL. 
 
4.2.2 HIV-1 RNA and DNA quantification 
Whole blood was collected at two time points (baseline, S0, and second sampling, S1). On 
the day of collection PBMC and plasma were separated, as described in Chapter 3, and 
stored at -800C. We measured HIV-1 RNA in plasma with our in-house SCA. In brief, 8mL of 
plasma were concentrated with ultra-centrifugation. HIV-1 RNA was measured in the 
concentrate with the Abbott m2000 platform and HIV-1 copies/mL were calculated from the 
formula: 10^[(Ct-Intercept)/Slope]/8. Samples with undetectable HIV-1 RNA were assigned 
the value of 0.5 copies/mL (Mens et al., 2011). The assay detection rates for 5, 3 and 1 HIV-
1 RNA copies/mL were 100%, 80% and 60%, respectively. 
Total HIV-1 DNA in PBMC was extracted with the QIAamp® DNA Mini and Blood Mini kit. 
DNA extract concentration was quantified by spectrophotometry (NanoDrop 1000, Thermo 
Scientific) and adjusted to 50 ng/μL corresponding to yield 1 μg DNA per PCR reaction. A 
real-time qRT-PCR targeting an LTR region was applied to measure the copies of HIV-1 DNA 
per 106 PBMC (Avettand-Fenoel et al., 2009).  
 
4.2.3 Plasma drug levels 
Plasma concentrations of EFV, DRV and lopinavir (LPV) were measured by validated high-
performance liquid chromatography–tandem mass spectrometry (HPLC–MS) at the 
Department of Pharmacology, University of Liverpool, as previously described (Dickinson et 
al., 2005). Time of sample relative to dose intake was recorded. We used untimed drug levels 
and categorised them as optimal or suboptimal based on target trough concentrations as 
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per drug manufacturer's prescribing information for drug-susceptible virus: 1,000 ng/mL for 
EFV, 1,000 ng/mL for LPV and 550 ng/mL for DRV (Acosta et al., 2012, Gonzalez-Serna et al., 
2016). To investigate HIV-1 RNA levels in relation to drug levels we stratified samples as <1 
copy/mL or undetectable (UD), 1 to 10 copies/mL or residual viraemia (RV) and >10 
copies/mL or LLV. 
 
4.2.4 Statistical analysis 
Data were analysed with SPSS version 25 (IBM) as in Chapter 3. We utilised the McNemar 
test for repeated measurements of categorical data. The paired t-test (parametric) and 
Wilcoxon rank sum test (non-parametric) were used for repeated (correlated) variables. A 





4.3.1 Individual characteristics 
Almost two third (60%, n=32) of subjects from our original cohort of patients were sampled 
twice (n=64 samples). The majority (81%, n= 26) were on first line NNRTI-based regimens 
with EFV (n=25) and rilpivirine (RLP, n=1). Ritonavir boosted PI-based ART included DRV 
(n=5) and LPV (n=1). Baseline characteristics for our longitudinal cohort and for patients on 
EFV are shown in Table 4.1. The median duration of first-line ART at the time of sampling 
was 205 weeks (IQR: 80-356) with a range between 37 and 672 weeks and the median 
duration of suppression was 193 weeks (IQR: 63-351).  CD4 count, HIV-1 RNA in plasma, 
total HIV-1 DNA in PBMC and drug levels for EFV, DRV and LPV were measured at two time 
points separated by a median 4 months (IQR: 3-6, range: 2-7) interval (Table 4.2). CD4% was 
around 33% and mean total HIV-1 DNA in PBMC was 2.6 log10 copies/106 cells at each 
sampling point (Table 4.2). No treatment changes or interruptions were recorded during this 
period and VL remained suppressed (50 copies/mL) at routine clinic visits. 
 
4.3.2 Residual viraemia 
Of 32 patients, 17 (53%) had undetectable HIV-1 RNA in plasma at both time points and 8 
(25%) had consistently detectable HIV-1 RNA. Undetectable HIV-1 RNA was preceded (n=4) 
or followed (n=3) by detected viraemia in seven subjects (Figure 4.1 & Appendix Figure A.1). 
The median plasma HIV-1 RNA level was 0.5 copies/mL (IQR: 0.5-2) at each time point (Table 
4.2).  
Of 23 samples with detectable HIV-1 RNA, 18 (78%) samples from 13 patients had residual 
viraemia between 1 and 10 copies/mL and 5 samples from 3 subjects had LLV between 10 
and 40 copies/mL. Samples with quantifiable HIV-1 RNA had median 3 copies/mL (IQR: 2-9) 
and 4 copies/mL (IQR: 2-7) at S0 and S1, respectively. Patients with residual viraemia at one 
or both time points (n=12) fluctuated within a very confined range of 0 to 6.5 copies/mL 
(median 1.5; IQR: 1.5-3.3) (Figure 4.1 and Appendix Figure A.1).  Only one patient crossed 
the adapted threshold of 10 copies/mL and had LLV (20 copies/mL) at S0 and residual 




4.3.3 Drug levels 
Drug levels were measured in 59 of 64 samples for which the volume was adequate. Plasma 
levels of EFV relative to time post dosing were measured in 48 samples (23 at S0 and 25 at 
S2) and they are shown in Figure 4.2. The concentration of EFV was above the recommended 
threshold of 1,000 ng/mL for the majority of samples (n=42, 87.5%). Sub-optimal levels 
timed between 12 and 16 hours after dosing were identified in six samples from five patients 
(one patient, P5-Figure 4.2, had EFV <1,000 ng/mL at S0 and S2). The highest EFV levels were 
above the upper therapeutic target of 4,000 ng/mL in six samples from three female patients 
at both time points (Figure 4.2). 
Concentration of DRV and LPV in the plasma was above the recommended threshold for all 
11 samples (inadequate volume for one DRV specimen at S0). The median time of dosing 
was 10.5 hours (IQR: 4.3-15.3) prior to S0 and 13 hours (IQR: 6.6-16.8) before S1. 
 
4.3.4 HIV-1 RNA level and drug levels 
Of the 59 samples, 37 (62.7%) were UD and 17 (28.8%) and 5 (8.5%) were categorised as RV 
and LLV, respectively. Drug levels were optimal in 92% (n=34) of the UD samples. This 
proportion lowered to 88% (n=15) and further to 80% (n=4) in samples with RV and LLV, 
respectively. Of the 53 samples with optimal drug concentration, 36% (n=19) had detectable 
HIV-1 RNA in plasma between 1 and 40 copies/mL of which 28% (n=15) had residual viraemia 
(1-10 copies/mL). 
A sensitivity sub-analysis was performed for samples taken from patients on EFV (25 
patients, 48 samples). Baseline characteristics are shown in Table 4.1. There were no 
differences in HIV-1 RNA in plasma and total HIV-1 DNA in PBMC between the two time 
points (Table 4.3). The proportions of UD, RV and LLV were 65% (n=31), 29% (n=14) and 6% 
(n=3), respectively. Of the 48 samples with EFV levels, six (13%) had sub-optimal 
concentration. Of those six, three were UD, two RV and one LLV. The proportion of samples 
with EFV levels less than 1,000 ng/mL and detectable HIV-1 RNA (RV and LLV combined) was 
almost twice the proportion of those with UD [17.6% (3/17) vs. 9.7% (3/31)]. One patient 
had RV (7 copies/mL) with sub-optimal EFV levels (417 ng/mL) at S0 and UD with optimal 
drug concentration (1,263ng/mL) at S1. However, another patient with sub-optimal EFV 
levels at S0 and S1 had detectable HIV-1 RNA only at S1.  
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Figure 4.1: Reproducibility of HIV-1 RNA in plasma.  
 
a. S0  
 
Undetected Detected  
S1
 
Undetected 17 (53%) 4 (13%) 21 (66%) 
Detected 3 (9%) 8 (25%) 11 (34%) 





(a) frequency of patients with detected and undetected HIV-1 RNA at baseline (S0) and 
second sampling (S1) and (b) level of HIV-1 RNA in plasma measured with a single copy assay 
at least 24 weeks after starting anti-retroviral therapy (ART). Each line represents a patient 
and the dots represent baseline sampling (S0) and second sampling (S1). The 10 copies/mL 






































10 copies/mL cut-off 
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Figure 4.2: Efavirenz levels in plasma at baseline (S0) and second sampling (S1) in patients 




Outliers have been labelled with patient number (P1-5) and sampling point (S0 or S1). P5 is 










































Time post dose, hours
Undetected HIV-1 RNA Detected HIV-1 RNA
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Table 4.1: Baseline characteristics of the whole cohort and of patients on efavirenz based 
regimens at recruitment.  
 
Characteristic Total (n=32) EFV (n=25) 
Age (years), mean (SD) 42 (10.3) 42 (10.7) 
Gender, n (%) Male 
Female 



















Time from diagnosis to start of ART, median 
months (IQR) 
10 (2 – 36) 5 (2-17) 





















Nadir CD4 count, mean cells/mm3 (SD) 229 (102) 199 (77.5) 
Pre-ART VL, mean log10 copies/mL (SD) 4.6 (0.7) 4.6 (0.7) 


















Subjects with NRTI backbone changes¥, n (%) 6 (19) 6 (24) 





Characteristic Total (n=32) EFV (n=25) 
Duration of ART median weeks (IQR) 205 (80-356) 266 (127-378) 
Duration of VL suppression median weeks 
(IQR) 
193 (63-351) 261 (114-371) 
 
 
¥: number of changes was one with the exception of one subject who had two changes  
EFV: efavirenz; VL: viral load; SD: standard deviation; MSM: men who have sex with men; 
IQR: interquartile; TDT: transmitted drug resistance; ART: anti-retroviral therapy; TDF: 
tenofovir; FTC: emtricitabine; ABC: abacavir; 3TC: lamivudine; RPV: rilpivirine; NVP: 




 Table 4.2: Comparative analysis of virological parameters, CD4 and drug levels between the 
two time points (S0 and S1). 
  
Characteristic S0 (n=32) S1 (n=32) p-value 
Residual HIV-1 RNA, median 
copies/mL (IQR) 
0.5 (0.5-2) 0.5 (0.5-2) 0.900** 







Total HIV DNA mean log10 
copies/106 PBMC (SD) 
 2.65 (0.41) 2.64 (0.38) 0.938* 
CD4 count (cells/mm3), mean (SD) 572 (202) 662 (226) 0.002* 
CD4 (%), mean (SD) 32.5 (9.7) 33.3 (8.4) 0.282* 
















LPV levels in plasma (ng/mL), n=1 9,050.4 7,857.2 N/A 
 
*Paired t-test (normally distributed continuous variables), **: Wilcoxon rank sum test (non-
normal continuous variables), †: McNemar's test (categorical variables), a: n=23 at S0 (x2 
missing values) and n=25 at S1, b: n=4 at S0 (x1 missing value) and n=5 at S1,   
S0: baseline sampling; S1: second sampling; IQR: interquartile range; SD: standard deviation; 





Table 4.3: Comparative analysis of virological parameters, CD4 and drug levels between the 
two sampling points (S0 and S1) for patients receiving efavirenz. 
 
Characteristic S0 (n=25) S1 (n=25) p-value 
Time post dose, median hours 
(IQR) 
13.6 (13-14.3) 13.7 (12.5-14.1) 0.654* 
Residual HIV-1 RNA, median 
copies/mL (IQR) 
0.5 (0.5-2) 0.5 (0.5-2) 0.964* 







Total HIV DNA mean log10 
copies/106 PBMC (SD) 
2.65 (0.38) 2.59 (0.38) 0.484** 
CD4 count (cells/mm3), mean (SD) 558 (198) 650 (215) 0.018** 
CD4 (%), mean (SD) 32 (10) 33 (9) 0.423** 
 
*Paired t-test (normally distributed continuous variables), **: Wilcoxon rank sum test (non-
normal continuous variables), †: McNemar's test (categorical variables)   
S0: baseline sampling; S1: second sampling; IQR: interquartile range; SD: standard deviation; 








We recruited a unique cohort of successfully treated patients on long term ART and we 
sampled more than half of them (32/53) twice within a median interval of four months (S0 
and S1). Most patients (n=25, 78%) were on suppressive first line ART for more than a year 
and viral reservoirs represented by total HIV-1 DNA in PBMC were stable between S0 and 
S1. The undetected and detected status of HIV-1 RNA in plasma was reproducible at second 
sampling in 78% of cases (n=17 and n=8, respectively). The level of residual viraemia also 
remained stable between time points. This remarkable reproducibility in our cohort reflects 
the stability of HIV-1 RNA levels in plasma during chronic effective treatment (Maldarelli et 
al., 2007, Palmer et al., 2008). 
We investigated if sub-optimal drug concentrations were associated with residual HIV-1 RNA 
in plasma. Over one third of samples had plasma HIV-1 RNA levels ranging from 1 to 40 
copies/mL despite optimal drug levels, of which the majority had residual viraemia (<10 
copies/mL). If we infer adherence from drug concentrations, our findings are consistent with 
previous studies demonstrating that one third to half of patients with persistent viraemia 
below 50 copies/mL had optimal adherence (Li et al., 2014, Maggiolo et al., 2017). These 
findings also support the hypothesis that residual viraemia derives from bursts of virus 
production from latently infected reservoirs which is quickly suppressed by ART. However, 
a small subset of samples with residual viraemia had sub-optimal drug levels reflecting the 
possible presence of viral replication replenishing HIV-1 RNA in plasma (Li et al., 2014, 
Maggiolo et al., 2017). Our study differs from previous work because we treated residual 
viraemia <10 copies/mL as a separate entity from LLV between 10 and 50 copies/mL. This 
was justified by the observation that there is a gradual increase in the risk of viral rebound 
with increasing HIV-1 RNA above 10 copies/mL (Doyle et al., 2012).  
We identified three outliers in our cohort having LLV between 10 and 40 copies/mL.  One 
subject had viral suppression for less than a year (23 and 35 weeks at S0 and S1, 
respectively), during which viraemia may be expected to continue to decline (Hatano et al., 
2010) and one had sub-optimal drug levels which may reflect poor adherence (Li et al., 
2014). The third subject went from LLV (S0) to residual viraemia (S1) but none of the above 
explanations could be applied.  
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Contrary to previous studies using drug refill and pill count, we utilised drug levels to 
measure adherence. Although it is indicated in Chapter 3 that all our patients reported 
optimal adherence, recall bias and social acceptance may result in an overestimate 
(Goldman et al., 2008). Liechty and colleagues showed that subtherapeutic untimed drug 
levels were an acceptable indicator of non-adherence, but therapeutic drug concentrations, 
particularly for EFV which has a long half-life, were not a good marker of adherence in clinical 
practice (Liechty et al., 2004). Therapeutic EFV levels have been associated with self-
reported adherence at 85% and above in a study investigating the aetiology of blips (Farmer 
et al., 2016). Sub-optimal untimed drug levels have not been associated with viral blips, but 
they have been proposed as an independent predictor of virologic failure in patients with 
episodic or recurrent viraemia between 50 and 1,000 copies/mL (Gonzalez-Serna et al., 
2016).  Taken together, we linked sub-optimal levels with decreased adherence, but we note 
that our untimed analysis cannot adjust for pharmacokinetic variability causing reduced 
levels. We also acknowledge that a small proportion of our patients with optimal drug levels 
in plasma may not have been 100% adherent to ART.  
Our effort to reduce variability by sampling a strictly pre-defined population stable on 
treatment came at the cost of a small sample size. As a result, we did not model repeated 
measures and treated each sample as independent in a descriptive analysis. The small 
number of patients and time points is the main drawback, which does not allow for robust 
findings. The study also lacked a longitudinal assessment of immunological parameters. 
Lastly, at the time of study conduct InSTI were not part of first line recommendations in 
guidelines, as they are now, and our subjects were on rather old-fashioned regimens. 
Nevertheless, we noted some interesting trends.  We report that HIV-1 RNA in successfully 
suppressed patients on ART fluctuated in less than half of patients and within a very 
stringent range between routine visits.  Residual virus still persists at a stable level despite 
optimal drug levels reflecting the presence of an active reservoir as the source of HIV-1 RNA 
in plasma. In a small proportion of patients, though, inadequate drug levels may contribute 






HIV-1 RNA in plasma persists in patients under suppressive ART and factors associated with 
residual viraemia remain elusive. Treatment initiation causes a rapid decline in VL which 
continues at a slower rate until HIV-1 RNA reaches a level around 3 copies/mL (Maldarelli et 
al., 2007, Palmer et al., 2008). In line with the kinetics of viral decay, our systematic review 
showed that patients who had been on suppressive ART for less than two years experienced 
LLV more frequently than those on longer duration of treatment (Leierer et al., 2015, 
Martin-Blondel et al., 2012, Pascual-Pareja et al., 2010).  Hints of this notion were also 
demonstrated in isolated cases of our observational cohort with residual viraemia. 
The terms of low level and residual viraemia have been widely used to stratify HIV-1 RNA 
levels, but their definitions vary significantly in literature. Our systematic review included 15 
studies and the proportion of patients with LLV was between 6% and 77%.  We adapted a 
threshold of 10 copies/mL to distinguish between the two entities, because the risk of viral 
rebound starts to increase gradually around this cut-off in proportion with the level of 
viraemia (Doyle et al., 2012, Maggiolo et al., 2012, Pugliese et al., 2013, Ryscavage et al., 
2014). Residual viraemia around 3 copies/mL is clonal and derives from reservoirs 
established during primary infection (Anderson et al., 2011, Bailey et al., 2006, Buzon et al., 
2010, Gianotti et al., 2012, Palmer et al., 2008, Wang et al., 2018). However, higher levels of 
HIV-1 RNA may result from additional mechanisms such as ongoing viral replication due to 
sub-optimal ART penetration at sanctuaries or moderate adherence (Fletcher et al., 2014, 
Konstantopoulos et al., 2015, Li et al., 2014, Nightingale et al., 2016), and drug resistant 
mutations (Delaugerre et al., 2012, Mackie et al., 2010, Taiwo et al., 2011). 
Consistent with the hypothesis of activation of cellular reservoirs as the source of residual 
HIV-1 RNA during suppressive ART, our systematic review and our observational study 
showed that LLV and residual viraemia, respectively, were associated with a larger cellular 
reservoir as measured by levels of total HIV-1 DNA (Charpentier et al., 2012, Falasca et al., 
2017, Leierer et al., 2015, Martin-Blondel et al., 2012, Pascual-Pareja et al., 2010, Reus et 
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al., 2013). Our review identified that higher pre-ART VL, longer time since HIV-1 diagnosis 
and advanced clinical stage were more frequently encountered in patients with LLV. These 
factors reflect a prolonged course of infection prior to treatment initiation resulting in an 
increased number of cells being infected (Hong and Mellors, 2015, Jain et al., 2013, 
Maldarelli et al., 2007). In this context, a larger latent reservoir in blood, as indicated with 
increased total HIV-1 DNA in PBMC, was associated with LLV in one of the included studies 
(Falasca et al., 2017). Among the population of our observational cohort, one third had 
residual viraemia around 3 copies/mL and HIV-1 RNA levels in plasma were reproducible at 
re-sampling. These findings are consistent with previous reports describing clonal expansion 
of cells harbouring HIV-1 DNA as a probable source of residual virus before being effectively 
suppressed by ART (Josefsson et al., 2013, Shen and Siliciano, 2008b). These cells may be 
circulating in peripheral blood as illustrated in our data by the observed association between 
total HIV-1 DNA in PBMC and residual HIV-1 RNA in plasma (Mullins and Frenkel, 2017). 
Virus replication, on the other hand, can be driven by inefficient ART penetration in tissues 
and decreased adherence. Patients on PI-based regimens or during ART holidays 
experienced LLV with increased frequency in our systematic review (Falasca et al., 2017, 
Leierer et al., 2015, Saison et al., 2013). A small proportion of our study patients were on PIs 
(n=11) and we performed drug levels in plasma on two different occasions in almost half of 
them which were found optimal. However, PI levels in lymphoid tissues may have been sub-
optimal and this may have caused some trends (e.g. higher frequency of patients with 
residual viraemia) seen in the PI group compared to the NNRTI group. A small fraction of 
EFV samples with detectable HIV-1 RNA in plasma had sub-optimal drug concentration. This 
observation implies that virus replication may generate residual viraemia in a limited 
number of patients with sub-optimal treatment and this warrants further investigation. 
Sometimes, both mechanisms may co-exist. In our review, we identified an association 
between enhanced microbial translocation and LLV (Falasca et al., 2017, Reus et al., 2013, 
Torres et al., 2014). Ongoing residual replication at the sanctuary of GALT causes structural 
changes and microbial translocation which may activate cells harbouring HIV-1 DNA and 
trigger immune responses with further local damage in a self-perpetuating manner (Chun 
et al., 2008, Cory et al., 2013). The interplay of immune activation is much more complex 
during residual viraemia (Hatano, 2013, Ruggiero et al., 2015, Younas et al., 2016). Increased 
PD1 expression on memory CD4 and CD8 subsets in our patients with undetectable HIV-1 
RNA entailed the existence of a pathway with immunoregulatory properties. At first this 
seemed contradictory to current evidence presenting PD1 as an indicator of immune  
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exhaustion and viral latency (Blattman et al., 2009, Filaci et al., 2018). However, PD1 
expression has also been associated with protective immune mechanisms via different 
pathways (e.g. interaction with PD-L2) in HIV-1 infection (Dyck and Mills, 2017b, 
Karunarathne et al., 2016, Locci et al., 2013). Moreover, PD1 expression on CD4 and CD8 T 
cells may exert opposite effects. It has been suggested that PD1 expression on regulatory 
CD8 T cells may hamper cytotoxic anti-viral responses against cellular reservoirs (Filaci et al., 
2018), whereas on memory CD4 T cells it may reflect increased frequency of Tfh which 
correlates with broadly neutralizing antibodies to residual virus (Locci et al., 2013). Further 
work is required to shed light on the role of PD1 as to activation of cellular reservoirs and/or 
viral replication. 
Our systematic review underscored poor inter- and intra-assay repeatability for viraemia 
around 50 copies/mL (Garcia-Diaz et al., 2013, Hopkins et al., 2015, Ruelle et al., 2012, 
Swenson et al., 2014). Discrepancies were identified in most studies between the two widely 
used commercial assays, the TaqMan v2.0 and the RealTime. An explanation could lie with 
co-amplification of cellular HIV-1 DNA along with HIV-1 RNA with the former platform 
(Fernandes et al., 2010, Taylor et al., 2013). Residual viraemia is quantified with ultra-
sensitive assays frequently employing modified protocols of these assays. Hence, technical 
variation should be factored in when comparing data derived from different platforms. 
Taken together these findings, residual viraemia appeared to be mainly the result of 
transient bursts of virus production which were quickly suppressed by ART. However, virus 
replication may have been allowed in a small subset of patients due to sub-optimal drug 
levels or dysregulation of immune checkpoints, such as PD1. In this context, residual 
viraemia and LLV are generated by similar mechanisms but to a different extent.   
In prospective work it would be interesting to investigate if the association between residual 
viraemia and viral reservoir persists with measurement of HIV-1 DNA in cells harbouring 
intact viruses lacking fatal defects such as large deletions and hypermutations which are 
found in the majority of reservoirs. Recently, Bruner et al. developed a novel method of 
quantification of intact HIV-1 DNA load (Intact Proviral DNA Assay, IPDA) which overcomes 
underestimation issues observed with quantitative viral outgrowth assays (Bruner et al., 
2019, Simonetti et al., 2020). Replication-competent HIV-1 DNA appeared to correlate with 
HIV-1 DNA in total CD4 cells in a cohort of suppressed patients, but treatment duration and 
history were unknown (Papasavvas et al., 2020). Application of IPDA in our cohort of 
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carefully selected patients would shed more light as to the degree of ongoing replication 
contribution to residual viraemia.  
Another aspect that warrants further investigation is the unexpected increase of PD1 
expression on memory CD4 and CD8 cells in patients with undetectable HIV-1 RNA 
compared to those with residual HIV-1 RNA presence in plasma. We would wish to confirm 
this finding in a larger longitudinal cohort including patients on InSTI regimens. The aim 
would be to better characterise memory CD4 and CD8 subsets by measuring additional 
checkpoint receptors and surface markers, such as CCRX5 for circulating Tfh and the T cell 
factor 1 (TCF) which differentiates between terminally exhausted (TCF1-) and self-renewing 
(TCF1+) T cells (Blank et al., 2019).  
The preliminary data of this work and the advancements in knowledge and techniques since 






This appendix contains: 
• Figure A.1, which depicts HIV-1 RNA level over time in patients with detected 
viraemia at one or both sample points (Chapter 4) 
• Table A.1, which illustrates the variability in the definition of LLV in literature by 
giving examples of LLV ranges used by different authors (Chapter 2) 
• Table A.2, which tabulates changes in the NRTI backbone in our study cohort 
(Chapter 3) 
• Table A.3, which details the steps of the backward selection process of the 
multivariate analysis and the effect of removing each variable on the model as 




Figure A.1: Reproducibility of HIV-1 RNA level (copies/mL) in subjects with detected viraemia 




Each line represents an individual. Starting dot at 0 months represents baseline sampling (S0) 






























VL assay or 
database 
Reference 
Dravid 21-999 India 





(Dravid et al., 
2018) 
Rupérez 150-999 Mozambique 
Abbott m2000 








(Chao et al., 
2012) 
Charpentier 21-49 France CAP/CTM v2.0 
(Charpentier 
et al., 2012) 
 
LLV: low level viraemia; VL: viral load; CAP/CTM v2.0: COBAS AmpliPrep/COBAS TaqMan HIV-











Reason for 1st change 
Third 
combination 
Reason for 2nd change 
Forth 
combination 
Reason for 3rd change 
1 AZT/3TC/EFV TDF/FTC/EFV Simplification     
2 ABC/3TC/EFV TDF/FTC/EFV CVD risk     
3 ABC/3TC/EFV TDF/FTC/EFV Low CD4 count     
4 AZT/3TC/EFV TDF/FTC/EFV Lipodystrophy     
5 AZT/3TC/EFV TDF/FTC/EFV Low CD4 count     
6 AZT/3TC/EFV TDF/FTC/EFV Simplification     
7 AZT/3TC/EFV TDF/FTC/EFV Update     
8 AZT/3TC/EFV ABC/3TC/EFV Update TDF/FTC/EFV Hepatitis C infection   
9 AZT/3TC/EFV ABC/3TC/EFV Update     
10 AZT/3TC/EFV DDI/3TC/EFV Anaemia  TDF/3TC/EFV Lipodystrophy TDF/FTC/EFV Hypercholesterolaemia 
11 AZT/3TC/LPV/r AZT/ABC/LPV/r Neuropathy AZT/ABC/DRV/r Diarrhoea   




AZT: zidovudine; 3TC: lamivudine; EFV: efavirenz; TDF: tenofovir; FTC: emtricitabine; ABC: abacavir; CVD: cardio-vascular disease; DDI: didanosine; LPV: 
lopinavir; r: ritonavir; DRV: darunavir; SQN: saquinavir: ATV: atazanavir 
147 
 
Table A.3: Steps of the backward selection process of the multivariate analysis and the effect 
of removing each variable on the model.  
 
Step No Independent variables 
Odds 
ratio 
95% CI p-value 
1 Age 
Third agent (PI vs. NNRTI) 
Time from suppression to recruitment 
Total HIV-1 DNA in PBMC 
CD8 
PD1 on CD8+/CD45RA-/CCR7+ 
PD1 on CD8+/CD45RA-/CCR7- 


























Third agent (PI vs. NNRTI) 
Time from suppression to recruitment 
Total HIV-1 DNA in PBMC 
CD8 
PD1 on CD8+/CD45RA-/CCR7- 























Time from suppression to recruitment 
Total HIV-1 DNA in PBMC 
CD8 
PD1 on CD8+/CD45RA-/CCR7- 




















Total HIV-1 DNA in PBMC 
CD8 
PD1 on CD8+/CD45RA-/CCR7- 


























Step No Independent variables 
Odds 
ratio 
95% CI p-value 
CD8 








Total HIV-1 DNA in PBMC 
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